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Abstract
Pulmonary arterial hypertension (PAH) is characterised by increased vascular resistance 
which leads to pulmonary artery remodelling and increased smooth muscle cell 
proliferation (Fishman 2004; Humbert et ah, 2004). Chronic hypoxia treated rats (to induce 
PAH) display alterations in cyclic nucleotide signalling pathways. Both cAMP and cGMP 
levels are reduced (MacLean et al., 1997), with a corresponding increase in PDE3A/B and 
PDE5A2 in pulmonary arteries of the chronic hypoxic rat (Murray et al., 2002). The 
objective of this study was to investigate the expression of PDE4 isoforms in the cellular 
model of PAH as the PDE4 family represents the major cAMP-hydrolysing activity within 
these cells (Palmer et al., 1998).
It was shown that in human pulmonary artery smooth muscle cells (hPASMC), the 
PDE4A10, PDE4A11, PDE4B2 and PDE4D5 isoforms all show significant increases in 
expression after 14 days exposure of chronic hypoxia (10% O2). The increase in PDE4 
expression did not correspond to an increase in PDE4 activity levels however. Levels of 
cAMP were tripled and PKA activity was doubled after 7 days in 10% O2 . The hypoxia 
induced increase in cAMP was determined to be ERK dependant as use of the MEK 
inhibitor, U0126, could reduce hypoxic cAMP levels to that of normoxic cells.
The autocrine loop shown previously in aortic smooth muscle cells (Baillie et ah, 2001), 
was demonstrated to be in effect in hPASMC. In this loop, active ERK led to the 
production of PGE2  through PLA2 . This increase in PGE2 stimulated adenylyl cyclase and 
increased the generation of cAMP. Using the COX-2 inhibitor, indomethacin, completely 
ablated the rise in cAMP levels in hypoxia. Exogenous PGE2  mimicked the hypoxia 
induced rise in cAMP in normoxic cells. Inhibition of ERK also led to a decrease in PDE4 
activity through the reduced level of cAMP generated and thus decreased the amount of 
PKA able to activate PDE4. This effect was not witnessed in hypoxia, suggesting 
desensitisation to cAMP stimulation had occurred. Indeed, it was observed that hypoxic 
cells produced less cAMP in response to cAMP agents such as rolipram or PGE2 than 
normoxic cells.
Vascular smooth muscle cells have been reported to proliferate in response to hypoxia. 
Indeed, it was demonstrated in this study that hPASMC do increase their proliferation in 
response to hypoxia in both serum starved cells and cells cultured in serum. The PKA RII 
subunit was demonstrated to be essential for normal proliferation of these cells. Both PKA
IV
RI and PKA RII can significantly reduce proliferation in both normoxic and hypoxic 
cells. Also, the recently discovered cAMP substrate Epac (de Rooij et al., 1998), elicits 
anti-proliferative effects on serum induced proliferation in hPASMC.
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Chapter 1
General Introduction
1.1 Cyclic nucleotide signalling pathways
1.1.1 Cyclic nucleotides
The cyclic nucleotides, cyclic 3'5' adenosine monophosphate (cAMP) and cyclic 3'5'- 
guanosine monophosphate (cGMP) are intracellular second messengers involved in a 
myriad of cellular events including metabolism, cell growth and proliferation, gene 
regulation and vascular tone (Pellegrino & Wang 1997; Dousa 1999). cAMP was 
discovered in 1958 (Sutherland & Rail 1958) and the second messenger concept was 
proposed whereby binding of hormones or neurotransmitters, so called ‘first messengers’, 
to cell-surface receptors elicited a signal which is transduced via an intracellular mediator 
(second messenger) such as cAMP.
Adenylyl cyclase catalyses the synthesis of cAMP from ATP and cAMP- 
phosphodiesterases (PDE), which are the only entities able to degrade cAMP, hydrolyse 
cAMP to the inactive form, 5'AMP. The cognate synthesis and degradation of cGMP exists 
with guanylyl cyclase providing the synthetic activity of cGMP and cGMP-PDEs being 
responsible for the degradation and inactivation of cGMP.
The well-characterised target for cAMP action within a cell is the cAMP-dependant kinase, 
protein kinase A (PKA). Stimulation of PKA results in the phosphorylation of a number of 
downstream targets leading to alterations in gene expression and cellular processes (Cho- 
Chung et al., 1995; Shabb 2001). Similarly, cGMP mediates the majority of its effects 
through cGMP dependant protein kinase (Lohmann et ah, 1997). Mammalian cGMP 
kinase exists in two isoforms, cGMP kinase I and cGMP kinase II which show cell specific 
distribution and different regulatory roles (Ruth 1999).
1.1.1.1 G-Protein Coupled Receptors
Adenylyl cyclase can be activated directly by forskolin or indirectly through interaction 
with an activated G-protein coupled receptor (GPCR). These receptors are seven 
transmembrane spanning proteins that form an a-helix with an extracellular N-terminus, 
three extracellular loops, three intracellular loops and an intracellular C-terminal tail. The 
superfamily of GPCRs include receptors for many different ligands and are therefore able 
to respond to numerous extracellular stimuli including taste, light, odour, neurotransmitters 
and hormones. GPCRs are responsible for the transduction of these signals into 
intracellular second messengers able to carry the message inside cells, thus achieving the 
correct response. Upon ligand binding, the GPCR undergoes a conformational change
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allowing interaction and activation of a heterotrimeric guanine nucleotide binding protein 
(G-protein). This conformational change allows the exchange of GDP for GTP on the G- 
protein a-subunit which activates the G-protein and promotes the dissociation of the Ga- 
and Gpy- subunits of the G-protein. The dissociated subunits are then free to act upon their 
effector protein, e.g. adenylyl cyclase, in a positive or negative fashion. The cAMP 
signalling pathway is activated by one of the Ga,s isoforms and can be inhibited by the Ga. 
isoforms. Activation of adenylyl cyclase is sustained until the GTP bound to the Ga.s is 
hydrolysed to GDP and the G-protein subunits reassociate.
GPCR signalling is regulated by mechanisms at the level of the ligand, the receptor, the G- 
protein and at numerous stages in the signalling pathway. The earliest method of regulation 
is removal of the agonist from the extracellular fluid by transporters or through 
degradation. The receptor itself is regulated by feedback mechanisms initiated by 
activation (reviewed in Bohm et al., 1997, Ferguson 2001). This receptor desensitisation is 
caused by the uncoupling of the G-protein from the receptor in response and can occur 
within seconds of activation. The most immediate cause of desensitisation is 
phosphorylation of the receptor by intracellular serine/threonine kinases (GRKs), which 
phosphorylate the intracellular loop and C-terminal tail of the GPCR. The G- protein 
receptor kinases (GRKs) selectively phosphorylate agonist occupied receptors promoting 
the recruitment of cytosolic binding proteins known as arrestins, which sterically uncouple 
the receptor from the G-protein (reviewed in Luttrell & Lefkowitz 2002). Arrestin binding 
is also thought to aid receptor endocytosis. Second messenger dependant kinases such as 
PKA or PKC can phosphorylate various GPCRs including those without agonist bound, 
whereupon they also serve to inhibit the interaction between the G-protein and receptor.
A growing number of proteins have been identified (Bohm et al., 1997) that both bind 
GPCRs and couple GPCRs to G-protein independent signal transduction pathways or 
affect G-protein specificity and agonist selectivity. These include GRKs, arrestins and A- 
kinase anchoring proteins (AKAPS).
1.1.1.2 Adenylyl Cyclases
Adenylyl cyclases (ACs) are encoded by multiple genes and are transmembrane proteins. 
Nine different isoforms have been cloned to date which show tissue-specific expression 
and differential regulation. AC isoforms from all families are highly expressed in brain 
tissue, although individual isoforms show distinct patterns of localisation within the brain. 
AC isoform expression in tissues outside of the brain shows a highly specialised
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distribution pattern (Antoni et al., 2000, Hanoune & Defer 2001; summarised in table 
1.1). For example, AC2, 3, 5-8 are all expressed in rat pulmonary vascular tissue with 
AC2, 5 and 8 being of functional importance (Jourdan et al., 2001).
Each AC isoform consists of two hydrophobic domains composed of six tiansmembrane 
helices (Ml and M2) and two cytoplasmic domains (Cl and C2) which contain the 
catalytic core. Cl and C2 share homology between different isoforms whereas the helices 
do not (Hanoune et al., 1997, Houslay & Milligan 1997).
All AC isoforms are regulated by G-protein subunits with type-specific effects. Group 1 
isoforms (ACl, 3, 8) are stimulated by calcium and calmodulin. Group2 (AC2, 4, 7) are 
activated by Py subunit and protein kinase C (PKC) phosphorylation. Group 3 (AC5, 6) are 
inhibited by low concentrations of calcium and Group 4 (AC9) is insensitive to calcium or 
the Py subunit. All isoforms are activated by the Ga^ subunit of the G protein (reviewed in 
Hanoune & Defer 2001, Cooper 2003; for a summary of AC regulation, see table 1.2). 
Even within these general subclasses, the cyclases are so different to one another that they 
have other regulators that act upon each of them in a specific fashion. For example, 
Ca^Vcalmodulin can regulate AC in a positive (ACl and ACS) or negative (AC3, 5 and 6) 
manner. PKA phosphorylation has also been shown to reduce AC activity by direct 
phosphorylation (Iwami et al., 1995). PKA phosphorylation affects AC5 and AC6 and 
causes a ‘switching’ of receptor coupling from Gas to Gai which exerts an inhibitory effect 
on AC activity and reduces cAMP synthesis. The diterpene, forskolin, can directly activate 
all AC isofoims with the exception of AC9.
1.1.2 Cellular Targets of cAMP
The range of action of cAMP is extremely wide with effects reaching cell differentiation, 
ion channel conductivity and gene transcription amongst others. Targets of cAMP action 
are cyclic nucleotide gated channels (Kraus-Friedmann 2000) and the Rap-GEFs Epac I 
and Epac 2 (exchange protein dkectly activated by cAMP). The first identified target of 
cAMP within cells was the cAMP dependant protein kinase A, PKA.
1.1.2.1 Protein Kinase A
The classically Icnown target of cAMP within cells is the cAMP dependant kinase, PKA. 
PKA is a heterodimeric enzyme consisting of two regulatory (R) and two catalytic (C) 
subunits. cAMP binds to the R subunit of PKA inducing conformational changes that 
dissociate the enzyme into an R subunit dimer with four molecules of cAMP bound and
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two, free, active C subunits able to phosphorylate target serine/threonine residues 
(reviewed in Skalhegg & Tasken 2000, PKA targets reviewed in Shabb 2001).
There are two types of PKA which differ in their regulatory subunits, RI or RII, which 
interact with an identical C subunit. As with AC, PKA exists in several isoforms. Four 
isoforms of the R subunit have been identified; RIa, Rip, R lla and RIIp, with several 
splice variants of RIa reported. The RI isoforms share high homology with each other, are 
ubiquitously expressed and are activated transiently by low cAMP levels. The RII isoforms 
also share a high homology with each other, are predominantly expressed in brain, fat, 
endocrine and reproductive tissues and require persistent levels of high cAMP stimulation 
for activation (Feliciello et al., 2001). The C subunit also exists in multiple forms; Ca, Cp 
and Cy, with splice variants of both Ca and Cp reported (Uhler et al., 1986; Showers et al., 
1986). A large number of PKA holoenzymes therefore exist with different biochemical 
properties (Skalhegg & Tasken 2000). Indeed it is known that the PKAI complex (RIa%C2 
or RIP2C2) is generally cytoplasmic whereas the PKAII complex is usually membrane- 
associated (Cho-Chung et al., 1995, Houslay & Milligan 1997, Skalhegg & Tasken 2000; 
Murphy & Scott 1998). PKAII is associated to membranes through tethering of the R 
subunit to A-kinase anchoring proteins (AKAPs) which are found throughout the cell 
tethered to various subcellular components, thus providing localisation of the PKA 
activity. PKAII is also known to be subject to autophosphorylation by the C subunit 
(Skalhegg & Tasken 2000, Shabb 2001 ; reviewed in Michel & Scott 2002).
1.1.2.2 A-kinase anchoring proteins
PKAII exists associated with a variety of subcellular structures including the plasma 
membrane, endoplasmic reticulum, microtubules, Golgi and nucleus (summarised in 
Murphy & Scott 1998, Feliciello et al., 2001). This association exists through an 
interaction of PKARII with an anchoring protein tethered to the membrane. These AKAPs 
bind an N-terminal region of the RII protein, at its dimérisation (RII: RII) interface, and 
contain a unique targeting domain responsible for localising the AKAP/PKAII to a specific 
subcellular structure (Murphy & Scott 1998, Michel & Scott 2002). A new group of 
AKAPs has also been identified that can bind both RII and RI (Huang et al., 1997). This 
anchoring of PKA provides tight regulation of cAMP levels in specific cellular locations. 
In addition, some AKAPs also act as scaffolding proteins by associating with other kinases 
and phosphatases. This is true in the case of AKAP79 which scaffolds PKA, PKC and the 
calcium/calmodulin dependant phosphatase PP2B to regions near the plasma membrane 
(Dodge & Scott 2000).
1.12.3 Exchange Protein Directly Activated by cAMP
PKA-independent actions of cAMP involve an exchange protein that is directly activated 
by cAMP, Epac (de Rooij et al., 1998). Epacl and Epac2 are guanine exchange factors for 
the small Ras like proteins, Rapl and Rap2 (de Rooij et al., 2000). A third Epac family 
member, Repac, lacks the regulatory sequences of Epac 1 and 2 but is still able to activate 
Rapl and 2 (de Rooij et al., 2000). Epac contains a cAMP binding domain (Epac 2 has two 
cAMP binding domains (Rehrmann et al., 2002)), a Dishevelled, Egl-10, Pleckstrin (DEP) 
domain shown to be responsible for membrane targeting of Epac (de Rooij et al., 2000), a 
Ras-exchanger motif, a Ras-association domain and a guanine nucleotide exchange factor 
(GEE) domain (Bos 2003). Epac 1 is ubiquitously expressed and displays a cell-cycle 
dependant localisation. At interphase, Epacl has been shown to be located at both the 
mitochondria and nuclear membrane and translocates to the mitotic spindle and 
centrosomes during metaphase (Qiao et al., 2002). This translocation is not mediated by 
cAMP as Epac is membrane bound in the presence and absence of cAMP. Epac 2 is 
predominantly expressed in the brain and adrenal gland.
The catalytic domain of Epac is regulated by a direct interaction between the cAMP 
binding domain and the GEE domain which acts in an inhibitory fashion. Upon binding 
cAMP, this inhibition is released by a conformational change in the protein which exposes 
the GEE domain and allows Epac to activate downstream pathways (de Rooij et al., 2000, 
Rehrmann et al., 2003).
It has been demonstrated that cAMP activation of Rapl is through Epac, whereas the 
cAMP induced inhibition of Rafl is mediated by PKA (Enserink et al., 2002). Rafl 
activates MEK which in turn activates ERK. cAMP has been demonstrated to have both 
stimulatory and inhibitory effects on the ERK pathway, but it is thought this occurs 
through PKA activation of Rafl through Ras and the direct inhibitory effect of PKA on 
Rafl. As such, the roles of Rapl only in cell signalling have been attributed to Epac. Epac 
activation of Rapl plays a major role in cell adhesion by regulating integrin signalling 
(Rangarajan et al., 2003). Epac2 has also been reported to be involved in insulin secretion 
in p-cells (Holz 2004).
1.2 The Phosphodiesterase Superfamily
Hydrolysis of cyclic nucleotides is the only method of inactivation in cells. Cyclic 
nucleotide hydrolysis is mediated by a large superfamily of phosphodiesterase enzymes
7
(PDEs). PDEs catalyse the hydrolysis of cAMP and cGMP at their 3'-phosphoester bond 
to form the con-esponding inactive 5' nucleoside monophosphate (S' AMP and S' GMP). 
There are cmrently eleven known families of PDEs with differential tissue distiibution, 
regulatory properties and sensitivity to inhibitors (summarised in table 1.3; reviewed in 
Francis et al., 1999; Dousa 1999; Soderling & Beavo 2000; Yuasa et al., 2000; Conti 2000; 
Mehats et al., 2002; Maurice et al., 2003). Each PDE family is encoded for by one to four 
genes, with multiple protein products arising from alternative splicing and multiple 
promoters resulting in over SO mammalian PDE isoforms. Each isoform is expressed in a 
tissue and cell-specific manner.
All PDEs shaie the same modular structure, with three functional domains; a conserved 
catalytic domain of -270 amino acids near the C-terminus, regulatoiy regions located at 
the N-terminus and the C-terminus {Figure LI),  The catalytic domain contains sequences 
essential for cyclic nucleotide hydrolysis including the common PDE motif; HD(X2) H(X4) 
N which contains consensus metal binding domains (Zn^ "^  and Mg^ "*"). The N-termini of 
PDEs are highly divergent and are conserved within a family, showing the N-terminus 
contains each family’s specific functional motifs. Regions in this domain include 
regulatory sequences such as phosphorylation domains and targeting regions. It has also 
been proposed that the N-terminal region of a PDE contains regions for dimérisation.
PDE inhibitors have been reported as being clinically useful in many disorders (table 1.4 
for summary of diseases PDEs are involved in; Toiphy & Page 2000). These include 
disease states such as depression, asthma, pulmonaiy arterial hypertension (PAH) and 
erectile dysfunction. Family specific PDE inhibitors have shown promising results in 
clinical trials and as such, many are attractive targets for drug development (Schmidt et al., 
1999; Torphy 1998; Burnouf & Pruniax 2002; Spina 2003; Michelakis et al., 2003; 
Eddahibi et al., 1998).
1.2.1 The PDE1 Family
The PDEl family is encoded for by three genes; PDEIA, PDEIB and PDEIC with splice 
variants of each, and is known to hydrolyse both cAMP and cGMP (reviewed in 
Sonnenburg et al., 1998; Kakkar et al., 1999). PDEIA and IB isoforms have a higher 
affinity for cGMP than cAMP and PDEIC hydrolyses both with equal efficiency. PDEl is 
referred to as the calcium/calmodulin (Ca^’^ /CaM) PDE due to the presence of Ca '^ /^CaM 
binding sites within the PDEl N-terminal region. Activity of the PDEl family can be 
regulated by both Ca^‘*'/CaM binding and phosphorylation/dephosphorylation by PKA and
CaM-dependant kinase H. Activation of PDEl enzymes occurs upon Ca^TCaM binding 
and thus reduces cAMP. As PDEIA is inhibited by PKA phosphorylation, PDEl provides 
a “cross-talk” between calcium and cAMP. PDEIB is inhibited by CaM-dependant kinase 
II phosphorylation. Both types of phosphorylation reduce the affinity of PDEl for CaM. It 
has also been reported that protein kinase C can induce PDEIB. PDEIC has been 
demonstrated to be essential for human smooth muscle cell (SMC) proliferation (RybaUdn 
et al., 2002). PDEIC is absent from quiescent arterial SMC and human aorta, but is 
induced in proliferating arterial SMC. Inhibition of PDEl by vinpocetine reduces SMC 
proliferation (Rybalkin et al., 2002).
1.2.2 The PDE2 Family
The PDE2 family are known as the cGMP-stimulated PDEs and hydrolyse both cAMP and 
cGMP with similar Vmax, although the affinity for cGMP is two-fold greater. There are 
three PDE2 isoforms arising from one gene, each containing two specific, noncatalytic 
cGMP binding domains in their N-terminus. Binding of either cyclic nucleotide induces a 
conformational change in the PDE2 enzyme, converting it to a more active form. As such, 
PDE2 provides a means of crosstalk between the two cyclic nucleotide signalling 
pathways.
PDE2 is predominantly expressed in the adrenal cortex (PDE2A1) and brain and cardiac 
tissue (PDE2A2). PDE2A3 contains a putative membrane targeting domain. PDE2 activity 
has been shown to have a role in Ca^ "^  channel regulation, olfactory signalling pathways 
and aldosterone secretion. Low levels of PDE2 have been detected in vascular smooth 
muscle cells, and it has been reported that PDE2 activity is involved in hypoxic pulmonary 
vasoconstriction yet a distinct function has not yet been identified (Haynes et al., 1996). 
The commonly used inhibitor of PDE2 is eryr/rro-9-(2-hydroxyl-3-nonyl) adenine, EHNA 
(de Jong et al., 1992).
1.2.3 The PDE3 Family
The PDE3 family also hydrolyses both cAMP and cGMP with high affinity (Km values 
range from 0.1 to 0.8pM) but with a 2-10 fold higher Vmax for cAMP (reviewed in 
Degerman et al., 1997). cGMP in micromolar concentrations binds to the catalytic site of 
PDE3 and competes with cAMP hydiolysis, hence the PDE3 family being dubbed the 
cGMP-inhibited PDEs. As the Vmax for cGMP is so low, cGMP hydrolysis is negligible 
and PDE3 behaves as a cAMP-specific PDE. PDE3A and PDE3B are also activated by 
PKA or PKB phosphorylation.
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PDE3 is encoded for by two genes; PDE3A and PDE3B with a higher similarity of 
PDE3A between human and rat than between human PDE3A and B. This is also tine for 
PDE3B. Alternative start codons give rise to three PDE3A isoforms. PDE3 is widely 
expressed. In tissues expressing both PDE3A and PDE3B, PDE3A levels are usually 
dominant. PDE3A is abundant in the cardiovascular system, including vascular* smooth 
muscle, and PDE3B is found predominantly in adipose tissue, hepatocytes and the renal 
collecting duct epithelium. PDE3 is found in both cytosolic and particulate fractions of 
cells (Liu & Maurice et al., 1998; Palmer & Maurice 2000). PDE3 has been implicated in a 
variety of roles including myocardial contractility, smooth muscle relaxation and 
proliferation of T-lymphocytes and vascular smooth muscle cells. In addition, PDE3B 
plays a key role in insulin signalling in adipocytes. In response to insulin, PDE3B is 
phosphoiylated and activated by Akt (Kasuga et al., 1999).
In vascular smooth muscle cells, both PDE3A and PDE3B are expressed. Sustained 
exposure to cAMP elevating agents in vivo increased both PDE3A2 and PDE3B in rat 
aortic quiescent SMC (Tilley & Maurice 2002). In cultured rat and human aortic SMC, 
prolonged cAMP elevation increases only PDE3B (Palmer & Maurice 2000). The reasons 
behind this difference are unclear. PDE3 inhibitors such as cilostamide or milrinone have 
also been demonstrated to relax arterial tissues and inhibit vascular SMC proliferation 
(Lindgren et al., 1989; Inoue et al., 2000).
1.2.4 The PDE4 Family
The PDE4 family of enzymes are the most diverse and extensively studied of all PDE 
families (reviewed in Muller et al., 1996; Salanova et al., 1998; Houslay 2001; Houslay & 
Adams 2003; for further details, see section 1.3). Four genes encode for PDE4; PDE4A, 
PDE4B, PDE4C and PDE4D which ai'e located on three chromosomes. Alternative 
mRNA splicing and multiple promoters have led to the discovery of over 20 different 
PDE4 mammalian isozymes. PDE4 isoforms share 80% sequence identify of their catalytic 
domain with unique regions shared among PDE4 isoforms of a subfamily. Splice variants 
differ in their N-terminal region which confers regulatory properties and capability for 
interactions with other cell strirctures. PDE4 isoforms are characterised by the presence of 
two conserved domains within their N-terminus known as Upstream Conserved Region 1 
(UCRl) and Upstream Conserved Region 2 (UCR2). PDE4 isoforms can exist as a “long 
form” with both UCR 1 and UCR2 intact, a “short form” with only UCR2, and “super 
short forms” with a truncated UCR2 only {see figure 1.2). PDE4 is expressed in almost all
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cells, with the exception of blood platelets, and displays differential subcellular 
localisation between isoforms.
Regulation of PDE4 activity can occur through phosphorylation by PKA (Sette & Conti 
1996; Ekholm et al., 1997; Hoffmann et al., 1998; Liu & Maurice 1999; MacKenzie et al., 
2002) where PKA phosphorylation at Ser''^ of PDE4D3 and the equivalent residue in the 
UCRl of other long forms induces activation of these enzymes. This provides a feedback 
mechanism for regulating the levels of cAMP.
The p42 MAP kinase, ERK2 also phosphorylates PDE4 isoforms resulting in activation of 
short forms and inhibition of long forms (Hoffmann et ah, 1999; MacKenzie et ah, 2000). 
This is with exception of PDE4A members, which do not act as a substrate for ERK2 
(Baillie et ah, 2000).
PDE4 is a cAMP-specific enzyme, with a Km of l-3pM for cAMP. It is insensitive to 
cGMP and Ca^'^/CaM and is specifically inhibited by Rolipram and Ro 20-1724. PDE4 
inhibitors are of great interest due to the role PDE4 activity has been shown to play in 
disease states including asthma, chronic obstructive pulmonary disease (COPD) and 
depression (reviewed in Spina et ah, 1998, Spina 2003 and Burnouf & Pruniaux 2002).
1.2.5 The PDE5 Family
PDE5 enzymes are known as the cGMP binding, cGMP specific PDEs and are 
characterised by the presence of two cGMP binding domains located N-terminally to the 
catalytic unit. PDE5 is encoded for by a single gene that gives rise to four splice variants; 
PDE5A1, PDE5A2, PDE5A3 and PDE5A4, which have differential tissue distribution but 
share identical catalytic domains. PDE5 is expressed in several tissues including vascular 
smooth muscle cells, heart and lung (Loughney et ah, 1998; Giordano 2001).
Binding of cGMP to both PDE5 cGMP binding domains does not affect PDE5 activity, but 
does induce a conformational change that allows phosphorylation by PKG, the cGMP 
dependant kinase, and PKA at Ser^^ (Thomas et ah, 1990; Corbin & Frances 1999). 
Phosphorylation leads to an increase in PDE5 activity. PDE5 is also activated by Zn^ "^  ions 
which are essential for catalysis. Specific inhibitors for PDE5 include DMPPO; a 
compound currently under investigation in models of hypoxia induced pulmonary 
hypertension due to its vasodilatory properties (Eddahibi et ah, 1998); and Sildenafil, a 
treatment for male erectile dysfunction that has also been shown to reduce the hypoxic
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increase in pulmonary arterial pressure (PAP) in models of hypoxia induced pulmonaiy 
hypertension (Zhao et ah, 2001; Michelakis et ak, 2003). PDE5 levels and activity have 
been reported to increase in hypoxia induced models of pulmonary hypertension and the 
selective dilation of the pulmonary vasculature by Sildenafil provides a new target for 
treatment of pulmonary hypertension (Murray et al., 2002).
1.2.6 The PDE6 Family
The PDE6  family are expressed in retinal rods and cones and play a key role in the visual 
transduction cascade. Due to this, PDE6  are more often referred to as the photoreceptor 
PDE family. PDE6  is highly specific for cGMP and is the only known family of PDE to be 
regulated by G-proteins. They exist as hetero- or homotetramers comprised of catalytic 
subunits (a, a', P) and inhibitory subunits (y and 5). The two types of photoreceptor cells, 
rod and cone, express different forms of PDEy. The visual cascade is initiated by photons 
that interact with rhodopsin, resulting in the activation of the G-protein transducin (TaPy). 
Active transducin (Ta-GTP) dissociates from TPy and binds to the inhibitory y subunits of 
membrane bound PDE6 . This relieves inhibition of PDE6  and decreases cGMP, closing the 
cGMP-gated channel and resulting in hyperpolarisation of the membrane.
Rod PDEy is also expressed in lung, kidney, heart, pulmonary smooth muscle and airways. 
In these systems. Rod PDEy is phosphorylated by the G-protein receptor kinase (GRK) 2 
which regulates the epidermal growth factor (EGF) stimulation of ERKl/2 in human 
embryonic kidney 293 cells (HEK 293; Wan et al, 2001) This regulation also involves the 
Src kinase which exists in a complex with PDEy and upon stimulation with EGF, GRK2 
associates with this complex. Src irrhibitors block activation of ERKl/2 by EGF as does 
mutation of the Thr^  ^residue of PDEy (Wan et al., 2003).
1.2.7 The PDE7Family
The PDE7 family are high affinity cAMP PDEs, similar to that of PDE4, but are rolipram 
insensitive (Michaeli et al., 1993). The PDE7 family are comprised of two genes and three 
individual PDE7 isoforms have been identified, PDE7A1, PDE7A2 and PDE7B1. 
PDE7A1 is expressed in the immune system, PDE7A2 is highly expressed in skeletal 
muscle and heart and PDE7B is abundant in the pancreas, brain, heart and skeletal muscle 
(Hetman et al., 1999). PDE7A was initially suggested to play a role in T-cell activation and 
proliferation (Li et al., 1999), however studies using PDE7 knockout mice have disproved 
this (Yang et al., 2003). Recently, it has been discovered that PDE7 activity can be 
inhibited by spiroquinazolrnones (Lorthiois et al., 2004; Bemardelli et al., 2004).
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1.2.8 The PDES Family
The PDE8  family are cAMP specific with an affinity for cAMP to rival that of PDE4 and 
were discovered screening a database of ESTs (expressed sequence tags) to identify PDE 
ESTs (Soderling et ah, 1998; Soderling & Beavo 2000; Hayashi et al., 2002). Two variants 
of PDE8  exist, PDE8 A and PDE8 B. PDE8 A is highly expressed in testis, eye, liver, 
kidney, skeletal muscle, embryo, ovary and brain (Soderling et al., 1998). PDE8 B is 
expressed highest in the human thyroid gland, brain and kidney.
PDE8  is unique in that it contains a single PAS domain (Per, Amt, and Sim proteins)at the 
N-terminus which regulates proteimprotein interactions. Specific functions for the PDE8  
isoforms remain to be discovered. PDE8  is, unusually, insensitive to inhibition by the so- 
called general PDE inhibitor, 3-Isobutyl-1 -methylxanthine, (IBMX).
1.2.9 The PDE9 Family
PDE9 is a cGMP specific PDE expressed in many tissues including spleen, small intestine, 
kidney, heart and brain tissue (Fisher et al., 1998). Unlike other cGMP PDEs, PDE9 lacks 
a non catalytic cGMP binding domain. Four variants of PDE9 have been identified but 
their function is as yet unclear. The only compounds known to date to inhibit PDE9 are the 
PDE5 and PDEl inhibiting compounds, zaprinast and SCH518866 (Dousa, 1999).
1.2.10 The PDE10 Family
PDE 10 is a dual substrate family with of 0.05pM for cAMP and 3pM for cGMP. The 
Vmax for cGMP hydrolysis is approximately five times greater than that for cAMP. This 
suggests cGMP hydrolysis by PDE 10 can be inhibited by cAMP, therefore PDEIO has 
been referred to as the cAMP-inhibited, cGMP specific PDE (Soderling et al., 1999; 
Fujishige et al., 1999). Two splice variants of PDEIO have been identified with PDElOAl 
and PDE10A2 containing two N-terminally located domains that are similar to the cGMP 
binding domains of PDE2, PDE5 and PDE6 . Unlike the other cGMP specific PDEs 
however, the cGMP binding domains in PDEIO are not thought to primarily function as 
such. PDEIO is sensitive to inhibition by IB MX (Soderling & Beavo 2000).
1.2.11The PDE11 Family
The PDEl 1 family also catalyse the hydrolysis of both cAMP and cGMP and contain a 
GAF (so named for cGMP binding and stimulated phosphodiesterase, Anabaena adenylyl 
cyclases, and Escherichia coli FhlA) domain at their N-terminus, relating them to the 
other GAF containing PDEs, PDE2, 5, 6  and 10. There have been four isoforms of PDEl 1 
identified to date (Yuasa et al., 2000) with each containing variations of the GAF domain.
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PDEl 1 Al, PDE11A2 and PDEl 1 A3 contain one intact GAF domain and one 
incomplete GAF domain. PDEl 1 A4 contains two complete GAF domains (Yuasa et al.,
2001). PDEll isoforms also display differential tissue expression with PDEl 1 A3 being 
specifically expressed in testis and PDEll A4 are predominantly expressed in the prostate. 
PDEllA l is abundant in skeletal muscle (Yuasa et al., 2001). No physical functions have 
been related to any of the PDEl 1 isoforms as yet.
1.3 Organisation and Regulation of the PDE 4 Family
The Drosophila melanogaster dunce gene was the first gene to be discovered that 
specifically affected behaviour. Mutations in the dunce gene led to defects in learning and 
memoiy (Davis & Dauwalder 1991). The mammalian PDE4 family are homologues of the 
dunce gene. Cloning of the dunce PDE led to discoveries surrounding the regulation and 
kinetics of cAMP PDEs and the subsequent cloning of mammalian PDE4 genes. Four 
mammalian PDE4 genes were discovered located on three chromosomes with a high 
conservation between species. These foui’ genes each give rise to multiple splice variants 
with unique N-terminals that are all characterised by their ability to be specifically 
inhibited by rolipram.
1.3.1 Modular structure of PDE4
The PDE4 family are further characterised by the presence of upstream conserved regions 
known as UCRl and UCR2 at their N-teiminus. The region that links UCRl and UCR2 
together is called linker region 1 (LRl), and linker region 2 (LR2) connects UCR2 to the 
catalytic domain (see figure 1.2). In contrast to UCRl and UCR2, the linker regions differ 
between the different PDE4 families, perhaps conferring isoform-specific functional 
properties. The alternative mRNA splicing of members of the PDE4 family occurs at two 
major splice sites, one at the extreme N-termini and the other at the beginning of UCR2. 
This means both “long” isoforms containing both UCRl and UCR2 and “short” isoforms 
with only UCR2 are produced. An additional splice site also generates “super-short” 
isoforms which have an N-terminally truncated UCR2. UCRl and UCR2 have no 
homology to one another, yet aie conserved in PDE4 homologs, suggesting they are of 
functional importance.
Studies have revealed that the C-terminal of UCRl interacts specifically with the N- 
terminal of UCR2 (Beard et al., 2000; Lim et al., 1999; MacKenzie et al., 2000). PKA 
phosphorylation is known to affect this interaction, but some investigators suggest it
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strengthens the interaction (Lim et al., 1999), whilst others have shown that it can 
weaken it (Beard et al. 2000). UCR2 has also been shown to act as a regulatory domain on 
the catalytic region (Beard et al., 2000; Lim et al., 1999). N-terminally truncated PDE4, 
with the N-terminus of UCR2 removed, causes an increase in PDE4 activity indicating the 
role of the UCR2 as an inhibitory domain on the catalytic unit of PDE4. This has been 
demonstrated to be the case with the PDE4D and PDE4A5 isoforms (Lim et al., 1999; 
Beard 2002). UCR2 has also been implicated in the targeting of PDE4 isoforms.
1.3.2 Regulation of PDE4 activity
The PDE4 family is regulated through the actions of protein kinases. Long forms of PDE4 
contain two PKA phosphorylation sites. In PDE4D3, these are Ser^^ and Ser '^ .^ Ser'^ is 
located at the unique N-terminal of the isoform and Ser^ "^  is located within UCRl. PKA 
phosphorylation elicits activation of the PDE4 enzyme (Alvarez et al., 1995; Sette & Conti 
1997; Hoffmann et al., 1998; Beard et al., 2000; Oki et al., 2000). Only the Ser '^  ^ residue 
has been shown to be essential for activation by PKA phosphorylation in the PDE4D3 
isoform by mutation of Ser^ "^  to Ala^ "^  (Sette & Conti 1996). Replacing Ser '^  ^with Asp^ "^  or 
Glu^'^can mimic enzyme activation (Hoffmann et al., 1998). The PKA consensus sequence, 
RRESF, is also found within the UCRl region of other PDE4 long forms, suggesting all 
can be activated by PKA phosphorylation. Other work has shown that this is the case for 
PDE4A8, PDE4B1, PDE4C2 and PDE4D5 as well as PDE4D3 (MacKenzie et al., 2002). 
PKA phosphorylation induces a conformational change in the PDE4 enzyme which 
increases the affinity of UCRl for UCR2. This relieves the auto-inhibitory actions of 
UCR2 on the catalytic domain and allows PDE4 to bind cAMP (Lim et al., 1999). 
Although PKA does phosphorylate Ser*^ in PDE4D3 unlike other PDE4 long forms, the 
functional consequences of this are still unclear (MacKenzie et al., 2002).
The extracellular kinase (p42), ERK2 is activated by dual phosphorylation (Prowse & Lew
2001) and phosphorylates the long form PDE4D3 at Ser^^^. This leads to a reversible 75% 
reduction in PDE4D3 enzyme activity (Hoffmann et al., 1999). More recent work has 
revealed that although isoforms encoded by the PDE4A, 4B, 4C and 4D genes all contain 
the ERK2 docking sites, KIM and FQF, (MacKenzie et al., 2000), only PDE4B, 4C and 4D 
act as substrates for ERK2 (Baillie et al. 2000). ERK2 phosphorylation of PDE4 long 
forms is transient, as it causes a localised increase in cAMP and thus activation of PKA. 
PKA phosphorylation can negate the ERK2 inhibition of PDE4 long forms, (Baillie et al., 
2000; Hoffmann et al., 1999) introducing feedback regulation. Studies have revealed that 
whereas ERK2 phosphorylation of PDE4 long forms causes inhibition of enzyme
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activation, ERK2 phosphorylation of PDE4 short forms surprisingly induces activation 
(Baillie et al., 2000). Thus there are opposing effects on ERK by cAMP. Inhibition of ERK 
is achieved through the Raf-1 isoform whereas ERK activation by cAMP is achieved 
through the B-Raf isoform. The cAMP signalling pathway is subject to many points of 
“cross-talk” between itself and the ERK pathway (Houslay & Kolch 2000). In human 
aortic smooth muscle cells, ERK stimulation feeds into an autocrine loop that results in 
activation of a PDE4 long form (Baillie et al., 2001, figure 1.3). Activated ERK caused an 
increase in PGE2 which was released from the cell and activated adenylyl cyclase. This 
indueed a rise in cAMP levels with a concomitant increase in PKA activity and resultant 
PDE4D5 phosphorylation. This phosphorylation ablated the effect of ERK phosphorylation 
and a net activation of PDE4D5 was observed.
1.3.3 The PDB4A subfamily
The PDE4A gene is located at chrl9pl3.1 and gives rise to seven different isoforms 
(Houslay et al., 1995; reviewed in Houslay 2001). It was originally thought that the 
inactivation of cyclic nucleotides was the only function of phosphodiesterases, but research 
suggests PDEs also play a role in signal compartmentalisation. The ‘super-short’ PDE4A 
isoform, PDE4A1, (also known as RDI), is exclusively membrane-associated, a feature 
unique among the PDE4 isoforms. It was initially revealed that the first twenty-five 
residues of the N-terminus of PDE4A1 are essential in membrane targeting (Pooley et al., 
1997; Houslay et al., 1995; Houslay et al., 1998). N-terminally truncated isoforms were 
found solely in the cytosol. Further work revealed that PDE4A1 was specifically targeted 
towards the Golgi complex in FTC cell lines (Pooley et al., 1997). Displacing PDE4A1 
from the membrane requires non-ionic detergents indicating that the binding involved 
hydrophobic interactions. Investigation by Baillie et al., 2002 revealed that PDE4A1 is 
inserted into the membrane in a manner due solely to an 1 1 -residue helical module within 
the N-terminus that also confers selectivity for interaction with phosphatidic acid (PA). 
Interaction with PA has previously been shown to alter PDE4 activity. The module 
identified has been named the tryptophan anchoring phosphatidic acid selective binding 
domain 1, (TAPAS-1). Insertion is Ca^’*' dependant and irreversible.
The human PDE4A4B, initially known as pde46, is a homologue of the rat PDE4A5 and is 
a ‘long form’ PDE. PDE4A4B selectively binds SH3 domains e.g. of Src family kinases 
and this binding alters PDE4A4B sensitivity to rolipram through a conformational change 
in the catalytic unit (McPhee et al., 1999; MacKenzie & Houslay 2000). The SH3 binding 
domains located in the N-terminus and UCR2 region also act to target the PDE4A4B/4A5
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isoform to the plasma membrane where it localises in membrane ruffles (Beard et al.,
2002). Perinuclear localisation of PDE4A4B/4A5 has been attributed to the N-terminal of 
UCR2. During apoptosis in Rat-1 fibroblasts and PC 12 cells, die SH3 domain is cleaved by 
caspase 3. PDE4A4B/4A5 loses its targeting ability and is found uniformly throughout the 
cell (Huston et al., 2000). Binding of rolipram to PDE4A4/4A5 also affects intiacellular 
distribution, inducing foci formation (Terry et al., 2003). Another ‘long form’ PDE4A, rat 
PDE4A8 (also known as rpde39), does not have a human homologue and has been shown 
to be exclusively expressed in the testes and hepatocytes (Bolger et al., 1996). PDE4A7 is 
a catalytically inactive isoform which is N- and C-terminally truncated (Johnston et al., 
2004). The inactivity of 4A7 is not through inhibitory actions of the N- or C-terminal 
domains as removal of either of these does not allow PDE4A7 to hydrolyse cAMP. The 
PDE4A10 isoform was originally cloned from a rat olfactory lobe cDNA library (Rena et 
al., 2001). PDE4A10 is another PDE4A ‘long form’ which migrates at approximately the 
same size as PDE4A4 and the newly characterised, PDE4A11 (Tm3) on SDS-PAGE 
(~121kDa) PDE4A10 is conserved between human, mouse and rat and displays a 
predominantly perinuclear localisation in COS7 cells (Rena et al., 2001).
1.3.4 The PDE4B subfamily
The human PDE4B gene is located at chrl and it provides four PDE4B isoforms. PDE4B2 
is a short form PDE, subject to activation by ERK2, and PDE4B1, 4B3 and 4B4 are all 
long forms (reviewed in Houslay 2001). All PDE4Bs are found in both particulate and 
cytosolic fractions of cells. It is well established that PDE4 is the predominant PDE in 
leukocytes and has been attributed with a role in inflammation as it is involved in the 
activation and proliferation of inflammatory cells (Banner et al., 1999; Banner et al., 2000; 
Ogawa et al., 2000). In addition, PDE4 inhibitors significantly reduce TNF-a and IL-j3 
release from EPS-stimulated macrophages (Kambayashi et al., 1995, Timmer et al., 2002). 
PDE4B has been singled out in inflammation as it is the predominant PDE4 in neutrophils 
and monocytes. In particular, the PDE4B2 isoform is the sole PDE4B variant expressed in 
these cells and is induced by lipopolysaccharide (EPS) in a manner inhibited by interleukin 
(IL)-IO and IL-14 (Wang et al., 1999).
Induction of PDE4B2 has also been observed in cells exposed to IE-Ip (Oger et al., 2002) 
or a combination of IL-lp and TNF-a (Hakonarson et al., 2001). The increase in PDE4B2 
has been reported to be due to the raised cAMP levels in response to IL-ip treatment. 
Exposing myométrial cells to IL-ip raised PGE% prior to induction of PDE4B2 and this 
induced an increase in PDE4 activity. IL-ip caused an initial increase in cAMP levels,
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peaking at twelve hours, before PDE4 activity increased to a peak at eighteen hours and 
cAMP levels were reduced. The non-specific inhibitor of PGE2 synthesis, indomethacin, 
was observed to completely block the rise in cAMP and the increased PDE4 activity (Oger 
et al., 2002). PDE4B2 induction in myométrial cells has also been observed directly in 
response to cAMP raising agents (Mehats et al., 1999) or naturally in near pregnant and 
pregnant myometiium (Mehats et al., 2000). PDE4B2 has also been implicated in the 
contraction of myométrial strips as PDE4 inhibitors can block spontaneous myométrial 
contraction (Mehats et al., 2002).
1.3.5 The PDE4C subfamily
The PDE4C gene is located at chrl9p 13.2 and is reported to give rise to three long forms 
of PDE4C (Obernolte et al., 1997). There is little research on the PDE4C subfamily, 
although it is known that the PDE4C2 isoform is subject to regulation by ERK2 
phosphorylation. Upon ERK2 phosphorylation at Ser^ ^^ , activity of PDE4C is inhibited 
(Baillie et al, 2000).
1.3.6 The PDE4D subfamily
The PDE4D gene is located at chromosome 5 and through two major and one minor splice 
points (see figure 1.2), nine splice variants have been reported so far (Bolger et al, 1997; 
Wang et al, 2003; Gretarsdottir et al, 2003), Only one of these is a short form, PDE4D1 
with a weight of 6 8  kDa. The super-short form PDE4D2 has an N-terminal truncation and 
is the same weight as PDE4D1. PDE4D6 is also another super short form with a predicted 
weight of 59kDa. PDE4D3, PDE4D4, PD4D5, PDE4D7, PDE4D8 and PDE4D9 are all 
long form PDE4Ds with weights of 95, 119, 105, 103, 96 and 95kDa respectively (weights 
of PDE7, 8  and 9 are predicted). The similarity in sizes on SDS-PAGE of PDE4D1 with 
PDE4D2; PDE4D3 with PDE4D8, 9; PDE4D5 with PDE4D7 and indeed PDE4A4 with 
PDE4A10 and PDE4A11 highlights the necessity of correct identification of PDE4 
isoforms by means other than SDS-PAGE.
The function of PDE4D has been investigated in knock-out mice models. Studies on 
PDE4D'^‘ mice have shown that PDE4D plays a major role in growth and contraction. 
These transgenic mice display a lower than normal weight due to a reduction in muscle and 
bone mass and decreased weight of internal organs (Jin et al, 1999). The airways of mice 
deficient in PDE4D are also refractory to muscarinic cholinergic stimulation (Hansen et al,
2000). Further studies revealed this was due to a five-fold increase in sensitivity to 
prostanoid stimulation and an enhanced cAMP synthesis. The tracheal response to the 
contractile agonist carbachol was reduced in transgenic mice and could be mimicked by
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treating wild-type mice with rolipram. Inactivation of PDE4B had no effect on tracheal 
contraction. The PDE4D’^ ' phenotype could be reversed by indomethacin (Mehats et al.,
2003).
1.3.6.1 Interactions and Targeting of the PDE4D subfamily
In COS7 cells, PDE4D1 and 4D2 were found solely in the cytosol while PDE4D3, 4D4 
and 4D5 were located in both the cytosolic and particulate fractions (Bolger et al. 1997). 
This confirms the involvement of the unique N-terminal in targeting as both 4D1 and 4D2 
are short forms and therefore do not possess it. Translocation of the 4D3 isoform from the 
particulate fraction of cells to the soluble fraction has been seen in vascular smooth muscle 
cells upon stimulation of both the ERK and PKA pathways (Liu & Maurice 1999).
Temporal compai'tmentalisation of the PDE signal has been shown in FRTL-5 cells (Jin et 
al. 1998). Upon stimulation with thyroid stimulating hormone (TSH), PDE4D long forms 
were activated at membranous structures almost immediately while 4D2 was activated in 
the cytosol after a period of time. PDE4D long forms ai*e targeted towards the 
Golgi/centrosome and filamentous stmctures within these cells.
In addition to PKA and ERK phosphorylation, PDE4D3 is also subject to regulation by 
PA. Accumulation of endogenous PA, through inhibiting the actions of PA degraders, 
induced an increase in PDE4 activity with a resultant decrease in cAMP and PKA activity 
(Nemoz et al., 1997). In FRTL5 cells, PDE4D3 was demonstrated to specifically bind PA 
in a unique binding site in the N-terminal region which contains the PKA phosphorylation 
site (Grange et al., 2000).
As with PDE4A4B/4A5, PDE4D4 has also been shown to contain an SH3 domain that 
predisposes PDE4D4 to bind selective SH3 domain proteins (Beaid et al., 1999). Binding 
of Src or Lyn SH3 domains are prevalent, with no detectable effect on the catalytic activity 
of PDE4D. It is postulated that this interaction is involved in targeting of the PDE4D 
isoform.
PDE4D5 specifically has been demonstrated to interact with the receptor for activated 
kinase (RACKl). This interaction does not affect activity of the enzyme, but does affect 
sensitivity to rolipram (Yarwood et al., 1999). No physiological role for this interaction has 
yet been uncovered.
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It has been recently shown that all PDE4 isoforms can interact with the scaffolding 
proteins, p-Arrestinl/2. Indeed, it has been demonstrated that PDE4D3 and PDE4D5 are 
targeted to activated GPCR along with P-Arrestin, aiding the localised degradation of 
cAMP (Perry et ah, 2002) and receptor desensitisation. The interaction of PDE4 and p- 
Arrestin is also involved in the “switching” of GPCR from the Gs subunit to the G; subunit 
of the G-protein. This occurs upon PKA phosphorylation of the receptor and leads to ERK 
activation within the cell. By using a catalytically inactive mutant of PDE4D5 which 
displaces active PDE4D5 from P-Arrestin, it was demonstrated that with inactive PDE4D, 
p2 -adrenoceptor can induce higher levels of PKA and increase the levels of receptor 
activated ERK (Baillie et al., 2003). PDE4 thus plays a key role in Pz-adrenoceptor 
regulation.
The scaffold protein myomegalin was identified as an interacting protein for PDE4D 
through yeast two hybrid analyses using PDE4D3 as bait (Verde et al., 2001). This 
interaction was demonstrated to localise PDE4D3 to Golgi/centrosomal areas and occurs 
through the N-terminus of UCR2 in PDE4D (Verde et al., 2001). As UCR2 is conserved in 
PDE4 long forms, it is possible that other PDE4 isoforms also interact with myomegalin. 
The UCR2 of PDE4D3 has also been shown to interact with AKAP450, targeting PDE4D3 
to the centrosomal region in Sertoli cells (Tasken et al., 2001). UCR2 is not the only 
putative targeting mechanism of PDE4. As each isoform differs only at their N-terminus 
and LR, it was proposed that these regions conferred isoform-specific targeting. Indeed, it 
has been demonstrated that the muscle-selective AKAP, mAKAP, interacts with the unique 
N-terminus of PDE4D3 and not PDE4D5, targeting it to perinuclear regions in cardiac 
cells (Dodge et al., 2001).
1.3.6.2 Induction of PDE4D by cAMP
Intronic promoters have been identified controlling the expression of the PDE4D1 and 
PDE4D2 isoforms. Within these promoters, cAMP response elements (CRE) have been 
identified that allow cAMP response element binding protein (CREB; reviewed in 
Montminy 1997; Shaywitz & Greenberg 1999; Mayr & Montminy 2001) to bind and 
induce expression. This was demonstrated to be the case in Sertoli cells, where raising 
cAMP levels upregulated the expression of PDB4D1 and PDE4D2 (Vicini & Conti 1997). 
A CRE site has also been uncovered in the PDE4D5 promoter and cAMP-dependant 
induction of PDE4D5 has been observed in human airway smooth muscle cells (Le Jeune 
et al., 2 0 0 2 ).
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1,4 PDE4 Inhibitors and Disease
It has long been known than an increase in cAMP levels can suppress the immune response 
and induce smooth muscle cell relaxation (Schudt et a l, 1999; Torphy 1998; Torphy et al., 
1999; Wong & Koh 2000; Essayan 2001). Studies revealed that the PDE4 family is 
responsible for the majority of cAMP hydrolysis in immune and inflammatory cells as well 
as pulmonary and airway smooth muscle cells.
For these reasons, there has been interest in the development of PDE4 inhibitors for use in 
such diseases as asthma and chronic obstructive pulmonary disorder, (COPD; Spina et al., 
1998; Landells et al., 2001; Spina 2003; Grootendorst et al., 2003; PDE4 inhibitors 
reviewed in Burnouf & Pruniaux 2002). Indeed, theophylline, a non-specific PDE 
inhibitor, has been used in the treatment of asthma for over 70 years. Unfortunately, non­
specific PDE inhibitors exhibit emetic properties due to raising cAMP levels in the emetic 
centres within the central nervous system. For this reason, PDE4 isozyme specific 
inhibitors are being developed and tested. These inhibitors demonstrated that PDE4A/4B 
inhibitors inhibited TNFa release from monocytes and attenuated the proliferation of T 
lymphocytes while PDE4D inhibitors had no effect on these responses (Manning et a l,
1999). PDE4C is absent in cells involved in the immune response. Other disease states for 
which PDE4 inhibitors have been considered include depression, rheumatoid arthritis, 
eczema and multiple sclerosis (Doherty 1999; Essayan 1999; Houslay et a l, 1998; Schmidt 
et al. 1999; Schudt et al. 1999; Souness & Rao 1997; Torphy 1998; Torphy et a l, 1999; 
Wong & Koh 2000). A new PDE4 inhibitor-cilomilast, is in development as a treatment for 
COPD and asthma (Giembycz 2001).
Recent research has implicated PDE4D7 and PDE4D9 isoforms in ischemic stroke 
(Gretarsdottir et a l, 2003). A decreased level of PDE4D7 and PDE4D9 was observed in 
EBV transformed B-cell lines from affected patients which correlated to an increased risk 
for the disease. The authors proposed that PDE4D is involved in atherosclerosis underlying 
ischemic stroke due to the previous research on PDE4 inhibitors. In vascular smooth 
muscle cells, PDE4 inhibitors have been demonstrated to significantly potentiate the 
antimigratory effects of forskolin (Palmer et a l, 1998; Goncharova et a l, 2003) and 
attenuate proliferation (Pan et a l, 1994; Johnson-Mills et a l , 1998). PDE3 and PDE4 
inhibitors used together act synergistically to dramatically reduce proliferation (Pan et a l, 
1994; Johnson-Mills et a l, 1998).
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1.4.1 Relaxant effects of PDE4 inhibitors
It is well known that raising cAMP levels in vascular smooth muscle cells initiates 
relaxation (Muixay 1990), an effect also seen with PDE inhibition. Studies have indicated 
that PDE4 and PDE3 inhibition exert the most potent relaxant effect. Indeed, in human 
intralobar pulmonary arteries, all PDE inhibitors tested induced a concentration dependant 
relaxation of which rolipram produced the most potent (Bardou et al., 2002). Other studies 
have confirmed the relaxant effect of PDE4 inhibitors, and the synergistic effect when used 
together with PDE3 inhibitors (Wagner et al., 1997; Eckly-Michel et al., 1997; Goirand et 
al., 2001; Pauvert et al., 2002). PDE4 inhibitors also potentiate the effect of cAMP 
elevating agents in rat aortic smooth muscle cell (Tilley & Maurice 2002). The 
vasorelaxant effect of PDE4 inhibitors has been demonstrated to require a functional 
endothelium present (Komas et al., 1991).
The vasorelaxant properties of PDE3 and PDE4 inhibitors are of considerable interest to 
reseai'chers regarding therapies for cardiovascular disease. In contrast with the systemic 
circulation, the pulmonary circulation contracts in response to hypoxia. Chronic hypoxia is 
associated witli several pulmonary diseases such as COPD and can be caused by vascular 
injuries, thrombosis and ischemic cardiovascular disease. Sustained chronic hypoxia leads 
to the development of pulmonary arterial hypertension (PAH, see section 1.5 for further 
details). The pulmonaiy vasoconstriction witnessed in hypoxia can be opposed by the use 
of PDE4 and PDE3 inhibitors (Pauvert et al., 2002; Goirand et al., 2001). In PAH, 
pulmonary artery relaxation is significantly attenuated in response to vasodilators. Studies 
investigating the responses of isolated pulmonary artery rings to agonists that induce 
relaxation in rat models of PAH, have demonstrated that PDE4 and PDE3 inhibitors can 
improve the response to vasodilators in the PAH rat (Wagner et al., 1997).
1.5 Pulmonary Arterial Hypertension
Pulmonary hypertension (PH) was previously grouped into two categories; primary 
pulmonary hypertension (PPH) or secondary pulmonaiy hypertension. Classification of 
the disease depended on the absence or presence of identifiable causes or risk factors. In 
2003, this classification was revised to take into account the identification of genetic 
factors and is now grouped into three categories, idiopathic PAH, familial PAH and PAH 
related to risk factors or associated conditions (see figure lA fo r  ‘Venice classification ’).
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Pulmonary arterial hypertension is a progressive and usually fatal disorder characterized 
by a maintained increase of pulmonary arterial pressure (PAP) caused by occlusion of the 
small pulmonary arteries (reviewed in Humbert et al., 2004). When the mean PAP exceeds 
25mmHg at rest and 30mmHg during exercise, this is diagnosed as PAH. Idiopathic and 
familial PAH is an uncommon disorder with an estimated occurrence of 1-2 cases per 
million people and is more commonly seen in females of 20-40 years of age. The 
symptoms of PAH are extremely variable and the age of onset differs dramatically between 
individuals. This generally leads to the disease being diagnosed in its latter stages. The 
variable age of onset and reduced penetrance of the disease also indicates environmental 
factors play a role in the development of PAH. Current treatment strategies include 
prostanoids such as beraprost, (Badesch et al., 2004), nitric oxide, endothelin receptor 
antagonists like bosentan (Channick et al., 2004; see section 1.5.5.1 for further details), 
vasodilators and in extreme cases, lung transplantation. PDE inhibitors are also included in 
the list of emerging therapies for pulmonary hypertension (Ghofrani et al., 2004).
In 1999, candidate gene mapping revealed a gene locus linked to familial PPH on 
chromosome 2q33 (Deng et al., 2000). Through further studies on this locus, known as 
PPHl, it has been indicated that mutations within a gene at this locus causes familial PPH 
(The International PPH Consortium, 2000; Machado et al., 2001). This gene is the bone 
morphogenetic protein type II receptor (BMPR-II). Germline mutations in BMPR2 are also 
found within at least 26% cases of sporadic PAH (Thomson et al., 2000; Machado et al.,
2001). To date, 46 unique mutations within the BMPR2 gene have been identified in cases 
of PAH (Machado et al., 2001). The mutations are dispersed throughout the gene except 
for in three of the thirteen exons, 5, 10 and 13. The nature of the mutations range from 
frameshift to nonsense mutations, resulting in truncated transcripts and variable nucleotide 
changes. It has been suggested that the inheritance mechanism of PPH is 
haploinsufficiency (Machado et al., 2001). This would indicate the pathway mediated 
through BMPR-II to be of critical importance in maintenance and repair of the pulmonary 
vasculature. BMPR2 encodes the transforming growth factor-13 (TGF-(3) type II receptor 
BMPR-II which is expressed in the endothelium and smooth muscle cells of the pulmonary 
and systemic vasculature.
Hypoxia-induced pulmonary hypertension is aggravated by the increased amount of 5-HT 
delivered to the lung in rats and this can be blocked with a 5-HT antagonist (Eddahibi et 
al., 1997). This occurs through a hypoxia-induced increase in 5-HT transporter (5-HTT)
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levels (Eddahibi et al., 1999). A study of patients with PAH revealed a link between the 
variant of 5-HTT expressed and susceptibility to PAH (Eddahibi et al., 2003).
PAH occurs more commonly as a consequence of serious disorders such as COPD, HIV 
infection or left ventricular failure. Additionally, secondary PAH can develop due to the 
use of appetite suppressants such as fenfluramine or aminorex phentermine and in response 
to sustained hypoxia caused by cardiovascular disease, vascular injury or due to high 
altitude. The prevalence of secondary PAH is difficult to estimate due to the large number 
of causes overlapping with symptoms of more common disease states preventing a clear 
diagnosis.
The most frequent initial stimuli of PAH are mechanical obstruction to pulmonary flow 
and hypoxia. Acute hypoxia causes a reversible PAP increase whereas chronic exposure to 
hypoxia induces alterations in the small pulmonary vessels and renders the resultant 
increase in PAP irreversible.
1.5.1 Models used in research of PAH
The most common animal model of PAH is the chronic hypoxic rat (Rabinovitch et al., 
1979). Male Wistar rats are exposed to low oxygen ( 1 0 %O2) by reducing the atmospheric 
pressure in a hypobaric chamber. A rise in PAP is observed after three days of hypoxia as 
well as right ventricular hypertrophy. After two weeks in hypoxia, hypertrophy of the 
pulmonary artery occurs (Vender 1994). A more recently utilised rat model is the Fawn 
hooded rat. The fawn hooded rats are used for their inherited sensitivity to the development 
of idiopathic PAH (Stelzner et al., 1992). Recently, other transgenic mice have provided 
valuable new models for study. For example, mice expressing a dominant-negative form of 
the BMPRII gene, dnBMPRII mice, display elevated PAP and pulmonary arterial 
muscLilarisation when the mutation is activated after birth (West et al., 2004). These mice 
confirm that a loss of function of the BMPRII gene is sufficient to produce a pulmonary 
hypertensive phenotype. Also, mice that overexpress the 5-HTT transporter, 5-HTT-i- mice 
(see section 1.5.7 for further details), exhibit increased right ventricular pressure compared 
with wild-type mice (MacLean et al., 2004). Under conditions of hypoxia, the 5-HTT+ 
mice display increased remodelling compared to wild-type.
Cells can easily be grown in a hypoxic environment, mimicking conditions that lead to the 
development of PAH. Pulmonary vasoconstriction is an inherent property of pulmonary 
vascular smooth muscle cells (Voelkel & Tuder 1997) and a direct effect of hypoxia on
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smooth muscle cells has been witnessed. After 1 week of hypoxia, the proliferation rates 
of PASMC from distal human pulmonary arteries were observed to increase (Yang et al., 
2002) and isolated PASMC cells have also been observed to contract in response to 
hypoxia (Murray 1990). Human PASMC (hPASMC) have therefore been utilised as a 
cellular model of PAH (Murray et al., 2002; Murray et al., 2003).
1.5.2 Pathology of PAH
PAH is associated with right ventricular hypertrophy and changes in the structure and 
funetion of smooth muscle cells, fibroblasts and endothelial cells leading to a sustained 
increase in PAP and vasoconstriction. These changes, along with the heterogeneity among 
cell phenotypes, contribute to the vascular remodelling (reviewed in Mandegar et al., 2004; 
Humbert et al., 2004), altered tone, thrombosis and vasoreactivity witnessed in PAH. 
Although the entire pulmonary vascular tree undergoes histological alterations, it is the 
smaller vessels which are primarily affeeted. Vaseular smooth muscle cells proliferation 
rate increases, resulting in medial hypertrophy and arteriolar musculaiisation, fibrosis, 
thrombosis. Endothelial cells increase in proliferation causes intimai thickening and the 
formation of plexiform lesions. The dysfunction of inflammatory cells is also considered to 
play a role in the development of PAH. All of these problems contribute to the remodelling 
of the pulmonary vascular tree. Medial hypertrophy is mainly due to abnormalities 
observed in pulmonary artery smooth muscle cell (PASMC) function, namely an increase 
in proliferation and migration (Yuan & Rubin 2001). Another characteristic of some forms 
of PAH is the formation of plexiform lesions arising from the concentric endothelial cell 
proliferation and smooth muscle cells migration. These lesions occur distally to obliterative 
intimai lesions.
Pathophysiological studies have highlighted the importance of several mediators in the 
development of PAH, namely, Endothelin-1 (section 1.5.5.1; Giaid et al., 1993), nitric 
oxide (section 1.5.5.2; Giaid et al., 1995), prostacyclin (1.5.5.3; Christman et al., 1992; 
Tuder et al., 1999) and serotonin (5-HT, section 1,5.7; Herve et al., 1995; MacLean et al., 
2000).
1.5.3 Pulmonary artery smooth muscle cells
Increased smooth muscle cell proliferation and hypertrophy have been implicated in the 
development of PAH (Yuan & Rubin 2001) and leads to musculaiisation of the pulmonary 
resistance vessels, Hypeiplasia is characteristic of the larger vessels, whereas the small 
vessels undergo more extensive remodelling (Humbert et al., 2004). The pulmonary ai'tery 
smooth muscle cells are normally present in a quiescent and contractile state, but injury to
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the vessel wall activates cells into a proliferative, migratory and secretory phenotype.
This phenotypical change has been reported to be dependant upon the growth factors 
transforming growth factor p (TGF-p), and basic fibroblast growth factor (bFGF; Boudreau 
et ah, 1991). The smooth muscle cells then migrate through to the intimai layer and can 
invade the lumen of the vessel forming concentric lesions. Thrombin induced hypertrophy 
has been demonstrated to occur through activation of a set of immediate early genes (lEG), 
whereas PDGF induced proliferation occurs through an alternative set of lEG (Rothman et 
al., 1994). ÏEG expression in both instances appears to be regulated by extracellular 
calcium, PKG and sodium (see below for further details).
In cultured PASMC, hypoxia inhibits the voltage gated potassium channels in PASMC 
causing a depolarisation of the membrane and a resultant increase in intracellular calcium 
(Platoshyn et al., 2001; Limsuwan et al., 2001; reviewed in Strange et al., 2002). The rise 
in Ca^ "^  occurs through many different mechanisms including activation of voltage 
dependant calcium channels, the production of inositol 1,4,5-triphosphate (IP3) thus 
facilitating the release of Ca^ "^  from intracellular stores, and the increase of Ca^ "^  levels by 
reversing NaV Ca^^ exchange (Madden et al., 2001). It has also been reported that the 
maintenance of Ca^^ levels is aided by the inhibition of Na"*"/ Ca^^ exchange (Wang et al.,
2000). A reduction in channel expression and function has been observed in PASMC 
from PAH patients (Yuan et al., 1998a; Yuan et al., 1998b; review of hypoxic effects on 
channels, Raj & Shimoda 2002) as well as in PASMC cultured in hypoxia (Wang et al.,
1997) or exposed to serum from patients with PAH (Limsuwan et al., 2001). The rise in 
intracellular calcium also leads to vasoconstriction and activation of PKC. PKC is a 
calcium dependant enzyme that stimulates DNA synthesis in systemic artery smooth 
muscle cells and PASMC will not proliferate in response to hypoxia unless PKC is 
activated. Recent studies using a PKC-e knockout mouse model confirmed the role of PKC 
in hypoxic vasoconstriction as the transgenic mice displayed reduced hypoxic pulmonary 
vasoconstriction (Littler et a l , 2002). As well as increased proliferation and hypertrophy, 
hypoxia also decreases apoptosis of PASMC. |
I
PASMC exposed to hypoxia also display an increase in Rho-kinase activity that has been |
reported to contribute to hypoxia-induced pulmonary vasoconstriction (Wang et a l , 2001).
This is mediated by Rho-kinase increasing myosin light chain phosphorylation. Use of the |
Rho-kinase inhibitor Y-27632 was able to ablate this effect. In addition, Rho-kinase j1activation causes an inhibition of myosin phosphatase, enabling PASMC to sustain 
constriction (Wang et a l, 2003).
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It has been shown that vascular smooth muscle cells display marked heterogeneity with 
several functionally distinct phenotypes (Frid et ak, 1997). Each distinct population of cells 
expresses different cytoskeletal and contractile proteins and channels and display different 
growth rates and responses to growth factors. In hypoxia, there is a redistribution of these 
cell types, altering the phenotype and responses of each pulmonary artery. This 
heterogeneity of smooth muscle cells adds complexity to an already complex interplay of 
many different factors involved in the response to chronic hypoxia and the development of 
PAH.
1.5.4 Pulmonary artery fibroblasts
An increase in extracellular matrix proteins and pulmonary arterial fibroblasts (PAF) is 
observed in PAH due to sustained hypoxia. This causes vascular hardening maintaining 
pulmonary vasoconstriction. Increased fibroblast proliferation has been shown to exceed 
that of PASMC and pulmonary artery endothelial cells (PAEC) in hypoxic animal models 
(Belknap et al., 1997). Hypoxia acts through Gui/o and Gq coupled Pay activation to 
promote fibroblast proliferation (Stenmark et al., 2002). Molecular studies have revealed 
that constitutive p38 MAPK (section 1.5.6) activity enhances PAF proliferation in 
remodelled vessels (Welsh et al., 2001).
Similar to PASMC, PAF also display marked heterogeneity (Stenmark et al., 2002). 
Responses to hypoxia are unique among the sub populations of cells, with some even 
displaying a reduction in DNA synthesis. Populations of PAF with hypoxia induced 
changes in proliferative and matrix-producing phenotypes also display the expression of 
smooth muscle a-actin, suggesting that some PAF transdifferentiate into myofibroblasts 
(Stenmark et al., 1995).
1.5.5 Pulmonary artery endotheliai cells
Endothelium-dependant mediators have been implicated in the modulation of hypoxic 
pulmonary vasoconstriction. Indeed endothelial dysfunction has long been considered to 
have a key role in the development of PAH. The endothelium releases vasoconstrictors 
such as endothelin and vasodilators including prostacyclins and NO. An imbalance 
between vasodilators and vasoconstrictors and an increase in PAEC proliferation is 
apparent in PAH.
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1.5.5.1 Endothe!in-1
Endothelin-1 (ET-1; Yanigasawa et al., 1988; Masaki et al., 1991) is a potent 
vasoconstrictor produced by both pulmonary and systemic endothelial cells. It is released 
upon stimulation by a range of agents including epinephrine, TGF-P and IL -1 and also by 
shear stress or hypoxia. Once released, ET-1 binds to type A receptors (ETa) found mainly 
in smooth muscle cells or type B receptors (E T b ) found on endothelial cells. E T a  receptors 
are generally thought to regulate vasoconstriction by facilitating the production of IP3 , 
while ETb receptors of endothelial cells lead to vasodilation through the release of nitric 
oxide (NO; Eddahibi et al., 1991). However, the distribution of receptors displays 
anatomical heterogeneity with ETa mediating vasoconstriction in the large arteries, while 
in the smaller resistance arteries atypical ETb receptors regulate vasoconstriction 
(McCulloch et al., 1998). No effect has been observed through the binding of ET-1 to 
endothelial cells, hence the contributory effect of ET-1 to sustained vasoconstriction. ET-1 
also contributes to vascular remodelling through increasing the proliferation of PASMC 
via E T a receptors (Janakideva et al., 1992; Zamora et al., 1993).
ET-1 can also indirectly increase cGMP levels through NO release and directly stimulate 
or inhibit the synthesis of cAMP in pulmonary arteries. The ET-1 induced increase in 
cGMP occurs in the larger pulmonary arteries alone through the E T a receptor. The 
increased synthesis of cAMP by ET-1 is observed in the small resistance arteries and could 
be blocked by an E T b receptor antagonist. ET-1 mediated reduction in cAMP levels is 
mediated in part by the E T a  receptor and occurs in the main pulmonary arteries. All these 
effects were endothelium independent (Mullaney et al., 2000). Under chronic hypoxic 
conditions, basal levels of cAMP are reduced in all but the small resistance arteries of the 
rat where cAMP levels are mildly increased (Mullaney et al., 1998). ET-1 induced cAMP 
responses were lost in the hypoxic rat. Reduction of cAMP in the large pulmonary arteries 
was no longer observed in hypoxic rats, instead, a significant increase of cAMP was 
observed. In the resistance arteries of the hypoxic rat, ET-1 was no longer able to increase 
cAMP (Mullaney et al., 1998).
ET-1 levels have been shown to be raised in systemic and pulmonary circulation in patients 
with primary and secondary PAH to a level sufficient enough to induce vasoconstriction 
(Stewart et al., 1991; Cody et al., 1992; Cacoub et al., 1997). The role of ET-1 in PAH 
(reviewed in MacLean 1998; MacLean 1999) has been investigated further through the use 
of chronic hypoxic rat models. In lungs from the chronic hypoxic rat, ET-1 levels and ETa 
receptor expression increase (Li et al., 1994). Further investigation into these alterations in
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the lung uncovered an increase in vasoconstriction mediated by the ETa receptor in the 
large and small pulmonary arteries (MacLean et al., 1995; McCulloch et al., 1998). ET 
receptor antagonists have thus been developed to investigate their therapeutic potential in 
PAH. To date, the E T a and mixed E T a /E T b receptor antagonists tested have proven to be 
effective at hindering the development of and even reversing PAH in chronic hypoxic rat 
models (DiCarlo et al., 1995; Chen et al., 1997; Underwood et al., 1998; reviewed in 
MacLean 1999). Currently, a mixed ET-1 receptor antagonist, bosentan, is in use as a 
treatment for PAH patients (Channick et al., 2004).
1.5.5.2 Nitric Oxide
Nitric oxide (NO) is a well characterised molecule with functions including inhibition of 
smooth muscle growth and constriction (Singh & Evans 1997). The effects of NO are 
mediated partly through the soluble guanylyl cyclase receptor which increases cGMP in 
cells and, in turn, increases PKG activity. PKG reduces the intracellular concentration of 
Ca^  ^ and hyperpolarises the membrane through inhibition of voltage and receptor Ca^  ^
channels and activation of K  ^ channels respectively. Smooth muscle relaxation is also 
induced through the activation of myosin light chain phosphatase by cGMP. Independently 
of cGMP, NO signalling in hypoxic conditions has been demonstrated to induce 
modifications in enzymatic activity and, more recently, activate the sarcoplasmic reticulum 
Ca^^-ATPase (SERCA) causing a decrease in intracellular calcium (Mingone et al., 2003).
NO is produced in endothelial cells during the conversion of L-arginine to L-citrulline 
which is catalysed by nitric oxide synthase (NOS). There are three known types of NOS, 
nNOS or type I NOS which is secreted by neurones. Type IE NOS or iNOS is inducible and 
secreted by various cells in response to cytokine stimulation. Type HI NOS or eNOS is a 
Ca^^-dependant, constituitively expressed isoform secreted by endothelial cells. eNOS 
deficient mice display mild PAH in a normal atmosphere and have an increased 
susceptibility to hypoxia induced pulmonary hypertension (Fagan et al., 1999). Similar 
studies in mice with disrupted iNOS or nNOS genes suggest these isoforms have a minor 
role in determining PAP in mice.
Results from studies investigating NO levels in hypoxic conditions and in PAH have 
produced conflicting results. In hypoxic rat lungs, eNOS and iNOS mRNA and protein 
levels have been reported to significantly increase (Igari et al., 1998). 
Immunocytochemical staining revealed the de novo eNOS and iNOS proteins appear in the 
small and medium sized arteries of hypoxic rats whereas these proteins appear* limited to
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large aiteries in normoxic rats (LeCras et al, 1996). Hypoxia has also been shown to 
induce iNOS in a HIF-1 dependant manner in PAEC and PASMC (Palmer et al, 1998). 
Lungs from patients with PAH also display an increased amount of eNOS, especially in the 
plexiform lesions (Mason et al, 1998). Lung NO production in PAH patients has been 
reported by several gi’oups to increase (Archer et al, 1998; Forrest et a l, 1999).
A number of studies have reported a reduction in NO levels in PAH. Both acute and 
chronic hypoxia were observed to attenuate NO production in the main puhnonary artery 
of the rat with a resultant decrease in intracellular levels of cGMP (Shaul et al, 1993; 
MacLean et al., 1996). In addition, pulmonary arteries from patients with PAH have been 
observed to exhibit reduced expression of eNOS (Giaid & Saleh 1995). More recent work 
on pulmonary arteries from the chronic hypoxic rat have shown that although endothelial 
NO production in response to carbachol was reduced, total NO protein was unaltered, 
indicating hypoxia affects eNOS activity at the post-translational level (Murata et al,
2002) Such results were the reason for use of inhaled NO therapy in PAH.
NO has been shown to inhibit ET-1 induced pulmonary vasoconstriction (Lang & Lewis 
.1991) and attenuate vascular remodelling (Horstman et al, 1998). Inhaled NO has proven 
beneficial to patients with short-term and reversible PAH, but not for patients requiring to 
use it over long periods due to its irritant properties and short action. Among patients 
treated with inhaled NO, the effects are varied and it is not always successful as a 
treatment. Underlying this could be the cause for opposing results from different research 
groups. As such, the definitive role of NO in PAH remains to be determined.
1.5.5.3 Prostaglandins
Arachodonic acid (AA) is metabolised through the cyclooxygenase and lipooxygenase 
pathways to form prostaglandins and leukotrines. Metabolites of arachodonic acid such as 
prostacyclin (PGU) and thromboxane (T^Ag) elicit vasoactive effects in the pulmonary 
circulation (reviewed in Christman, 1998). PGU is produced by endothelial cells and is a 
potent vasodilator and an inhibitor of platelet aggregation. PGU activation of prostacyclin 
receptors stimulates synthesis of cAMP, leading to vasodilation and reduced DNA 
synthesis in vascular smooth muscle cells. The net effect of this is a reduction in 
pulmonary vascular resistance. T^A2  is produced by platelets and is a vasoconstrictor.
Depending on experimental conditions, hypoxia has been reported to both increase and 
decrease prostacyclin release. Patients with severe PAH have an imbalance in production
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of PGI2 and TxA2 and a reduction in expression of PGI2 synthase (Christman et al., 1992; 
Tuder et al., 1999). An overexpression of PGI2 synthase has been reported to protect mice 
against hypoxia induced pulmonary hypertension (Geraci et al., 1999). Conversely, PGI2 
has been reported to increase in response to seven days hypoxia (Shaul et al., 1991). ET-1 
can also induce PGI2 production in rat lung (Barnard et al., 1991).
In most instances, the effects of PGI2 are mediated by the production of cAMP as 
responses can be mimicked in cultured cells using isoprenaline and forskolin, and 
potentiated using the general PDE inhibitor, IB MX.
Clinical studies investigating the use of prostacyclin analogues as a treatment in PAH 
revealed they increase survival rate (reviewed in Badesch et al 2004). However, short half- 
lifes and side effects compromise the benefits, therefore new prostacyclin analogues are 
under development and testing. Subcutaneous delivery of Treprostinil has beneficial 
effects on exercise and hemodynamics, however side effects including nausea, headaches 
and pain and erythema at the site of delivery. In Europe, another prostacyclin analogue, 
Iloprost, has recently been approved for the treatment of PAH and is delivered through 
inhalation. Inhaled iloprost has little effect on the systemic circulation, providing selective 
vasodilation of the pulmonary circulation as does inhaled nitric oxide, but only iloprost 
studies indicate an increased survival rate.
1.5.5.4 Vascular Growth Factors
Many vascular growth factors are secreted by PAEC and a number of these have been 
observed to be increased in PAH. The most well characterised example is the vascular 
endothelial growth factor (VEGF). Although VEGF is not secreted by endothelial cells 
under physiological conditions, it is present in plexiform lesions of PAH patients (Archer 
& Rich 2000). The only known target of VEGF is the endothelial cells themselves. In 
hypoxic conditions, the VEGF gene is stimulated almost instantly due to binding of the 
hypoxia inducible factor -1 (HIF-1; reviewed in Semenza 2000) to a hypoxia response 
element (HRE) in the promoter region (Gerber et al., 1997). VEGF is also known to be 
upregulated in PAH (Tuder et al., 1995).
Endothelial cells under hypoxic conditions are also known to release a platelet-derived 
growth factor (PDGF) which induces vasoconstriction and stimulates PAF migration and 
proliferation (Peacock et al., 1993; Faller et al., 1999). PDGF is also capable of inducing 
VEGF. Another growth factor upregulated in PAH is TGF-P (Acrot et al., 1993). In
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vascular cells, the predominant effects of TGF-p are growth inhibition, cell 
differentiation and stimulation of collagen synthesis. Other growth factors elevated in PAH 
include; bFGF (Arcot et ah, 1995); IGF-l (Perkett et ah, 1992) and EGF (Gillespie et ah, 
1989). The increase in secreted growth factors from endothelial cells can lead to increased 
proliferation of PASMC through feeding into the mitogen activated protein kinases 
(MAPK) pathways (Xiao 1993).
1.5.6 Mitogen Activated Protein Kinases
Mitogen activated protein kinases (MAPK) are activated by a wide range of stimuli 
including growth factors, hormones, extracellular matrix components, GPCR agonists, 
cellular stress and cytokines (reviewed in Gutkind 2000; Tibbies & Woodgett 1999; 
Wildman et ah, 1999). MAPK are split into groups according to their function. The best 
characterised MAPK are the extracellular regulated kinases 1 and 2, also known as p44 and 
p42 respectively. The functions of the ERKl/2 are extremely diverse and include 
regulation of cell proliferation (reviewed in Stork & Schmitt 2002), differentiation and 
tumoregenesis. Other well characterised MAPK are; the c-Jun NHz-terminal kinases also 
known as JNK/SAPK, and the p38 MAPK family. INK and p38 MAPK are involved in the 
cellular response to stressors. MAPK are activated through phosphorylation by a MAPK 
kinase (MAPK) which is activated through phosphorylation by a MAPKK kinase 
(MAPKKK). Each family of MAPK have specific MAPKK and MAPKKK and upstream 
activators (figure 1.4).
1.5.6.1 Activation of MAPK
The classical MAPK pathway of ERKl/2 is now well characterised (figure 1.5). Binding of 
epidermal growth factor (EGF) to its tyrosine kinase receptor (RTK) leads to the 
phosphorylation of the receptor itself and other substrates. Phosphorylated sites act as 
docking sites for adaptor proteins such as Grb2 which contains a Src homology 2 (SH2) 
domain and two SH3 domains or She which possesses a phosphotyrosine binding (PTB) 
domain, one SH2 and one SH3 domain. She acts as a substrate for the EGF receptor and 
upon phosphorylation binds the SH2 domain of Grb2, resulting in the recruitment of SOS. 
SOS induces the exchange of GDP bound to Ras for GTP and initiated the MAPKKK 
cascade. Once activated, ERKl/2 translocates to the nucleus and phosphorylates key 
transcription factors that ultimately regulate the expression of genes essential for processes 
such as cell proliferation. GPCRs can also influence cell growth and differentiation 
through activation of the ERKl/2 pathway (reviewed in Gutkind 2000). This occurs in the 
same manner as RTKs. In contrast, activation of the INK pathway occurs through GPCRs
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and not RTKs (Coso et al., 1995). How this occurs is as yet unclear as is the activation 
of the p38 pathway by GPCRs.
1.5.6.2 Hypoxia-induced activation of MAPK
Numerous studies have revealed hypoxia induced activation of the MAPK cascades in 
many different cell types (reviewed in Minet et al., 2000a). PAF and PAEC have been 
reported by several groups to display a marked activation of the ERKl/2 pathway under 
hypoxic conditions (Minet et ah, 2000b; Scott et al., 1998; Welsh et al., 2001). In addition, 
pulmonary arteries from chronic hypoxic rats also show an activation of ERKl and 2 that 
peaks at day seven (Jin et al., 2000). Increased phospho-ERKl/2 was observed in both 
large and small pulmonary arteries along with the activation of INK and p38.
The p38 family and JNKs have also been reported to display an increased activity in PAF 
exposed to acute hypoxia for up to 30 hours (Scott et al., 1998). Activation of p38 peaked 
at 6  hours and 24 hours while INK activation peaked at 6  hours before returning to basal 
levels. p38 activity is also increased in PAF, but not in aortic fibroblasts, under chronic 
hypoxic conditions (Welsh et al., 2001). The transient increase in activation can be 
explained by the induction of MAPK phosphatases in hypoxia or in response to MAPK 
activation (Laderoute et al., 1999; Ward et al., 1994). This feedback control could be to 
avoid apoptosis which has been shown to occur with sustained MAPK activation.
1.5.6.3 HIF-1 and ERKl/2
Hypoxia inducible factor -1 (HIF-1) is a transcription factor responsible for the induction 
of expression of glycolytic enzymes, metabolic enzymes, proteins involved in proliferation 
and proteins involved in vascular biology (reviewed in Semenza 1999; Huang & Bunn
2003). HIF-1 can be induced by various hormones, serum and hypoxia. HIF-1 is composed 
of two subunits, HIF-1 a and HIF-1 p. Both subunits are constituitively expressed, however 
HIF-1 a is rapidly degraded under normal conditions by proteasomal degradation. Under 
hypoxic conditions however, degradation of the HIF-1 a subunit is attenuated allowing a 
higher amount of functional dimers to form (Sutter et al., 2000). Thus, research has 
focused on HIF-1 a as the regulator of the hypoxic response. HIF-1 activates target genes 
by translocating to the nucleus and binding to a hypoxia response element (HRE) in the 
promoter region. HIF-1 a and HIF-1 P knockout mice models results in embryonic lethality. 
Partially HIF-1 a deficient mice display a marked reduction in vascular remodelling in 
response to hypoxia (Yu et al., 1999).
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HIF-1 a is highly phosphorylated in vivo which allows the stabilisation of the protein. 
Phosphorylation of HIF-1 a is mediated by an ERKl/2 dependant pathway (Minet et ah, 
2000b). The other well known MAPK, INK and p38 MAPK, do not phosphorylate HIF-1 a 
(Richard et ah, 1999). ERKl/2 phosphorylation has been shown to promote the 
transcriptional activity of HIF-la (Richard et ah, 1999). The effect of HIF-1 a on gene 
expression is also regulated by p53 which inhibits HIF-1 stimulated transcription 
(Blagosklonny et ah, 1998). Other regulators of HIF-1 include Jabl and p300/CBP (Bae et 
ah, 2002; Kallio et al., 1998).
1.5.7 Role of 5-Hydroxytryptamine in PAH
The use of appetite suppressants such as aminorex has been determined to be a significant 
risk factor for the development of PAH (Fishman 1999). These drugs belong to a vast class 
of amphetamine and epinephrine like dr ugs that act by increasing local and circulating 5- 
HT levels. This increase is achieved by the inhibition of 5-HT transporters (5-HTT), 
release of platelet 5-HT and preventing 5-HT clearance by inhibiting monoamine oxidase 
(MAO).
5-HT is a vasoconstrictor of the pulmonary circulation and a co-mitogen of vascular 
smooth muscle cells in culture. 5_hTT is also involved in 5-HT signalling through 
activation of NAD(P)H oxidase to produce reactive oxygen species (ROS) and ERKl/2 
activation which is involved in 5-HT induced smooth muscle cells hyperplasia or 
hypertrophy (Lee et ah, 1999). 5-HT levels have been reported to increase under several 
conditions that lead to the development of PAH (reviewed in MacLean et ah, 2000). Levels 
of the 5-HTT are also observed to increase in lung tissue and pulmonary arteries from PAH 
patients with a resultant enhancement of PASMC proliferation in response to 5-HT 
(Eddahibi et al., 2001). This has also been observed in hypoxic PASMCs (Eddahibi et ah,
1999). The increased expression of the 5-HTT is also associated with a polymorphism of 
the 5-HTT promoter (Eddahibi et ah, 2001). It has previously been shown that mice with 
targeted 5-HTT gene disruption are less prone to develop PAH than control mice (Eddahibi 
et al., 2000). 5-HTT inhibitors have been observed to attenuate hypoxia induced PAH.
Vasoconstriction induced by 5-HT occurs through the 5-HT ib/id and 5-HT2a receptors 
depending on vascular tone and in a species specific manner. In humans, vasoconstriction 
is mediated by the 5-HT ib receptor (MacLean 1999). In rat pulmonary arteries, 
vasoconstriction usually occurs through the 5-HTzA receptor, however in the chronic 
hypoxic rat model, vasoconstriction is mediated by the 5-HTib and 5-HTzA receptors
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(MacLean et ai., 1996). 5-H T ib/ id receptors are coupled to the Gaj protein and induce 
contraction by decreasing cAMP levels. Contraction through the 5 -HT2A receptors occurs 
through stimulating the Guq pathway, leading to an increase in intracellular calcium and 
activation of PKC.
1.5.8 Cyclic nucieotide pathways in PAH
1.5.8.1 Cyclases
Functionally important isoforms of adenylyl cyclase found in the rat lung are AC2, AC-6 
and AC-8 (Jourdan et al., 2001). AC-2 is potently stimulated by PKC (Jacobowitz & 
Iyengar 1994) and is insensitive to calcium. AC-6 is inhibited by both PKA and PKC, as 
well as by calcium (Lai et al., 1999; Iwami et a l, 1995; Cooper et al., 1995). AC-8 is 
stimulated by calcium binding and PKC has no effect (Cali et al., 1994). Taken together, 
these regulatory properties of the AC isoforms found in the lung allows for a tight 
regulation of cAMP levels, able to tailor stimulation or inhibition when required in 
response to specific effectors. Under chronic hypoxic conditions, it has been demonstrated 
that AC activity measured under GTP, forskolin or isoproterenol stimulation is reduced in 
rat hearts (Pei et al., 2000; Hrbasova et al., 2003). Hypoxia has also been demonstrated to 
affect guanylyl cyclase. Soluble GC levels and activity have been reported to increase in 
chronic hypoxic rats (Li et a l, 1999).
1.5.8.2 Cyclic nucleotides
Many of the effects of the pathways mentioned exert their effects through cyclic 
nucleotides. Stimulation of the cAMP or cGMP pathways in smooth muscle leads to 
relaxation while inhibition of these nucleotides would lead to contraction of smooth 
muscle. This is mediated by the cAMP- and cGMP-dependant kinases, PKA and PKG.
An increase in either cAMP or cGMP is known to inhibit vascular smooth muscle cell 
proliferation (reviewed by Koyama et a l, 2000; Hayashi et a l, 2000). Through the actions 
of PKA, cAMP attenuates proliferation by antagonising mitogenic pathways and causes a 
cell cycle block by arresting cells in the Gi phase and also in the G2/M phase (Kronemann 
et a l, 1999; Stewart et a l, 1999; Van Oirschot et a l, 2001). Growth factors such as PDGF 
induce the ERK pathway in early G| phase of the cell cycle. Several studies have indicated 
the regulation of ERK activation by cAMP (reviewed in Schmitt & Stork 2001). cAMP can 
inhibit growth factor mediated activation of ERK and also suppress activity of the ERK 
pathway (Bornfeldt & Krebs 1999; Yu et a l , 1997). It is believed this is achieved through 
the antagonism of Raf activation. However, inhibition of the ERKl/2 pathway is not
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always required for cAMP induced growth arrest (Balmanno et al., 2003). Inhibition of 
ERK by cAMP is cell-specific, in certain cell types cAMP can lead to the activation of 
ERK. In cells expressing COX-2, activation of the ERK cascade acts as a negative 
regulator of proliferation through the production of cAMP (Bornfeldt and Krebs 1999).
Raising cGMP levels also attenuates smooth muscle cell proliferation, although not as 
potently as cAMP (Yu et ah, 1997). In contrast to the cAMP-induced block of the cell 
cycle, it has been observed that cGMP delays Gi/S transition in smooth muscle cells 
(Fukumoto et ah, 1999). This indicates the pathways governed by cAMP and cGMP 
involved in proliferation are distinct.
In addition to its inhibitory effects on proliferation, cAMP also inhibits migration of 
smooth muscle cells (Goncharova et ah, 2003; Newman et ah, 2003). It is unclear how this 
is achieved, although a link between PKA and inhibition of cell migration is clear in 
several studies, although this effect is again cell-specific (Sun et ah, 2002; Kaufman et ah,
2002). In addition, cAMP inhibits the synthesis of some extracellular matrix proteins (Kaji 
et ah, 1996) and also, as mentioned previously is involved in the role of smooth muscle 
cell contraction/relaxation. It appears that raising cAMP levels is able to inhibit most of the 
processes involved in the response to vascular injury in smooth muscle cells, making 
cAMP signalling pathways an attractive therapeutic target in cardiovascular disease such 
as PAH. Indeed it has been shown that the chronic hypoxic rat displays reduced levels of 
both cyclic nucleotides in all pulmonary arteries with the exception of the resistance 
arteries (MacLean et ah, 1996). The differing effects of hypoxia on the cyclic nucleotide 
levels in separate arteries can be explained by the heterogeneity of the smooth muscle cells 
in each branch. It should be noted that other studies have indicated a rise in cGMP levels in 
chronic hypoxic rats compared to controls (Cohen et ah, 1996). An increase in cyclic 
nucleotides would be beneficial under hypoxia, aiding to restore the normal tone of the 
pulmonary circulation. In fact, it has been suggested that hypoxia initially leads to an 
increase in cAMP through PGH activation, yet after prolonged exposure to hypoxia, 
desensitisation occurs and pathways are initiated to remove cAMP. In addition, it has been 
shown that PKA can activate PDE3A and PDE4 in smooth muscle whilst inhibiting AC6 , 
altogether reducing cAMP levels (Murthy et ah, 2002).
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1.5.8.3 CREB
The cAMP response element binding protein (CREB) is activated by PKA and is 
responsible for cAMP effects on gene expression (reviewed in Mayr & Montminy 2001; 
Shaywitz & Greenberg 1999). PKA activates CREB through phosphorylation on Ser’^^ . 
Phosphorylated CREB is then able to bind to cAMP responsive elements (CRE) in the 
promoter region of cAMP inducible genes.
CREB has also been reported to be phosphorylated at Ser^^  ^ by PKG (Pilz et ah, 2003), 
Akt (Shaywitz et ah, 1999), and PKC (Saeki et al., 1999) amongst other kinases (reviewed 
in Johannessen et al., 2004). Other sites in CREB also act as phosphoacceptor sites 
including Ser^'^ and Ser'^' including hypoxia induced kinases (Taylor et al., 2000).
Hypoxia has been shown to lead to a rapid phosphorylation of CREB at Ser‘^^  in a manner 
more potent than that of forskolin in PC 12 cells (Beitner-Johnson & Millhorn 1998). 
CREB phosphorylation was not mediated through PKA or any of the pathways known to 
activate CREB. In addition, the phosphorylation of CREB was sustained for 24 hours 
which is in contrast with the typical rapid phosphorylation/dephosphorylation of CREB. 
The authors of this study suggested that the maintained CREB phosphorylation implicated 
a role for CREB in the cells adaptive response to hypoxia. Indeed, it is already known that 
the CREB coactivator CBP/p300 interacts with H IF-la and participates in the 
transcriptional regulation of hypoxia induced genes (Arany et al., 1996). In smooth muscle 
cells, active CREB is apparent in proliferating cells and reduced in those that are 
proliferation-resistant (Klemm et ah, 2001). Indeed, it was reported that CREB levels were 
reduced in hypoxia where smooth muscle cells are known to exhibit increased 
proliferation. The activity of CREB was not measured however. These studies implicate 
CREB in the hypoxic response and a further investigation of CREB regulation and 
function could aid in the understanding of hypoxia regulated gene expression.
1.5.8.4 Phosphodiesterases
Phosphodiesterase (PDE) activity is critical for the tight regulation of cyclic nucleotide 
levels. An increase in PDE activity reduces the levels of cyclic nucleotides and thus the 
effect of cAMP or cGMP on smooth muscle functioning. The lung is known to express all 
PDEs except the retinal specific PDE6 (Poison & Strada 1996; Soderling & Beavo 2000; 
Yuasa et ah, 2000; Koyama et ah, 2001). This presents the possibility that the actions of 
cyclic nucleotides in the pulmonary circulation are dependant on the activities of the PDE 
families. Indeed, it has been demonstrated that both cAMP-PDE and cGMP-PDE activity
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increase in the pulmonary arteries of the chronic hypoxic rat (MacLean et ah, 1997). 
Within the pulmonary artery, PDEl, PDE2, PDE3, PDE4 and PDE5 activities have all 
been demonstrated (Pauvert et ah, 2002). Inhibitors of each of these families were also 
demonstrated to relax preeontracted vascular smooth muscle preparations (Pauvert et ah, 
2002).
A role for PDE 1C in vascular smooth muscle cells has already been mentioned (Rybalkin 
et ah, 2002) and it is also recognised that PDE 1C isoform expression in vascular smooth 
cells differs between species (Palmer & Maurice 2000). This is also thought to be the case 
with PDE2 expression in vascular smooth muscle cells.
PDE2 displays low activity levels and although PDE2 inhibitor use uncovered a role for 
PDE2 in hypoxic pulmonary constriction in rat lung in one study (Haynes et ah, 1996), a 
regulatory function for PDE2 in vascular smooth muscle cell function has not been 
reported.
Both genes of the PDE3 family are expressed in vascular smooth muscle cells and have 
been demonstrated to be induced in response to cAMP-elevating agents in vivo (Tilley & 
Maurice 2002). However, maintained increases in cAMP levels in cultured rat and human 
aortic SMC only increased levels of PDE3B (Palmer & Maurice 2000). Chronic hypoxia 
has been observed to increase PDE3 activity in rat pulmonary vessels (MacLean et ah,
1997). This increase can be explained by the induction of both PDE3A and PDE3B in 
chronic hypoxic rat pulmonary arteries (Murray et ah, 2002). In the same study, a cAMP- 
mediated increase of the PDE3A isoform in hypoxic hPASMC was demonstrated.
The use of PDE3 inhibitors on vascular SMC has been demonstrated to inhibit 
proliferation (Johnson-Mills 1998), migration (Palmer et ah, 1998) and act as a vasodilator 
(Bardou et ah, 2001). Indeed, cilostamide attenuates hypoxia induced PAH (Phillips et ah,
2000). Unfortunately, PDE3 inhibitors also affect the systemic circulation and could lead 
to harmful side effects if employed as a treatment. Thus, newly developed PDE3 inhibitors 
are currently under investigation as putative therapies for cardiovascular diseases. 
Milrinone and SCA40 have been shown to be potent relaxants of preconstricted pulmonary 
arteries (Jeffrey & Wallstall 1998). Milrinone has also been reported to significantly 
decrease PAP in the hypoxic dog and heart failure patients (Jaski et ah, 1985; Kato et ah,
1998).
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In rat and human vascular SMC, PDE5A1 and PDE5A2 are expressed (Murray et a l, 
2002; Rybalkin et al., 2002). PDE5 is well known to be involved in the regulation of 
smooth muscle cell relaxation. Under conditions of chronic hypoxia, PDE5 expression and 
activity are observed to increase in rat pulmonary arteries and hPASMC (Murray et al.,
2002), specifically the PDE5A2 isoform. In other animal models of PAH, this result is also 
observed (Hansen et ah, 1998; Black et al., 2001). Consistent with these studies, inhibitors 
of PDE5 are observed to inhibit proliferation and migration of vascular SMC, enhance NO- 
protection against vascular leakage and act in a pulmonary specific manner (Osinski et al., 
2001; Schutte et al., 2000; Eddahibi et al., 1998). All of these mechanisms can attenuate 
the development of PAH. Indeed, the PDE5 inhibitor sildenafil has been shown to be 
effective at improving the prognosis for PAH patients with no effect on the systemic 
pressure (Zhao et al., 2001; Michelakis et al., 2003). In the chronic hypoxic rat, treatment 
with sildenafil prior to hypoxic exposure protects against the rise in PAP and inhibits 
vascular remodelling (Sebki et al., 2003).
PDE4 inhibitors have been developed for use in inflammatory conditions such as COPD 
due to their ability to suppress the activity of immune and inflammatory cells and reduce 
airway smooth muscle hypertrophy and hyperplasia (Vignola 2004; Schmidt et al., 1999; 
Essayan 1999; Spina 2003). Recently, new PDE4 inhibitors, cilomilast (Ariflo) and 
roflumilast, have been developed for use in the treatment of COPD and asthma (Giembcyz 
2001; Compton et al 2001; Underwood et al., 1998). Investigation into the role of PDE4 
identified PDE4A and PDE4B as the major regulators of inflammatory cell functions with 
4D also mediating in part (Manning et al., 1999). PDE4 and PDE3 inhibitors are able to 
cause relaxation of bronchial rings and when used in tandem, a much greater 
bronchorelaxant effect is seen than when used separately. Airway SMC proliferation has 
also been shown to be regulated by cAMP levels (Tomlinson et ah, 1995). PDE4 inhibitors 
are known to display similar results in vascular SMC and therefore have been considered 
for use in pulmonary disorders. Indeed PDE4 inhibitors are also capable of inhibiting SMC 
migration (Palmer et ah, 1998) and proliferation (Chen et al 2002, Ogawa et al 2002). In 
both proliferation and migration studies, PDE4 inhibitors or PDE3 inhibitors used alone 
have mild effects, when used together they synergise to potentiate their effect (Palmer et 
al., 1998). Due to the success of clinical trials using PDE4 inhibitors as a treatment for 
COPD, the potential for PDE4 inhibitors in modulating the response to hypoxia is 
apparent. It is as yet unknown what effect, if any, hypoxia has on PDE4 in vascular SMC. 
However, a differential expression of PDE4 in cases of COPD has been observed (Barber 
et al., 2004). It would therefore be beneficial to uncover the PDE4 isoforms expressed in
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pulmonary arterial cells and to distinguish isoform-specific functions. In this study, I set 
out to identify the PDE4 isoforms expressed in human pulmonary artery smooth muscle 
cells and investigate their role in the altered cyclic nucleotide levels apparent in hypoxia. 
In addition, the cAMP regulation of proliferation was investigated.
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Adenylyl Cyclase 
Isoform
High Expression Potential
Function
1 Brain Circadian rhythm, 
learning, memory
II Brain, lung Synaptic plasticity, 
cell proliferation 
arrest
III Olfactory
epithelium,
pancreas
Odorant
stimulation
IV W idespread
V Brain, heart,
VI Heart, kidney, 
widespread
Cell proliferation
VII W idespread Ethanol
dependancy
VIII Brain, pancreas Synaptic plasticity
IX Pituitary,
w idespread
Table 1.1 Summary of adenylyl cyclase isoform distribution.
This table summarises the current knowledge of specific adenylyl cyclase isoform
distribution throughout the body and potential associated functions.
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Adenylyl Cyclase 
Isoform
Gsa GsPy Ca2+ PKC
I + - + 0
II 7 0 +
III + 0 7 7
IV + + 0 7
V + 0 -
VI + 0 - 7
VII + + 0 +
VIII + 7 + 7
IX + 7 0 (inhibited 
by calcineurin)
7
Table 1.2 Summary of adenylyl cyclase regulation
This table summarises the regulation of each adenylyl cyclase isoform. Question marks 
represent modes of regulation that have not been fully investigated for that isoform. 
Stimulation is represented by + and inhibition by -. 0 signifies no effect on that isoform.
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PDE family fhiclec^kfe Inhibitors Pegu W o n
PDE1 cAMP/cGMP Nicardipine, vinpocenfme, 
zaprinast
(+) Ca^Vcalmodulin 
(-)PKA/PKG, CamKII
PDE2 cAMP/cGMP EHNA (+) cGMP, PKC
PDE3 cAMP Cilostamide, cilostazol, 
milrinone, amrinone
(+) PKA, PKB 
(-) cGMP
PDE4 cAMP Roflumilast, Rolipram, 
Ro-20-1724, 
cilomilast, denbufylline, 
BAY 19-8004
(+)PKA, ERK, PA 
(-)ERK, caspases
PDE5 cGMP Sildenafil, DMPPO, 
vardenafil, tadalafil 
Zaprinast
(+) cGMP, PKA, PKG 
(-) caspases
PDE6 cGMP Zaprinast, dipyridamole, 
sildenafil, DMPPO
(+)Transducin 
(-) cGMP
PDE7 cAMP Dipyrimidamole (+/-) PKA
PDE8 cAMP Dipyridamole PAS domain
PDE9 cGMP Zaprinast
PDE10 cAMP/cGMP Dipyramidole (-) cAMP
PDE11 cAMP/cGMP Dipyramidole, zaprinast
Table 1.3 Summary of phosphodiesterase family regulation
This table summarises substrate specificity and regulatory mechanisms for each of the 
phosphodiesterase families. Compounds known to inhibit each family are also shown, not 
all are selective. Stimulation is represented by +, and inhibition by -.
NH:
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Variable
Regulatory —
Conserved
Catalytic
Variable
Regulatory COOH
•Allosteric regulation -Substrate binding
•Membrane-targeting site
•Autoinhibition -Inhibitor binding site
•Dimérisation
Figure 1.1 Modular structure of phosphodiesterases
All phosphodiesterase families share a common modular structure with a unique N- 
terminal involved in regulation, a catalytic domain responsible for nucleotide hydrolysis 
which is conserved throughout all PDEs and a unique C-terminal domain.
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‘Long form’
LR1 LR2
59aa 360aa
UCR2 Catalytic COOH
~24aa 10-28aa
‘Short form’
NH, UCR2 Catalytic COOH
‘Super-short form’
NHg"^ UCR2 ^  Catalytic
71 COOH
Figure 1.2 Splice variants of the PDE4 family
The PDE4 family are characterised by the presence of upstream conserved regions known 
as UCRl and UCR2 at their N-terminus. The region that links UCRl and UCR2 together is 
called linker region 1 (LRl), and linker region 2 (LR2) connects UCR2 to the catalytic 
domain. The linker regions differ between the different PDE4 families. Alternative mRNA 
splicing of members of the PDE4 family gives rise to “long” isoforms containing both 
UCRl and UCR2 and “short” isoforms with only UCR2 are produced. An additional splice 
site also generates “super-short” isoforms which have an N-terminally truncated UCR2.
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Active 
ERK -►PLA2 C0X2
Arachldonic 
acid
PGE2
PDE4D5
Adenylyl 
cyclase
PKA ^ cAMP
Figure 1.3 Autocrine activation of PDE4D5 by ERK
ERK activation inhibits PDE4D5 activity through direct phosphorylation. In human aortic 
smooth muscle cells however, ERK leads to the autocrine production of PGE? which 
stimulates adenylyl cyclase. cAMP levels then rise and PKA is activated and can then 
phosphorylate PDE4D5. Due to the rapidity and magnitude of ERK dependant PKA 
phosphorylation of ERK, activation overall is achieved (Baillie et al., 2001 ).
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PDE Family Disease states In 
which PDE plays a 
role
References
PDE1 Parkinsons’s disease 
Tumorigenesis
Kakkar et al., 1999; Kakkar et al., 
1997
PDE3 PAH Wagner et al., 1997; MacLean et 
al., 1997; Murray et al., 2002
PDE4 Asthma, COPD, 
depression, malignant 
gliomas, PAH, acute 
lymphoblastic 
leukemia, ischemic 
stroke
Torphy 1998; Schmidt et al.,
1999; Schudt et al., 1999; Torphy 
et al., 1999; Spina 2003; Gale et 
al., 2002; Nemoz et al., 1985; 
Grootendorst et al., 2003; Chen et 
al., 2002; Ghoframi et al., 2004; 
Hatzelmann & Schudt 2001 ; 
Wagner et al., 1997;Goirand et 
al., 2001 ; Ogawa et al., 2002; 
Gretarsdottir et al., 2003
PDE5 Lung ischemia 
reperfusion injury, PAH
Schutte et al., 2000; Sebkhi et al., 
2003; Michelakis et al., 2003; 
Eddahibi et al., 1998; Goirand et 
al., 2001 ; MacLean et al., 1997; 
Murray et al., 2002
Table 1.4 Summary of disease states PDEs are reported to play a role
This table summarises some of the diseases PDE inhibitors are therapeutic in or diseases in 
which the PDE family has been implicated. References for the named disorders are also 
included.
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Revised Clinical Classification of Pulmonary Hypertension (Venice 2003)
1. Pulmonary arterial hypertension (PAH)
1.1 Idiopathic (IPAH)
1.2 Familial (FPAH)
1.3 Associated with (APAH):
1.3.1 Collagen vascular disease
1.3.2 Congenital systemic-to-pulmonary shunts
1.3.3 Portal hypertension
1.3.4 HIV infection
1.3.5 Drugs and toxins
1.3.6 Other
1.4 Associated with significant venous or capillary involvement
1.4.1 Pulmonary veno-occlusive disease (PVOD)
1.4.2 Pulmonary capillary hemangiomatosis (PCH)
1.5 Persistent pulmonary hypertension of the newborn
2. Pulmonary hypertension with left heart disease
2.1 Left sided atrial or ventricular heart disease
2.2 Left sided valvular heart disease
3. Pulmonary hypertension associated with lung diseases and/or hypoxemia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Sleep-disordered breathing
3.4 Alveolar hypoventilation disorders
3.5 Chronic exposure to high altitude
3.6 Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease
4.1 Thromboembolic obstruction of proximal pulmonary arteries
4.2 Thromboembolic obstruction of distal pulmonary arteries
4.3 Non-thrombotic pulmonary embolism
5. Miscellaneous
Figure 1.4 Venice classification of pulmonary arterial hypertension.
With the variety of new disorders proven to lead to pulmonary arterial hypertension, the 
previous classification of PAH was considered to be outdated. Thus, in the Venice 2003  
meeting, the classification was revised. Adapted from Simonneau et al., 2004.
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Growth factors e.g. EGF
k-Raf, B-Rar 
_ c-Raf-1 >
MEK1,MEK2
ERK1, ERK2
Elk-1, Etsi, 
Sapla, c-Myc, 
pQO'’^ '^  S6 kinasei
Growth,
differentiation
Cellular stress/cytokines
MEKK4, DLK PAK
MKK4, MKK7 MKK3, MKK6
INKI, JNK^ 
^  JNK3 .
Elk-1, c-Jun, 
ATF-2, 
p53, NFAT41
Growth,
differentiation,
survival,
apoptosis
MAPKAP kinase, 
ATF-2, Elk-1,MEF2C
Apoptosis,
cytokine
production
MKKK
MKK
MAPK
Figure 1.5 Activation of MAPK
The ERK, JNK and p38 cascades arc the classic examples of MAPK cascades. Upon 
stimulus, a MAP kinase kinase kinase, MAPKKK, activates its MAP kinase kinase 
MAPKK. This leads to activation of the MAP kinase which can then relocate to the 
nucleus and regulate gene expression through its action on transcription factors.
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Tyrosine kinase GPCRreceptor
cAMP
EPAC
\
c-Raf-1 B-Raf
MEK1/2
Figure 1.6 ERK pathway
The ERK pathway can be activated through the actions of a stimulated G-protein coupled 
receptor or activated tyrosine kinase receptor. The intracellular cascades have different 
points of cross talk where they can ‘finely-tune’ the ERK response following stimulation. 
Red arrows signify the cAMP pathway involved in ERK activation.
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Chapter 2
Materials and Methods
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2.1 Mammalian Ceil Culture
2.1.1 Maintenance of hPASMC
2.1.1.1 Human Pulmonary Artery Smooth Muscle Cells
Human Pulmonary Artery Smooth Muscle Cells (hPASMC) are obtained commercially 
from Cambrex Biowhittaker and are derived from 1®* and 2^ ^^  order pulmonary arteries. 
Each vial of cryopreserved cells came with a certificate of analysis showing guaranteed 
viability of cells, presence of smooth muscle cell markers and negative viral detection. 
hPASMC were maintained in Smooth Muscle Growth Medium (SmGm, Cambrex) which 
had been optimized for the growth of smooth muscle cells. The SmGm was prepared using 
Smooth Muscle Basal Medium (SmBm) supplemented with 5% Foetal Calf Serum (PCS), 
gentamycin GA-1000 (50pg/ml) penicillin/streptomycin (100 units/ml), human fibroblast 
growth factor-B (2ng/ml), human EGF (0.5 ng/ml) and insulin (5jJ,g/ml). These were all 
available from Cambrex in single use aliquots as a SmGm-2 bullet kit. Cells were seeded 
into 25cnf flasks at the recommended seeding density of 3500cells/cm^ using the 
following calculations:
Max. area that can be plated = No. of cells available/Recommended seeding density
Max. no. flasks prepared = Max. surface area that can be plated/Growth area of flask
Flasks were prepared with 1ml SmGm-2/5cm^ growth area of flask at 37°C in a 5% CO2  
atmosphere for 30 minutes prior to seeding. The day after seeding, and every other day 
thereafter, the SmGm-2 was replenished to remove unattached cells and waste from the 
cells. As the cells became more confluent, 2ml SmGm-2/5cm^ growth area of flask was 
used. Cells were maintained in a Heraues CO2 incubator set at 37°C in an atmosphere of 5% 
CO2 . The cells were examined daily for any signs of stress, for example atypical 
morphology. Each vial of cells arrived at passage 3 and were used at passage 5-7 for all 
experiments. Cambrex guarantee normal morphology and proliferation rates of cells until 
passage 1 0 .
2.1.1.2 Passaging of hPASMC
Cells were passaged at 85% confluency. This was achieved by rinsing the cells in SmBm 
to remove all traces of semm. To detach the cells from the eulture vessel, 2mls/100mm 
plate of Trypsin/EDTA (145mM NaCl, 5.4mM KCl, 8.2mM Na2HP04, 1.5mM KH2PO4, 
42mM Trypsin, lOmM Glucose and 0.7mM EDTA) was added to the culture flask which
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was then left at room temperature. After 5 minutes incubation with Trypsin, the culture 
vessel was rapped gently to detach any remaining adherent cells. Complete cell detachment 
was checked by microscopic examination. The cells were then collected in 2mls/100mm 
plate of fresh SmGm-2 and centrifuged at 700rpm for 3 min in the MSE Mistral 1000 
swinging bucket centrifuge. The Trypsin/SmGm-2 solution was aspirated off the cells 
before resuspending them in prewarmed SmGm-2. The cells were then plated out at the 
optimal seeding density of 3500 cells per cm^ of growth area. SmGm-2 was replaced every 
other day.
2.1.1.3 Hypoxic hPASMC Model
At the desired passage number and confluency, the culture vessels were split into two 
groups following replenishment of SmGm-2. One group was returned to the normoxic 
incubator whilst the other group were transferred to a hypoxic incubator (Wolf 
Laboratories -  Galaxy CO2 Galaxy incubator with 2-99% oxygen control) at an atmosphere 
of 5% CO2 (550 bar), 10% O2 balance N 2 (300 bar). Cells were initially maintained in the 
hypoxic incubator for 24 hours -  14 days to determine the optimal time point to investigate 
signalling. At all times, the hypoxic cells were treated identically to the control cells.
2.1.1.4 Treatment of hPASMC with Agonists/Inhibitors
Prior to treating hPASMC with various drugs, the cells were quiesced for 24 hours by 
replacing the growth medium with SmBm.
2.1.2 Transfection of hPASMC with the Amaxa Nucleofactor
hPASMC were transfected using a nucleofector and human aortic smooth muscle cell 
nucleofector kit (Amaxa) according to manufacturer’s instructions. Briefly, hPASMC were 
trypsinsed as in section 2.1.1.2 and 1x10^ cells/transfection were resuspended in lOOpl 
nucleofector solution. This was placed into a cuvette and inserted into the nucleofector that 
was set at programme U-25. Once the programme was finished, the cells were gently 
transferred into 3 wells of a 6 -well culture plate containing SmGm and left at 37“C in an 
atmosphere of 5% CO2 for 4-24 hours.
2.1.2.1 Transfection of siRNA constructs
Using the nucleofector as described in section 2.1.2, siRNA samples were transfected into 
hPASMC. The siRNA samples were diluted to 60nM prior to use and after nucleofection, 
the cells were gently transferred into 3 wells of a 6 -well culture plate containing SmGm 
and left at 37°C in an atmosphere of 5% CO2 for 24 hours.
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2,2 Proliferation Analysis
2.2.1 DNA Synthesis Assays
2.2.1.1 Assay preparation
hPASMC were plated out into 96-well tissue culture plates at a seeding density of 1000 
cells/well 5 days prior to the DNA synthesis assay. Cells were quiesced in SmBm for 24 
hours prior to treatments. Smooth muscle growth medium containing 5% PCS was 
reintroduced after this time.
2.2.1.2 Addition of [^H]-Thymidine
Twenty hours after additions, 0.5pCi/well [^H]-Thymidine (Amersham) was added to the 
plates. The cells were placed in their respective incubators for a further four hours to allow 
the tritiated Thymidine to incorporate before the plates were placed at -20°C to stop 
proliferation.
2.2.1.3 Measuring radioactivity
The 96-well tissue culture plates were allowed to thaw at room temperature for two hours 
before using a Betaplate 96-well harvester (Wallac) to harvest the plates onto glass fibre 
filter mats (Wallac). These were then placed into sample bags (Wallac) before being placed 
into a 1205 Betaplate Liquid Scintillation Counter (Wallac) and [^H]-Thymidine 
incorporation, expressed as counts per minute (cpm), was measured.
2.3 Biochemical Analysis
2.3.1 Harvesting Cell Lysate
2.3.1.1 Whole cell lysate production
Cells were harvested on ice and all buffers were pre-chilled. Cell media was removed from 
plates and the cells were rinsed in ice-cold PBS. The cells were drained before scraping 
into a 1.5ml eppendorf in 350pls / 100mm plate complete KHEM buffer (50mM KCl, 
lOmM EGTA, 1.92mM EGTA, 59mM HEPES-KOH pH 7.2 plus complete, EDTA-free 
protease inhibitor cocktail tablets (Roche) and 1% Triton X-100. The cells were 
homogenized by passing them through a 26 gauge needle 12 times whilst on ice. The cells 
were then centrifuged at 13000rpm at 4°C for 3 minutes (Biofuge fresco, Heraeus) to 
remove cellullar debris. The supernatant was then removed, aliqnoted and used for analysis 
or snap frozen in dry ice before being stored at -80°C.
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2.3.2 Determination of protein concentration (Bradford assay)
Protein assays were carried out in 96 well microtitre plates. 2pl of sample was added to 
48pl dHaO and 200pl Bio-rad reagent (diluted 1/5 with distilled water). Each sample was 
analysed in triplicate. Protein concentration of samples was calculated by measuring the 
absorbances and constructing a standard curve using known concentrations of Bovine 
Serum Albumin (BSA). This was achieved by using the Revelation package on the 
computer, connected to an MRX microtitre plate reader, which read absorbance at a 
wavelength of 590nm. Protein concentrations were determined by plotting the standard 
curve and using least squared regression analysis to obtain the line of best fit. The equation 
of the line was used to determine the protein concentration of the samples.
2.3.3 SDS-PAGE Electrophoresis
2.3.3.1 Sample preparation for SDS-PAGE electrophoresis
Lysates were obtained from 100mm dishes scraped into 350|xl of cKHEM + 1% Triton X- 
100 buffer and spun at 13000 rpm for 3 mins at 4°C. The supernatant was kept and used for 
protein measurement before boiling in Hannah sample buffer (260 mM Tris/HCl (pH6.7), 
55.5% Glycerol, 8 .8 % SDS, 0.007% Bromophenol blue, 11.1% 2-mercaptoethanol, 
Laemmli et al., 1970), for 5 minutes to denature the proteins.
2.3.3.2 Casting and running an acrylamide gel
When using over 50pg protein, a Bio-Rad Protean II system was used. 16cm thick plates 
were rinsed with distilled water and ethanol prior to use. The apparatus was assembled 
according to the manufacturer’s instructions. A resolving gel containing the appropriate 
percentage of acrylamide (determined by the molecular weight of the protein of interest), 
usually 1 0 % unless otherwise stated, was cast between the two plates of the gel apparatus 
(10% 29:1 acrylamide:N,N’-methylenebisacrylamide mix, 375mM Tris/HCl (pH8 .8 ), 0.1% 
SDS, 0.1% Ammonium persulphate, 0.06% N,N,N’,N’,-tetramethylethylenediamine 
(TEMED)).This was overlaid with water to ensure an even gel and allowed to polymerise 
at room temperature for one hour. The water was then removed and a 5% stacking gel was 
poured, (5% 29 :1 acrylamide:N,N’-methylenebisacrylamide mix, 125mM Tris/HCl 
(pH6 .8 ), 0.1% SDS, 0.1% Ammonium persulphate, 0.1% TEMED). A comb was carefully 
inserted immediately between the plates. The stacking gel was allowed to polymerise for 
30 minutes before the comb was removed and the wells were washed with tank buffer 
(192mM Glycine, 25mM Tris, 0.15% SDS) to remove any unpolymerised acrylamide. The 
gels were then placed in a running tank containing tank buffer in both upper and lower 
reservoirs. Bio-Rad prestained broad range precision protein markers were loaded into the
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first well to allow determination of protein weight by gel electrophoresis migration. 
Prepared samples were loaded into the wells and the gels were run at the appropriate 
current (8 mA overnight) until the dye front reached the bottom of the gel.
2.3.3.3 Running a NuPAGE gel
When using less than 50pg protein, the Novex NuPAGE gel systems were used with 
Invitrogen pre-cast 4-12% Tris-Glycine gels. Samples were prepared as in 2.3.3.1. Tank 
buffer used was either MOPS buffer or MES buffer depending on the size of the protein 
wishing to visualize. Gels were run for 45 minutes at 200V.
2.3.4 Western Blotting
2.3.4.1 Protein transfer from acrylamide gel to nitrocellulose membrane 
Following electrophoresis, the gels were placed into a transfer cassette. Under transfer 
buffer (192mM Glycine, 25mM Tris, 20 % Methanol), a piece of foam was overlaid with a 
piece of Whatmann 3MM filter paper. The gel was placed on top of this and overlaid with 
a piece of Protran nitrocellulose paper (Schleicher & Schuell). The nitrocellulose was 
covered with another piece of Whatmann filter paper and finally another piece of foam. 
During assembly, care was taken to ensure air bubbles were excluded from all layers. The 
cassette was closed and placed into a Hoefer transfer tank filled with transfer buffer with 
the nitrocellulose side of the cassette to the positive electrode. The proteins were 
transferred for 0.06 amps overnight or 0.6 amps for 1.5 hours.
2.3.4.2 Blocking of nitrocellulose
Once the proteins had been transferred onto the nitrocellulose as in section 2.3.4.1., the 
membrane was washed with distilled water followed by visualisation of the transferred 
proteins with Ponceau S stain (0.1% Ponceau S, 3% Trichloroaceatic acid). The Ponceau S 
stain was added to the nitrocellulose for a few minutes until the protein became stained, the 
nitrocellulose membrane was then washed with water and rinsed with Tris-buffered saline 
(TBS-tween 20) (137mM NaCl, 20mM Tris/HCl (pH7.6), 0.1% tween20) before 
immunological detection of protein. The unoccupied protein binding sites on the 
nitrocellulose were blocked with 5% skimmed milk powder (Marvel) in TBS-tween20 for 
1 hour at room temperature with gentle agitation.
2.3.4.3 Immunoblotting
After blocking, the appropriate primary antibody was added at the relevant dilution (see 
table 2.1) in 2% skimmed milk powder in TBS-tween20. This incubation was carried out 
for l-2h at room temperature or overnight at 4“C with vigorous agitation. The membrane
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was washed three times in TBS-tween20 for 5 minutes before being incubated with the 
appropriate diluted secondary antibody mix for 1 hour at room temperature with vigorous 
agitation. The secondary antibody (Sigma) was a horse-radish peroxidase (HRP) 
conjugated anti-immunoglobulin (IgG) antibody directed against the primary antibody. 
This antibody was diluted 1:5000 in 2 % skimmed milk powder in TBS-tween20. The 
nitrocellulose was finally washed 3-5 times in TBS-tween20 for 5 minutes. To detect 
immunoreactive bands, the membrane was incubated with ECL reagents (Amersham) for a 
minute with gentle rocking. A piece of x-ray film (Kodak) was exposed to the membrane 
in a darkroom for the appropriate amount of time and then developed using a Kodak X- 
omat,
2.3.5 Phosphodiesterase 4 Activity Assay
Phosphodiesterase activity was measured using a modification of the two step procedure of 
Thompson and Appleman [Thompson and Appleman., 1971], as described previously by 
Marchmont and Houslay [Marchmont and Houslay, 1980]. The first step is the hydrolysis 
of the ^H-cyclic nucleotide ( 8  position of the adenine or guanine ring) by the 
phosphodiesterases, which generates labelled nucleotide monophosphate. In the second 
step, incubation with snake venom, (which has 5’-nucleotidase activity), converts the 
mono-phosphate ring to the corresponding labelled nucleoside. The unhydrolysed cyclic 
nucleotide was separated from the nucleoside by batch binding of the mixture to Dowex 
1X8-400 anion exchange resin. This binds only the charged nucleotides and leaves behind 
the uncharged nucleosides.
2.3.5.1 Activation of Dowex
To activate the Dowex 1X8 -400, 41 of IM NaOH was added to 400g of the resin, the 
mixture was stirred for 15 min at room temperature. The resin was allowed to settle and the 
supernatant was poured off. The resin was then washed 30 times with 41 distilled water. 
The resin was then resuspended in 41 IM HCl and stirred for 15 min at room temperature 
before being allowed to settle by gravity. The resin was then washed 5 times with 41 
distilled water. The activated resin was stored at 4°C as a 1:1 slurry with distilled water 
until required.
2.3.5.2 Sample preparation for assay
Into 1.5ml eppendorf tubes an appropriate amount of cell lysate was placed (30-60 pg 
protein depending on the concentration of the sample) and made up to a volume of 50pl 
with PDE assay diluting buffer (20mM Tris/HCl, pH7.4). Each sample tube was repeated 
in triplicate. All tubes were set up on ice, and remained on ice until all components for the
57
assay had been added. To each tube 50pl of 2pM cAMP containing 3pCi [^H]cAMP in 
20mM Tris/HCl /lOmM MgClz pH7.4 was added, the tubes vortexed and incubated at 
30°C for 10 min. After this time, the tubes were boiled for 2 min to inactivate any PDE 
present and then cooled on ice for 15 minutes. 25pl of 1 mg/ml snake venom in 20mM 
Tris/HCl, pH 7.4 was added to each tube, mixed by vortexing and incubated at 30°C for 10 
minutes. The tubes were then cooled on ice for 15 minutes and 400pl 
Dowex/ethanol/water, in a 1:1:1 ratio, was added to the tubes, vortexed and incubated on 
ice for at least 20 min. The tubes were vortexed again, the dowex removed by 
centrifugation at 13000 rpm for 3 min (Heraeus bench top centrifuge) and 150pl of the 
clear supernatant added to 1ml Opti-scint scintillation fluid and counted on a Wallac 1409 
liquid scintillation counter.
2.3.5.3 Determination of PDE3 and PDE4 activity
The PDE3 family is specifically inhibited by the drug eilostamide (Hidaka et al., 1979) and 
the PDE4 family by rolipram (Wachtel, 1982). PDE inhibitors were dissolved in 100% 
DMSO as lOmM stocks and diluted in PDE assay dilution buffer for use in assay. The 
residual levels of DMSO do not affect PDE activity at the concentrations used (Spence et 
al., 1995). Measurement of PDE activity with and without eilostamide (lOpM) and with 
and without rolipram (lOpM) present gave the contribution of PDE3 and PDE4 
respectively.
2.3.6 Immunoprécipitation
2.3.6.1 Pre-clearing agarose beads
Protein G beads were used when the target protein was immuno-precipitated with a 
monoclonal antibody or a polyclonal antibody raised in a sheep and protein A beads were 
used when the target protein was immuno-precipitated with any other polyclonal 
antibodies. 25 pi of the appropriate beads were washed in 200 pi cKHEM buffer and 
recovered by centrifugation at 13000 rpm for 2  min at 4 °C in a refrigerated bench-top 
centrifuge. 300 pg of protein from cell lysate, diluted to a total of 500 pi with lysis buffer 
supplemented with protease inhibitors, was added to the washed beads and incubated with 
end-over-end rotation at 4 °C, for 30 min.
2.3.G.2 Binding target protein to antibody
After pre-clearing the beads were collected by centrifugation at 13000 rpm at 4 °C for 2 
min (Heraeus refrigerated bench-top centrifuge), the supernatant was removed and placed
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into a fresh eppendorf tube. To this fresh tube 7 pi of the polyclonal antibody or 3 pi 
monoclonal antibody was added and the tube rotated end-over-end at 4 °C for at least 2 h, 
to enable the protein and antibody to bind. The solution was then transferred into a tube 
containing 60 pi pre-washed protein beads (A or G as required) and rotated end-over-end 
overnight at 4 °C. The beads were isolated from solution by centi'ifugation at 13000 rpm at 
4 °C for 2 min (Heraeus refrigerated bench-top centrifuge) and washed to remove any non- 
specifically bound protein. The beads were washed firstly in lysis buffer supplemented 
with 500 mM NaCl, secondly with lysis buffer supplemented with 0.1 % SDS and then 
washed with 0.1 % NP-40 in 10 mM Tris pH 7.4. The final wash was carried out in 20 mM 
Tris (pH 7.4) to prepare samples for use in a PDE assay.
2.3.7 Cyclic AMP Assay
Intracellular cAMP levels were measured using a modification of the procedure of Savage. 
(Savage, 1995). The assay involves the measurement of cAMP by the use of the cAMP- 
binding protein, cyclic AMP-dependant protein kinase. (Brown, 1972) Briefly, following 
stimulation of the cells, they were lysed to release the cytosolic cylic nucleotides. After 
neutralization, the lysate was incubated with [5', 8 ' -^ Pl] cyclic AMP and cyclic AMP 
binding protein, allowing competition of labelled and unlabelled cyclic AMP for a limited 
number of binding sites on the binding protein. Activated charcoal was then added to the 
sample to bind any free cyclic nucleotide and the charcoal pelleted by centrifugation. The 
radioactivity of the supernatant was then measured. A standard curve was generated by 
incubating a range of known concentrations of cAMP with the fixed amounts of binding 
protein and radioactive cyclic AMP. It was then possible to determine cAMP 
concentrations from the radioactivity counted by reference to the standard curve.
2.3.7.1 Agonist Treatment
Cells were plated out in 6 -well plates at the optical seeding density of 3500cells/cm^ four 
days prior to treatment. Cells were serum starved overnight prior to agonist stimulation. 
Agonists were usually made to a stock solution of lOmM in 100% DMSO and were diluted 
in SmBm to a desired concentration prior to addition to cells. Each treatment was 
performed in triplicate in each assay.
2.3.7.2 Lysate extraction for assay
To halt agonist treatment, the media was aspirated from the cells and lOOgl of 2% 
Perchloric acid was added directly onto the cells. The media was kept to be used for 
measuring extracellular cAMP levels. Following incubation on ice for 15 minutes, the cells 
were scraped into eppendorfs and the precipitated protein pelleted by centrifuging the
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samples in a microfuge at 13000rpm for 3 mins. Two wells from both normoxic and 
hypoxic plates were lysed into lOOpl cKHEM + 1% Triton X-100 as in section 2.3.3.I. to 
be used for protein quantification.
2.3.7.3 Neutralisation of the sample
The supernatant from section 2.3.6.2 was added to 5pl universal indicator solution (BDH) 
and it turned pink. The samples were neutralised by gradual addition of 2M KOH, 0.5M 
Triethanolamine until the solution turned light green, indicating a pH of 7-7.5. 
Centrifugation at 13000rpm for 3 minutes pelleted the potassium perchlorate precipitate.
2.3.7.4 Reagent preparation for assay
cAMP assay buffer: 50mM TrisMmM EDTA kept at 4°C.
The following solutions were prepared fresh on the day of the assay.
cAMP Standards: Stock of ImM cAMP in cAMP assay buffer diluted 1:100 and an initial 
dilution of 32pmol/50pl generated. A series of two-fold dilutions from this concentrated 
standard generated the dilutions used in the assay.
[5’, 8' - H] cyclic AMP: 8.7pl [5', 8 ' -^H] cAMP
1 Omis cAMP assay buffer.
Binding Protein: 1 Omg Bovine Crude Fraction
125mg BSA
25mls cAMP assay buffer.
Diluted 1:5 in cAMP assay buffer for use on day of assay.
Charcoal Solution: 2% w/v activated charcoal
1 % w/v BSA
30mls cAMP assay buffer.
Charcoal solution was stirred on ice for 20 minutes prior to use in assay.
2.3.7.5 Sample preparation for assay
A standard curve was obtained for each assay by including a set of tubes containing known 
quantities of cAMP ranging from 0.00625 and 16pmol. The standards tubes were set up in 
duplicate on ice with the unknown samples in the order as follows (with binding protein
being added last):
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Tube No
cAMP
(pm ol/50pl)
Buffer
( M l )
['HI-cAMP
( M l )
Binding Protein 
( M l )
1-2 Blank 200 100 0
3-4 Zero 100 100 100
5-6 0.0625 50 100 100
7-8 0.125 50 100 100
9-10 0.25 50 100 100
11-12 0.5 50 100 100
13-14 1 50 100 100
15-16 2 50 100 100
17-18 4 50 100 100
19-20 8 50 100 100
21-22 16 50 100 100
23 onwards Unknown 50 100 100
The first two tubes with no binding protein were included as a blank to determine the 
amount of cAMP that remained after nucleotide binding by charcoal. Tubes 3 and 4 
indicated the maximum cAMP bound in the absence of unlabelled cAMP and tubes 5 to 22 
were prepared with known concentrations of unlabelled cAMP to aid in the construction of 
a standard curve to allow calculation of unknown cAMP values.
Tubes 23 onwards were set up as shown using samples prepared as in 2.3.6.1 or media 
from the cells. The tubes were vortexed and incubated on ice for 2 hours. After this time, 
25pl charcoal solution was added to each tube. The tubes were vortexed and centrifuged at 
13000rpm for 3 minutes. 300pl supernatant from each tube was added to 1ml Opti-scint 
scintillation fluid, vortexed until clear and counted on a Wallac 1409 liquid scintillation 
counter.
2.37.6 Construction of standard curve
Microsoft Excel was used to plot standards (pmol cAMP vs 1/DPM-mean blank) and 
generate a formula for the best fit curve.
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2.3.7.7 Calculation of cAMP levels
After generating the best fit formula for the standard curve, this was used with the 
unknown samples to calculate their cAMP concentrations. Results were calculated as pmol 
cAMP/ng protein and expressed as mean percentage normoxic basal ± S.E., with normoxic 
basal = 1 0 0 %.
2.3.8 PKA Assay
2.3.8.1 Cell lysate extraction for PKA assay
Cells were grown in both normoxia and hypoxia for seven days, after which time the cell 
media was removed, the cells washed with PBS and drained thoroughly. The monolayer of 
cells was scraped into 500|ll extraction buffer (5mM EDTA, 50mM Tris, pH 7.5) and 
homogenized by drawing through a 13 gauge needle 12 times. The cell debris was then 
removed by centrifugation for 2 mins at 13000 rpm at 4°C (Heraeus refrigerated bench-top 
centrifuge) and the supernatant was used for a PKA assay.
2.3.8.2 PKA assay tube pre-incubation
For each cell lysate, the following were set up on ice in 1.5 ml eppendorf tubes. The cell 
extract was added last and the samples were incubated on ice for 2 0  min to allow the 
inhibitor to bind PKA.
Tube Cell Extract Diluent 4x PKA Inhibitor 4x PKA Activator
A lO u l 2 0 ul Oui Oui
B lO u l lO u l lO ul Oui
C lO u l lOmi Oui lO u l
D lO ul Onl lO u l lO u l
PKA Assay Diluent: 50mM Tris, pH7.5.
4 X PKA Inhibitor: 4|iM PKI( 6  -22) amide, 50mM Tris, pH7.5. 
4 X PKA Activator: 40p,M cAMP, 50mM Tris, pH7.5.
4 X PKA substrate: 200p,M Kemptide, 400(liM ATP, 40mM MgCh, 1 mg/ml BSA, 
50mM Tris, pH7.5.
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2.3.8.3 PKA assay reaction
To 1ml of the 4 x PKA substrate, 6000 |iCi/mmol of [y-^^P]ATP was added whilst 
maintained on ice. To the first assay tube, (lA), lOpl of radioactive 4 x PKA substrate 
solution was added. The sample was mixed gently before being placed in a waterbath at 
30°C for 10 minutes. 20 seconds after substrate addition to the first tube, 10 jii of the 
radioactive substrate was added to the next tube, (IB), which was then mixed and 
incubated. This method of addition of substrate to tubes every 20 seconds continued until 
substrate had been added to all samples and they were incubating at 30 °C. After the 10 
min incubation of the first tube, 2 0 |il of the reaction mix was removed and spotted onto a 
pre-marked piece of ion exchange phosphocellulose paper P81 (Whatman). This was 
carried out for all tubes after they had each undergone the 1 0  min incubation with the 
substrate. The phosphocellulose pieces were then placed into a large beaker containing 1 
%(v/v) phosphoric acid (H3PO4 ) and washed for 3 min with slight agitation. The waste 
acid was removed and the acid wash repeated. The phosphocellulose was then washed 
twice in dHzO before being placed in 1.5 ml eppendorf tubes, to which 1 ml scintillation 
fluid was added. The ^^P incorporated into the peptide bound to the phosphocellulose was 
counted on the Wallac 1409 liquid scintillation counter. Two separate vials were set up 
with 10|il of the radioactive 4 x PKA substrate added to I ml scintillation fluid to enable 
the determination of the total counts from the substrate solution.
2.3.8A Calculations for PKA assay data 
Step 1.
Total counts \nmol , , , ,---------------- ^ -------------- — cpm/pmol phosphate4nmolATP \000pmol
Step 2.
(cpm/phosphocellulose)x2 
STEPl
Step 3.
STEP 2 , .----------- = pm ol/ min /assay tube
1 0  min
total pmol peptide -  incorporated phosphate
Step 4.
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STEP 3
0 .0 1 m/ extract = pm ol/m in/m l
Step 5.
Tube A -  Tube B = pmol/mm activated PKA 
Tube C - Tube D = pmol/min total PKA 
Step 6 .
pnw l/m m  activa±e±PKA^^^^ ^  PKA
pmol/ min total PKA
2.4 Molecular Biology
To prevent any contamination all glassware, tubes, tips, buffers and media used for 
molecular biology were sterilised.
2.4.1 DNA Production
2.4.1.1 Small scale production of DNA
5ml LB growth media (580mM NaCl, 0.5 % (w/v) BactoYeast Extract, 1 % (w/v) Bacto- 
Tryptone pH7.5) supplemented with antibiotics in a sterile 25 ml universal tube was spiked 
with a pipette tip from a glycerol stock of transformed cells containing the DNA of 
interest. The culture was incubated at 37 “C overnight with agitation and the cells 
harvested the next day by centrifugation at 3000 rpm for 5 min (Heraeus bench-top 
refrigerated centrifuge). The DNA was extracted from the cells using the QIAprep spin 
miniprep kit according to the manufacturer’s instructions. Briefly: The bacterial pellet was 
resuspended in 250|ul Buffer PI (resuspension buffer), to which 250p.l Buffer P2 (lysis 
buffer) was added. The solutions were mixed and incubated at room temperature for 5 
minutes. 350)il of Buffer N3 (neutralisation buffer) was then mixed with the lysed cells 
and the solution was centrifuged for 10 min at 13000 rpm. The supernatant was added to 
the QIAprep spin column and centrifuged at 13000 rpm for 1 min. The flow through was 
discarded and the column washed with 750|il Buffer PE. The column was centrifuged for 1 
min prior to the elution of the bound DNA to ensure removal of all buffer. 50pl dHiO was 
placed onto the resin in the column and incubated for 5 minutes and the DNA was eluted
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from the column by centrifugation for 1 min at 13000 rpm (Heraeus bench-top refrigerated 
centrifuge).
2.4.1.2 Large scale production of DNA
400ml LB growth media supplemented with antibiotics in a 21 flask was spiked with a 
pipette tip from a glycerol stock of transformed cells containing the DNA of interest. The 
culture was incubated at 37°C overnight with agitation and harvested the next day by 
centrifugation at 5000g for 10 minutes using the JA-14 rotor in the Beckman refrigerated 
centrifuge. The DNA was extracted from the cell pellet using the Promega Wizard 
Maxiprep kit according to the manufacturer’s instructions. Briefly: The bacterial pellet was 
resuspended in 15ml resuspension solution, to which 15ml lysis buffer was added. The 
solutions were mixed gently and inverted for 15 minutes. 15ml of neutralisation buffer was 
then added to the lysed cells and the mixture was gently inverted three times. The cell 
lysate was clarified by centrifugation of the solution at 13000 g for 15 minutes at room 
temperature and then passed through muslin to separate out clumps. 0 . 6  x volume 
Isopropanol was added and mixed before centrifugation at 13000g for 1 hour at room 
temperature. The DNA pellet was then washed and resuspended in 2mls TE buffer. lOmls 
DNA purification resin was added and mixed with the resuspended DNA pellet. The 
resin/DNA mix was then passed through a Maxi column by attached to a vacuum manifold 
and applying a vacuum. To wash the columns, 25mls column wash solution was added and 
drawn through by vacuum. The resin was rinsed with 5mis of 80% ethanol. To ensure all 
ethanol was removed, the maxicolumn was centrifuged at 1300g for 5 minutes and the 
resin was then dried by applying a vacuum for 5 minutes. Following this, 1.5mls preheated 
(70°C) nuclease-free water was added to the maxicolumn to elute the DNA into a 50ml 
screw cap tube. The water was left on the column for 5 minutes at room temperature before 
centrifugation at I300g for 5 minutes.
2.4.1.3. Quantification of DNA & RNA
DNA and RNA concentrations were quantified by a WPA Lightwave spectrophotometer 
blanked with distilled water. 5pi DNA or RNA was diluted to 1ml with distilled water and 
absorbance measurements were taken at 260nM and 280nM. The concentration of nucleic 
acid was then calculated using the following approximations:
An absorbance reading of 1 at 260 nM corresponds to;
50pg/ml double stranded DNA 
40pg/ml single stranded RNA
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Therefore, [DNA] (pg/ml) = Azeox 50 x 200 (Dilution Factor)
[RNA] (pg/ml) = A260 X 40 X 200 (Dilution Factor).
The ratio between the absorbance measurements at 260nM and 280nM provided an 
indication of the purity of the nucleic acid. In solution, pure DNA or RNA typically have 
A 2 60 : A28 0 ratios of between 1.8 and 2.
2.4.2 Glycerol Stock Production
A 500pl sample from an overnight culture of transformed cells was taken aseptically and 
placed into a sterile screw top cryovial to which 500pl sterile 80% glycerol was added. The 
sample was mixed well and stored at -80°C for further use.
2.4.3 Reverse Transcription PCR
2.4.3.1 Total RNA extraction
For isolation of total RNA from hPASMC, a Qiagen RNeasy kit was used. Cells were 
trypsinised as described in section 2.1.1.2, pelleted and the medium aspirated. The cell 
pellet was then either frozen at -80°C for use at a later date or resuspended in 600pl Buffer 
RLT containing lOpl/ml of 14.5M P-Mercaptoethanol. Lysates were then loaded onto QIA 
shredders to ensure maximum homogenization of sample and the manufacturer’s 
instructions for the kit were followed.
In order to prevent potential contamination from genomic DNA, an incubation step with 4 
units DNase at room temperature for 15 minutes was included. The clean up protocol was 
also used to ensure maximal purity. Total RNA was eluted in RNase free H2 O and stored at 
-20°C.
To determine the concentration and purity of RNA, the absorbency of the sample was 
measured at 260nm and 280nm in a spectrophotometer. (WPA, Lightwave).
2.4.3.2 cDNA synthesis
First strand synthesis was carried out in each reaction using 2p,g total RNA catalysed by 
the enzyme Superscript II reverse transcriptase (Invitrogen). The reaction was primed 
using 500ng of 01igo(dT)15 (Promega), in a final volume of 20]li1. The reverse 
transcription mixture contained ljul of lOmM stock dNTP mix, 4|Li1 5X First strand buffer, 
2|il O.IM DTT, 40 units of RNasin Ribonuclease inhibitor and 200 units of Superscript II 
RNase H“ Reverse Transcriptase or 1|li1 H20(molecular biology grade) as a negative
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control for PCR. The mixture was incubated at 42°C for 50 minutes before heating to 70°C 
for 15 minutes to terminate the reaction. Control reactions were carried out without 
enzyme.
2.4.3.3 PCR reaction
The PCR reaction was set up using Platinum Pfx DNA Polymerase (Invitrogen). Ipg 
cDNA (generated in 2.4.3.2) was added to 2.5pl of lOX Pfx amplification buffer, 0.75pl of 
lOmM dNTPs, 0.5jal 50mM MgS0 4 , 0.75pl lOpM of each of sense and antisense primers 
for detection of the transcript of interest, 0.75pl lOpM of sense and antisense primers for 
cyclophylin, 0.25pl of Platinum Pfx DNA Polymerase and made up to a total volume of 
25pi with RNase- free water. Tubes were also set up as blanks using the control reactions 
without enzyme from section 2.4.3.2.
The PCR conditions used were as follows:
95°C for 2 minutes,
94°C for 30 secs,
’"58/60'^C for 30 secs, ]>- 40 cycles
72°C for 1 minute,
12°C for 10 minutes,
4®C forever.
'■‘T he  annealing temperature for 4D5 was 58°C whereas it was 60°C for all other isoforms. 
2.4.3A Semi-Quantitative RT-PCR
The PCR reaction was set out as in section 2.4.3.2 in triplicate. One tube per sample was 
removed after 30 cycles, one after 35 cycles and another was left to undergo another 5 
cycles. To ensure even comparison, there was no final extension step of 72°C for 10 
minutes.
2.3A .5 Visualisation of PCR Products
DNA was visualised using agarose gel electrophoresis, the percentage of agarose used in 
the gel was dependent on the size of DNA fragment to be identified, usually 2 %. For a 2 
% agarose gel 2 % agarose was dissolved in 1 x TBE (45mM Tris/HCl, ImM EDTA, 0.9M 
Boric Acid) by heating until the agarose dissolved. To this, 0.01 % ethidium bromide was 
added, which enabled visualisation of the DNA under a UV light source. The molten agar 
was poured into the gel apparatus, set up according to the manufacturer’s instructions and 
allowed to set completely. The comb and end stoppers were removed, the gel tank filled 
with Ix TBE and the samples loaded into the lanes. All DNA samples were diluted 6:1 in 
6x sample buffer (0.25 % Bromophenol Blue, 0.25 % xylene cyanol blue, 30 % glycerol in
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H2O). In order to size the DNA fragments, the moleeular size marker XIV (Promega) was 
loaded alongside the samples. The gel was run at 100 volts until the dye front moved 
sufficiently through the gel. The gel was removed from the tank and the DNA observed 
under UY light.
The range of separation of linear DNA molecules according to agarose concentration;
Percentage Gel Size of Fragment (kb)
0.9 0.5 -7
1.2 0.4 -6
1.5 0.2 -3
2 0.1 -2
2.5 Microarray Analysis
2.5.1 RNA Extraction
2.5.1.1 Extraction of total RNA
Total RNA from both normoxic and hypoxic samples was isolated as in section 2.4.3.1 
using the Qiagen RNeasy kit. RNA concentration was determined and samples were stored 
at '80°C until needed.
2.5.1.2 Clean up of total RNA
RNA was cleaned up following the add-on protocol of the Qiagen RNeasy kit to increase 
purity and remove potential contaminants.
2.5.2 Incorporation of Fiuorophores
2.5.2.1 cDNA synthesis
Two reaction tubes were set up together, one with either normoxic or hypoxic RNA and 
Cy3 or Cy5 -dCTP. cDNA was synthesised using 25 pg of total RNA mixed with 12pg 
random hexamers and incubated at 70°C for 10 minutes to allow the primers to anneal. 
First strand cDNA synthesis was performed using 400U Superscript II (Invitrogen) and 40 
pM of one of Cy-3 or Cy-5. This reaction was mixed and incubated at 25°C for 10 minutes 
then 42°C for five hours before stopping the reaction then cleaning up the cDNA using a 
QIAquick column.
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2.5.3 Hybridisation
2.5.3.1 incubation of mioroarray with sample
Both sets of cDNA were mixed together with a hybridisation buffer and incubated at 95°C 
for 3 minutes before being placed on ice for 1 minute. This mixture was then placed on the 
microarray and covered with a coverslip. The microairay was then rotated gently at 42°C 
for 24 hours.
2.5.3.2 Washing of microarray
The microairay was washed gently with SSC buffer three times by being placed inside a 
50ml centrifuge tube with buffer and placed horizontal on a rotator set at the lowest setting. 
The microarray was then dried by brief centrifugation.
2.5.4 Analysis
Analysis of microairay was canied out by Dr. Ian McPhee. A Genetic Microsystems 418 
array scanner was used to obtain the data with Imagene 5.0 to determine the values. Gene 
sight light 3.2 was used to normalise the data and calculate ratios.
2.6 Statistical Analyses
Data was analysed by two-way ANOVA with Bonferroni's post test using GraphPad Prism 
version 4.00 for Windows, GraphPad Software, San Diego California USA, to analyse raw 
data. Where only two groups of data were to be analysed, an unpaired t-test was 
performed, and =^ p<0.05 was considered to be significant.
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Antibody Company Dilution Incubation Time Secondary
PDE4A,B,C,D ICOS 1:10000 1 hour Anti-mouse IgG
PDE4A,B,C,D SAPU 1:5000 1 hour Anti-goat IgG
4A4 Genosys 1:5000 2 hours Anti-rabbit IgG
4A10 Genosys 1:1000 2 hours Anti-rabbit IgG
pERKl/2 Cell Signalling 1:1000 Overnight Anti-mouse IgG
ERKl/2 Cell Signalling 1:1000 Overnight Anti-mouse IgG
PKA RIa BD Transduction 1:1000 1 hour Anti-mouse IgG
PKA Rlla BD Transduction 1:1000 1 hour Anti-mouse IgG
PKA RIip BD Transduction 1:2000 1 hour Anti-mouse IgG
a - tubulin Sigma 1:10000 1 hour Anti-mouse IgG
Table 2.1 Antibodies and Dilutions
This table shows the antibodies used for western blotting throughout this study and the 
conditions determined to get an optimal immunoreactive signal.
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Chapter 3
Effect of Chronic Hypoxia on PDE4 in hPASMC
I l
3.1 Introduction
3.1.1 Pulmonary Arterial Hypertension
3.1.1.1 Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is eharaeterised by increased vascular resistance 
which leads to pulmonary artery remodelling and increased smooth muscle cell 
proliferation (Fishman 2004; Humbert et al., 2004). Normal mean adult pulmonary arterial 
pressure is ~14mm Hg whereas patients with pulmonary hypertension have a mean PAP 
exceeding 25mmHg at rest and 30mmHg during exercise. Pulmonary hypertension can 
occur without apparent cause, previously known as Primary Pulmonary Arterial 
Hypertension (PPAH) It is now known that PAH can be due to mutations in the bone 
morphogenetic protein receptor II, BMPR2, or 5-HT transporter gene (The International 
PPH Consortium et al., 2000; Thomson et al., 2000; Machado et al., 2001; Eddahibi et al., 
2003). Hence these forms have been classified as familial pulmonary arterial hypertension 
(FPAH; table 1.5). These cases only account for 6% of all PPAH patients. The occurrence 
of PPAH in the population is rare, with only two cases per million. PPAH can occur in 
men, women and children of all ages though it is most commonly seen in females between 
20 and 40 years old. PAH occurs more often secondary to pulmonary vascular disorders, 
such as chronic obstructive pulmonary disorder (COPD), and exposure to hypoxic 
conditions. This form of PAH is now classified as PAH’PAH with lung disease and /or 
hypoxemia’ and is relatively common but is underdiagnosed due to the large number of 
causes. As such, an estimate of the prevalence of secondary PAH is difficult to obtain. 
PAH is usually progressive and fatal.
There is cmrently no cure for PAH. Current treatments for PAH include anticoagulants, 
diuretics, calcium channel blockers and vasodilators. Vasodilators used include inhaled 
nitric oxide (NO), ACE inhibitors or prostacyclin. So far, only treatment with prostacyclin 
analogues such as iloprost have improved survival. Heart and/or lung transplantation is 
considered in extreme cases. Promising results have been found with sildenafil, a PDE5 
inhibitor, which has been shown to significantly reduce pressure in severe PPAH patients 
(Michelakis et al., 2003; Prasad et al., 2000). It has even been shown to be more effective 
than inhaled NO in decreasing PAP and reducing pulmonary vascular resistance 
(Michelakis et al., 2002). The responses to medication are varied between patients so it can 
take time before a successful drug therapy is achieved. If a cure is to be found for PAH,
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then the underlying cellular and molecular changes, along with the physiology of the 
disease, must be determined.
3.1.1.2 Hypoxia-induced Puimonary Hypertension
Hypoxia causes high altitude-induced PAH and is also thought to play a role in PAH 
associated with COPD. The mechanism underlying this is currently unclear. Animal and 
cellular models have been utilised to investigate PAH, and to suggest possible treatment 
targets.
Chronic hypoxia can lead to the structural remodelling of pulmonary arteries. In contrast to 
systemic arteries, the pulmonary arteries are distinct in that they constrict in response to 
hypoxia (Voelkel & Tuder, 1997). This is required for ventilation-perfusion matching in 
which pulmonary capillary blood flow is automatically adjusted to match alveolar 
ventilation.
It is known that vasoconstriction is an intrinsic property of pulmonary vascular smooth 
muscle cells (Voelkel and Tuder 1997) and it has been shown that hypoxia can have a 
direct effect on smooth muscle cells. After I week of hypoxia, proliferation rates of 
PASMC from distal human pulmonary arteries were observed to increase (Yang et al 
2002). The cells were also observed to contract in response to hypoxia (Murray 1990). Due 
to this, hypoxic PASMC have been used as a cellular model of PAH.
3.1.2 Cyclic Nucleotide Signalling in Models of Hypoxia-induced Puimonary 
Hypertension
3.1.2.1 Cyclic Nucleotides in Hypoxia
The second messengers’ cAMP and cGMP have been shown to play vital roles in the 
regulation of vascular smooth muscle tone (Murray et al., 1990b). cAMP and cGMP relax 
smooth muscle through the activation of protein kinase A (PKA) and protein kinase G 
(PKG) respectively. PKA and PKG can induce relaxation by acting on downstream targets 
of Ca2+ mobilisation (Shabb 2001; Marin et al., 1998). Activation of these kinases is 
achieved by either stimulating adenylyl or guanylyl cyclase or through inhibiting the action 
of cyclic nucleotide phosphodiesterases (PDEs). These pathways have been of interest to 
researchers to uncover the mechanisms underlying PAH (MacLean et ah, 1996). 
Investigation of the hypoxic Wistar rat model uncovered that the levels of both cyclic 
nucleotides are seen to decrease, with a corresponding increase in PDE activity, in 
response to two weeks of 10% O2 (MacLean et ah, 1997).
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3.1.2.2 Phosphodiesterases in Hypoxia
In the rat pulmonary arterial circulation, the predominant cyclic nucleotide 
phosphodiesterases are from the PDEl, PDE3, PDE4 and PDE5 families (Rabe et ah, 
1994), although PDE2 is also present (MacLean et ah, 1997).
Investigations into the expression of these PDEs in hypoxia have revealed that their 
profiles aie altered. PDE activity was examined in pulmonary arteries from control and 
hypoxia-induced pulmonary hypertensive rats (MacLean et ah, 1997). cAMP-PDE activity 
was increased in first-branch and intrapulmonary arteries from the hypoxic rats. cGMP- 
PDE activity was also increased in the first, intrapulmonary and main pulmonary arteries 
of the hypoxic rat. Investigation of these increases attributed it to an increase in PDE3, 
PDEl and PDE5 activities (MacLean et al 1997).
Using human PASMC and rat pulmonary artery homogenates, it was discovered that PDE3 
and PDE5 expression levels and activity were increased after two weeks exposure at 10% 
O2 (Murray et ah, 2002). The increase in the PDE3A isoform in hPASMCs was observed 
to be PKA-dependant and could be mimicked by cAMP analogs (Murray et ah, 2002). 
There was also an increase in PDE3 and PDE5A2 mRNA and protein levels in pulmonary 
arteries from the chronic hypoxic rat model (Murray et ah, 2002).
The role of PDE inhibitors as a therapy for PHT is under investigation. PDE inhibitors 
have been shown to reduce smooth muscle cell proliferation, migration and induce 
vasodilation of the pulmonary circulation (Koyama et ah, 2001; Ghofrani et ah, 2004; 
Wagner et al., 1997; Bardou et ah, 2002; Goirand et ah, 2001; Palmer et ah, 1998; Osinski 
& Shror 2000). Zaprinast, rolipram, eilostamide and theophylline can all oppose 
pulmonary vasoconstriction seen in hypoxia (Pauvert et ah, 2002, Goirand et ah, 2001). 
PDE3 or 4 inhibitors can also improve responses to ^-adrenergic agents that are attenuated 
in hypoxia. When both PDE3 and PDE4 inhibitors are used, they act synergistically to 
potentiate this effect (Wagner et ah, 1997). Rolipram has been obseiwed to be more potent 
than PDE3 or PDE5 inhibitors at relaxing human intralobar pulmonary arteries (Bardou et 
ah, 2002).
3.1.2.3 PDE4 in Hypoxia
PDE4 is a cAMP-specific, rolipram-inhibited PDE that is known to be the major 
hydrolysing enzyme of cAMP in vascular smooth muscle cells. There aie eighteen known 
human PDE4 isoforms with differing subcellular locations and modes of regulation
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(reviewed in Houslay 2001; further details in general introduction, sections 1.2.4 and
1.3). General PDE4 inhibitors are currently being tested as a putative therapy for such 
diseases as asthma and COPD (Giembycz 2001; Spina 2003). However, little is known 
about the effect hypoxia has on PDE4 isoforms in vascular smooth muscle cells. In this 
chapter, I set out to investigate PDE4 expression and activity in hPASMC under normoxic 
and hypoxic conditions.
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Results
3.2 Characterisation of PDE4 Profile in hPASMC
All methods used in this chapter are described in full in section 2, materials and methods.
3.2.1 Analysis of PDE4 expression
To determine the PDE4 profile in hPASMC, western blotting was employed as described 
in section 2.3.4. PDE4A, 4B, 4C and PDE4D antibodies have been raised against peptide 
sequences from the C-terminal of each PDE4 family. This has generated subfamily- 
specific isoforms as the C-terminal is only conserved among subfamily members, i.e. all 
PDE4A isoforms but not any PDE4B, PDE4C or PDE4D isoforms (Huston et al, 1996; 
Mackenzie et al., 1998). These PDE4 subfamily specific antibodies were used to probe 
hPASMC lysates to identify the PDE4 family isoforms present within these cells. The 
results gained were further specified and confirmed by RT-PCR analysis.
3.2.2. PDE4A profile in hPASMC
3.2.2.1 Western blot analysis of PDE4A isoforms in hPASMC
To identify whether PDE4A isoforms were expressed in hPASMC, cell lysates were 
immunoblotted with a 4A monoclonal antibody (Materials and Methods 2.3.4) raised 
against the sequence EEFVVAVSHSS, which is found at the C-termini of all known active 
human PDE4A isoforms. This detected a single PDE4 splice variant that co-migrated with 
recombinant PDE4A4 (Genbank accession L20965) and PDE4A10 (Genbank accession 
AF073745) isoforms, having an apparent Mwt of 120kDa when analysed by SDS-PAGE 
(Figure 3.1). PDE4A11 (Genbank accession AF069488) is also known to migrate at this 
weight. Thus, isoform specific antibodies were employed to identify this band. The 
PDE4A4 specific antibody did not react with hPASMC lysate indicating the absence of 
PDE4A4 in these cells. The specificity of this PDE4A4 specific antibody was confirmed 
by detecting PDE4A4 recombinant protein, but not PDE4A10 or PDE4A1. The specificity 
of the PDE4A10 antibody was confirmed by the detection of the PDE4A10 recombinant 
protein and not PDE4A4 or PDE4A1. This PDE4A10 specific antibody identified a band at 
l20kDa, confirming the presence of the PDE4A10 isoform in hPASMC. A PDE4A11 
antibody has not yet been successfully generated so it was impossible to confirm the 
absence or presence of PDE4A11 by western blotting.
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3.2.2.2 RT-PCR analysis of PDE4A isoforms in hPASMC
RT-PCR was employed to identify thel20kDa immunoreactive species detected through 
western blotting (Materials and Methods 2.4.3). As the long human PDE4A isoforms, 
PDE4A4, PDE4A10 and PDE4A11, all migrate at this weight on an SDS-PAGE gel, 
isoform specific primers were used to investigate transcript expression of these three splice 
variants. Primers to PDE4A1 and PDE4A7 were also used to investigate if transcripts for 
these isoforms were present or not. This was because PDE4A7 is truncated at the C~ 
terminus and there is no antibody available to detect it. Also, in the case of PDE4AI, it is 
possible that it could be expressed at such low levels that western blotting would be unable 
to detect it. RT-PCR analysis of total RNA identified the presence of PDE4A7, PDE4A10 
and PDE4A11 transcripts in hPASMC but not those for PDE4A4 {Figure 3.3).
3.2.3 PDE4B profile in hPASMC
3.2.3.1 Western biot analysis of PDE4B isoforms in hPASMC
To identify if any PDE4B isoforms are expressed in hPASMC, cellular lysates were 
immunoblotted with a PDE4B specific polyclonal antibody (Materials and Methods 2.3.4) 
raised against the sequence DPENRDSLGETDIDIATED, which is found at the C- 
terminus of all known, active PDE4B isoforms. This antisera detected a single PDE4B 
splice variant that co-migrated with the recombinant PDE4B2 standard (Genbank 
accession L20971) This PDE4B2 standard recombinant protein migrated at 80 kDa on 
SDS-PAGE {Figure 3.4).
3.2.3.2 RT-PCR analysis of PDE4B isoforms in hPASMC
As a means of confirming the presence of the PDE4B2 isoform, RT-PCR was employed to 
identify transcripts for the single immunoreactive species observed at 80kDa through 
western blotting (Materials and Methods 2.4.3). Primers specific to PDE4BI, PDE4B2 and 
PDE4B3 were also used to investigate transcript expression of these three known human 
PDE4B splice variants. RT-PCR analysis of total RNA using such isoform specific primers 
identified the presence of PDE4B2 transcripts but failed to detect those for PDE4B1 and 
PDE4B3, thus confirming the absence of expression of the PDE4BI and PDE4B3 long 
isoforms in hPASMC (Figure 3.6).
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3.2.4 PDE4C profile in hPASMC
3.2.4.1 Western blot analysis of PDE4C isoforms in hPASMC
To identify whether PDE4C is expressed in hPASMC, cellular lysates were immunoblotted 
(Materials and Methods 2.3.4) with a polyclonal PDE4C specific antibody, which detects a 
sequence located in the extreme C-termini of all known active PDE4C isoforms. This 
detected a single reactive species which co-migrated with recombinant PDE4C2 (Genbank 
accession U66346), which migrated with an apparent molecular weight of 80kDa on SDS- 
PAGE 7.7)
3.2.4.2 RT-PCR analysis of PDE4C isoforms in hPASMC
As a means of confirming the presence of the PDE4C2 isoform, RT-PCR was employed to 
identify the reactive species observed at 75kDa through western blotting (Materials and 
Methods 2.4.3). Primers specific to PDE4C2 were used to investigate transcript expression. 
RT-PCR analysis of total RNA using isoform specific primers identified the presence of 
PDE4C2 transcripts in hPASMC, thus confirming the western blot data that identified 
PDE4C2 expression (Figure 3.8).
3.2.5 PDE4D profile In hPASMC
3.2.5.1 Western blot analysis of PDE4D isoforms in hPASMC
To identify if any PDE4D isoforms are expressed in hPASMC, cellular lysates were 
immunoblotted with a PDE4D specific monoclonal antibody (Materials and Methods 
2.3.4) raised to a peptide corresponding to the sequence; TQDSESTEIPLDEQVEE, 
located at the C-termini of all known PDE4D isoforms. This detected three 
immunoreactive bands. These co-migrated with recombinant PDE4D1/2 (Genbank 
accession U50157, U50158 respectively), PDE4D3 (Genbank accession L20970) and 
PDE4D5 (Genbank accession S: 1059276), whose molecular weights are 68 kDa, 95kDa 
and 105kDa, respectively, on SDS-PAGE (Figure 3.9).
3.2.5.2 RT-PCR analysis of PDE4D isoforms in hPASMC
To confirm the presence of the PDE4D1/2, PDE4D3 and PDE4D5 in hPASMC, RT-PCR 
was employed to identify the reactive species observed through western blotting (Materials 
and Methods 2.4.3). Primers specific to PDE4D1, PDE4D2, PDE4D3 and PDE4D5 were 
used to identify transcript expression. Primers to PDE4D4 were also used to determine if 
this isoform was present at such low levels that western blotting would be unable to detect 
it. RT-PCR analysis of total RNA using isoform specific primers identified transcripts for
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PDE4D1, PDE4D2, PDE4D3 and PDE4D5, thus confirming their expression in 
hPASMC, but failed to identify transcripts for PDE4D4, confirming the inability to detect 
this isoform immunologically in hPASMC (Figure 3.11).
3.2.6 cAMP-PDE activity in hPASMC
PDE3 and PDE4 are known to be the main cAMP hydrolysing enzymes expressed in 
vascular smooth muscle cells (Palmer et al., 1998). In order to determine how much of this 
is attributable to PDE4 within hPASMC, a cAMP-PDE activity analysis (Materials and 
Methods 2.3.5) was carried out in the presence and absence of either the PDE4 selective 
inhibitor rolipram (Nemoz et al., 1985) or the PDE3 selective inhibitor, eilostamide. 
Briefly, the PDE activity of cell lysates was assayed in the presence of IpM cAMP in 
either the absence of presence of lOpM of the PDE4-specific inhibitor rolipram or the 
PDE3-specific inhibitor eilostamide. Analysis revealed that the main cAMP hydrolysing 
enzyme in hPASMC, contributing 53 ± 7% (SEM; n = 6) of the total cAMP-PDE activity, 
is the rolipram-sensitive fraction, namely PDE4 activity. It was found that a further 25 ± 
8% (SEM; n=3) of the activity is due to PDE3 activity (Figure 3.12). Total cAMP-PDE 
activity was 66.5 ± 4.7 pmol/min/mg protein (SEM; n=6), PDE4 activity was 37.1 ± 5.3 
pmol/min/mg protein (SEM; n=6) and PDE3 activity was 16.9 ± 0.7 pmol/min/mg protein 
(SEM; n=3).
3.3 Effect of chronic hypoxia on PDE4 In hPASMC
3.3.1 Examining the effect of chronic hypoxia on PDE4
Previous research into models of pulmonary hypertension has indicated that cAMP 
signalling is altered. Thus, once the PDE4 profile and activity had been determined in 
hPASMC, I set out to investigate whether these were altered by exposing the cells to 
hypoxic conditions. Initially, the cells were maintained in a 10% oxygen (balance N2) 
environment for a period of two weeks as done before (Murray et al 2002) and to 
determine the optimal time point to study the cells.
3.3.2 Analysis of PDE4 isoforms expression in chronic hypoxia
Cells were placed under hypoxic conditions (Materials and Methods 2.1.1.3) with a 
corresponding set of normoxic controls. Cells were harvested for lysate or total RNA as 
required and examined for PDE4 expression compared to normoxic.
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3.3.2.1 PDE4A
3.3.2.1.1 Western blot analysis of PDE4A
Cells were harvested and probed with the PDE4A subfamily antibody as described in 
materials and methods 2.3.4. PDE4A expression was seen to alter throughout the two 
weeks of hypoxia (Figure 3.13). The PDE4A isoform which migrated at 120 kDa on SDS- 
PAGE, and was thus the combined PDE4A10+PDE4A11 band, was seen to increase to 209 
± 58% (SEM; n=3) of basal levels after 24 hours exposure to hypoxia and this increase 
was maintained throughout the 14 days of incubation. Normoxic PDE4A10/4A11 only 
increased to 102 ± 63% (SEM; n=3) of basal levels.
3.3.2.1.2 Semi-quantitative RT-PCR analysis of PDE4A
In order to gain insight into whether the increase in PDE4A was due to either PDE4A10 or 
PDE4A11, I undertook semi-quantitative RT-PCR analysis on total RNA isolated from 
cells maintained under hypoxic conditions for seven days and the conesponding normoxic 
controls (Materials and Methods 2.4.3.3). Primers specific for PDE4A10 and PDE4A11 
were used and PCR was carried out on total RNA isolated from seven day normoxic and 
hypoxic cells. Primers for cyclophilin were also included to use as a control. It was seen 
that an increase in both PDE4A10 and PDE4A11 (Figure 3.14a) after seven days of 
hypoxia was confiimed. PDE4A10 levels were seen to increase to 138 ± 15.9% (SEM; 
n=3) as compared with normoxic. PDE4A11 increased to 124 ± 8% (SEM; n=3) of 
normoxic levels (Figure 3.14b).
3.3.2.2 PDE4B
3.3.2.2.1 Western blot analysis of PDE4B
The PDE4B subfamily specific antibody was used to probe cell lysates (Materials and 
Methods 2.3.4) collected over a two week period of exposure to 10% oxygen to examine 
any effect on the expression of the PDE4B2 isoform. The expression of PDE4B2 changed 
throughout the two weeks exposure with a transient increase at day 5-7 to 250 ± 64 % 
(SEM; 11=3) of basal levels and then this gradually decreased to 120 ± 2% over a further 
seven days of hypoxia (Figure 3.15).
3.3.2.2.2 Semi-quantitative RT-PCR analysis of PDE4B
Total RNA from cells collected after seven days hypoxia and noimoxia was used for semi- 
quantitative RT-PCR with PDE4B2 specific and cyclophilin primers to examine the 
increase observed in PDE4B2 seen through western blotting (Materials and Methods
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2.4.3.3). Transcript levels of PDE4B2 at day seven were seen to be 125 ± 16% (SEM; 
n=3) that of normoxic controls (Figure 3.16). This increase was considered insignificant in 
an unpaired t-test.
3.3.2.3 PDE4C
3.3.2.3.1 Western blot analysis of PDE4C
Lysates from hypoxic and normoxic cells were collected over the two week period and 
probed with the PDE4C specific antibody (Materials and Methods 2.3.4). PDE4C protein 
expression was observed to remain at basal levels throughout the two weeks with only a 
104 ± 3% (SEM; n=3) increase detected at day 7 (Figure 3.17).
3.3.2A PDE4D
3.3.2.4.1 Western blot analysis of PDE4D
To examine the protein levels of PDE4D within hypoxic and normoxic cells, the cells were 
harvested and the cell lysate probed with the PDE4D specific antibody (Materials and 
Methods 2.3.4). A gradual increase in PDE4D5 protein levels, peaking at day five to 
seven, was observed (Figure 3.18). This increase was maintained for the duration of the 
fortnight. Levels of PDE4D5 were seen to rise to 172 ± 19 % (SEM; n=3) at day 7 and 177 
± 17% (SEM; n=3) at day 14 of basal levels. PDE4D1/4D2 and PDE4D3 were not 
observed to change.
3.3.2.4.2 Semi-quantitative RT-PCR analysis of PDE4D expression
Total RNA from seven day hypoxic and normoxic cells was used for RT-PCR with 
PDE4D1/2, PDE4D3 and PDE4D5 specific primers (Materials and Methods 2.4.3.3). 
PDE4D1/2 levels were seen to alter slightly, with an increase of 115 ± 8% of PDE4D1 and 
116 ± 7 % of PDE4D2 (SEM; n=3) of normoxic levels. PDE4D5 was confiimed to 
significantly increase after seven days hypoxia to 115 ± 1% of basal levels (Figure 3.19a, 
b).
3.3.3 Western blot analysis of HiF-la Expression
Cells were placed under hypoxic conditions (Materials and Methods 2.1.1.3) with a 
corresponding set of normoxic controls for seven days to reach the time point witnessed 
with maximal change in PDE expression. Cell lysate was used to perform western blotting 
with an anti-HIF-la antibody to identify a key example of the expression of hypoxia 
regulated genes at this time point (Figure 3.20). An anti-human monoclonal HIE-la 
antibody used in previous studies was procured from BD Pharmingen (Hanze et al., 2003)
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and identified an immunoreactive band at 120kDa in hypoxic samples only. This 
concurs with the known molecular weight for HIF-la.
3.3.4 Microarray Analysis of normoxic and hypoxic hPASMC
Total RNA from normoxic and seven day hypoxic cells was used for hybridisation onto 
custom made cell-signalling microarrays from MWG Biotech. RNA was hybridised onto 
the microarray chips and analysis was carried out by Dr. Ian McPhec of Scottish 
Biomedical. The chips contained ‘spots’ of hybridisation for specific PDE4 isoforms and 
other signalling effectors including PKA isoforms, Rap and ERK. Spots for general PDE4 
families were also included. As the normoxic and hypoxic cDNA samples had been 
synthesised from RNA, they had incorporated different fluorophores. In different 
experiments, this labelling of samples was reversed to allow for naturally differing 
intensities of the fluorophores. After hybridisation, fluorophores were excited and intensity 
values were taken for each fluorophore for each spot on the chip. After normalisation, this 
data was then interpreted as a ratio of normoxic over hypoxic. By corresponding these 
values to a ‘map’ of the chip, changes in gene expression could be identified.
The changes are listed in figure 3.21. It was observed that the increase seen through 
western blotting and RT-PCR in PDE4A10/4A11, PDE4B2 and PDE4D5 could also be 
seen by mieroarray analysis as the general PDE4A and PDE4B, along with the specific 
PDE4D5 spots produced values indicative of an increase in expression in hypoxia. Other 
PDE isoforms observed to increase were the PDE5A3, PDE8A, PDE9A and PDE3. 
Strangely however, the general PDE5A spot indicated an overall decrease in PDE5A 
isoforms. The largest increase in expression of a PDE was of the PDE3B isoform, this 
isoform has previously been reported to increase in hypoxic hPASMC (Murray et al., 
2002). Modulation of the cAMP pathway appears to occur in the hypoxic samples as the 
PKA isoforms and Rap lb also show a change in expression. PKARI expression is altered 
with a shift in the RIa to Rip ratio as PKARip expression is increased in hypoxia. As there 
was no indication of an RIa isoform decrease in hypoxia, this indicates an overall increase 
in the PKARI subunit of PKA. Also noteworthy were increases in p53, NFkB and iNOS, 
all of which are already known to increase in hypoxia (Graeber et al., 1994; Chiarugi et al., 
1999; Igari et a l, 1998; Palmer et a l, 1998).
3.3.5 Effect of chronic hypoxia on cAMP-PDE activity
With the observed increase in PDE4 expression in hypoxic hPASMC, I then set out to 
determine cAMP-PDE activity in normoxic and hypoxic cells to see if this was altered in 
hypoxic cells by the change in PDE4 expression.
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3.3.5.1 Total cAMP~PDE activity
Lysates from hypoxic and normoxic cells were assayed for cAMP PDE activity with IpM 
cAMP as substrate as described in section 2.3.5. Surprisingly, there appeared to be no 
significant increase in total cAMP-PDE activity (Figure 3.22). Normoxic total cAMP-PDE 
activity was 66.5 ± 4.7 pmol/min/mg protein (SEM; n=6), whilst a value of 70.8 ± 4.7 
pmol/min/mg protein (SEM; n=6) was noted after 7 days hypoxia.
3.3.5.2 PDE3
PDE enzymatic activity of seven day hypoxic cell lysates was assayed in the presence of 
lOpM of the PDE3-specific inhibitor cilostamide in order to determine PDE3 activity 
(Materials and Methods 2.3.5). As can be seen in figuie 3.22 no evident change in PDE3 
activity was observed. Normoxic PDE3 activity was 16.9 ± 0.7 pmol/min/mg protein 
(SEM; n=3) whilst a value of 19.6 ± 6.2 pmol/min/mg (SEM; n=3) was observed after 7 
days hypoxia.
3.3.5.3 PDE4
Cell lysates from seven day hypoxic and normoxic cells were assayed for PDE4 enzymatic 
activity. This was achieved by measuring total cAMP-PDE activity at IpM cAMP 
substrate concentration in the presence and absence of lOpM of the PDE4-specific 
inhibitor, rolipram (Materials and Methods 2.3.5). Again, little difference in PDE4 activity 
was noted (Figure 3.22). Normoxic PDE4 activity was 37.2 ± 5.3 pmol/min/mg protein 
(SEM; n=6), which increased to 44.3 ± 3.4 pmol/min/mg protein after 7 days hypoxia 
(SEM; 11=3).
3.3.5.4 immunoprecipitated PDE4 subfamilies
The total PDE4 activity is represented by four subfamilies within hPASMC. As each 
subfamily, and indeed individual isoforms, are subject to different modes of regulation, 
measuring total PDE4 activity would not reveal any change in specific PDE4 subfamily 
activities. Therefore, I used cell lysates from seven day hypoxic and normoxic cells to 
assay specifically for the different PDE4 subfamily enzymatic activities. This was achieved 
by selectively immunopurifying the respective PDE4 subfamilies, as described in section 
2.3.6, and using the resulting samples in a cAMP-PDE assay. An increase in the PDE 
activity for all four PDE4 subfamilies, including PDE4C, was observed (Figure 3.23). 
However, whilst the appaient increase in PDE4A, PDE4B and PDE4C activities was not 
significant that for the PDE4D subfamily was significantly increased (p<0.01) to 172% of 
normoxic PDE4D activity. Thus the key target for hypoxia-induced increase in PDE4 
activity is due to the PDE4D sub-family, but such an effect can be partially masked due to
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the activities of the three other PDE4 subfamilies, which are little if at all changed in 
hypoxia.
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3.4 Discussion and Conclusions
Exposing vascular smooth muscle cells to hypoxia has been shown to alter many cell 
signalling pathways including cAMP and cGMP signalling (MacLean et ah, 1997; MuiTay 
et ah, 2002). The decrease observed in cyclic nucleotides in hypoxia has been attributed to 
increased hydrolysis by PDEs as cAMP-PDE and cGMP-PDE activities have been 
reported to increase in the pulmonary arteries of the hypoxic rat (MacLean et ah, 1997). 
The cGMP-PDE PDE5 and the cAMP-PDE PDE3 have previously been reported to 
increase during chronic hypoxia in the pulmonary arteries of the rat and in hPASMC 
(Murray et ah, 2002). Although PDE4 activity represents a major cAMP-hydrolysing 
activity within these cells, their expression and activity have not been fully investigated.
Each cell type has a specific profile of cAMP-PDE isoforms, which is presumed to enable 
differential regulation of cAMP signalling (Houslay & Milligan 1997; Houslay 1998). It 
has previously been established that the major cAMP-PDEs present within vascular 
smooth muscle cells are PDE3 and PDE4 (Maurice et ah, 2003). Prior research has 
investigated PDE3 expression and shown that the PDE3A and PDE3B isoforms are present 
within hPASMC (Murray et al 2002). Investigation into the PDE4 profile showed 
conclusively that PDE4A7, PDE4A10, PDE4A11, PDE4B2, PDE4C, PDE4D1, PDE4D2, 
PDE4D3 and PDE4D5 are expressed in hPASMC. PDE4 activity contributes 
approximately 53% of the total cAMP-PDE activity within hPASMC with PDE3 being 
responsible for another 25% under basal/resting conditions.
Once I had established the PDE4 profile within hPASMC, I set out to investigate if this 
profile was altered in chronic hypoxia, initially through western blotting and then 
confirmation by RT-PCR. This enabled me to discover that the level of expression of the 
PDE4 isoforms, PDE4A10, PDE4A11, PDE4B2 and PDE4D5 were all increased to 
varying degrees over 14d of exposure to 10% O2 . The increase in both PDE4A10 and 
PDE4A11 was due to increased transcription with RT-PCR identifying a 138% and 124% 
increase in PDE4A10 and PDE4A11 respectively. This was the largest increase observed 
of the PDE4 isoforms increased in hypoxia. The increased transcription of 
PDE4A10/PDE4A11 is suggestive of a hypoxic transcription factor such as HIF-1 being 
responsible for the upregulation of these PDE4A isoforms. As PDE4A10 and PDE4A11 
are recently characterised PDE4A isoforms, their functional attributes have not yet been 
determined. It has been hypothesised that PDE4A10 could be involved in the inflammatory
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response due to the presence of possible sites for GATA within its promoter. This site is 
known to interact with the HiOa-activated USF (Andrews 2000) as well as CREB and 
NFkB. Indeed, acute hypoxia has been observed to increase GATA DNA binding activities 
(Jamali et al., 2004). It is known however that the PDE4A subfamily is not subject to 
regulation by ERK (Baillie et al. 2000). This means PDE4A10 and PDE4A11 activities are 
not susceptible to inhibition by the increased active ERK reported in hypoxic vascular 
smooth muscle cells (Minet et al., 2000b; Scott et al., 1998; Welsh et al., 2001).
The increase in the PDE4B2 isoform represented the largest increase in protein levels 
among the altered PDE4 isoforms with an increase to 250% of basal levels. Although RT- 
PCR identified an increase in PDE4B2 transcription to 125 % of basal, this increase was 
not deemed significant by an unpaired t-test due to the large standard error of the mean. 
PDE4B2 has been established as having a key role in the regulation of inflammatory 
responses (Ma et al., 1999; Wang et al., 1999; Oger et al., 2002). Myométrial contractility 
occurs due to intrauterine infections which induce an inflammatory response involving an 
increase in the levels of IL-lp. An increase in PDE4B2 expression has been reported to 
occur in human smooth muscle myométrial cells exposed to IL-lp due to the increased 
cAMP levels produced through induction of PGE2 (Oger et al., 2002), thereby acting in a 
feedback loop to regulate cAMP levels. IL-ip increased cAMP to maximal levels after 12 
hours and this induced an increase in PDE4 activity, increasing the hydrolysis of cAMP 
and returning cAMP levels to normal after a further 12 hours. An increase in PDE4B2 has 
also been observed directly in response to cAMP raising agents in human myométrial cells 
(Mehats et al., 1999). This suggests that the increase in PDE4B2 could be due to an 
increase of cAMP in hypoxia. In hypoxic rat pulmonary arteries however, a decrease in 
cAMP levels is observed (MacLean et al. 1997). This occurred after 14 days of hypoxic 
exposure. The increase in PDE4B2 protein levels observed here was transient as protein 
levels returned to normal after 14 days, suggesting a similar feedback loop to that shown in 
the myométrial cells (Figure 3.24). Hypoxia could initially induce an increase in cAMP 
levels through inflammatory mediators and cause an increase in PDE4B2 activity, 
reducing cAMP levels to below that of normal and alleviate the induction of PDE4B2 
expression.
Although previous studies have shown cAMP prevents the induction and maintenance of 
contraction in smooth muscle cells (Silver 1985), PDE4 inhibitors can block spontaneous 
myométrial contraction (Mehats et al., 2002). During this spontaneous contraction, 
PDE4B2 levels increase, suggesting a role for PDE4B2 in this response (Mehats et al.,
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2002). Therefore, this is suggestive of a remodulation of cAMP signalling during this 
contraction and infers PDE4B2 could be initially involved in the hypoxic pulmonary 
vasoconstrictive response seen in models of PAH.
PDE4D isoforms are involved in the maintenance of airway smooth muscle tone (Mehats 
et al., 2003). PDE4D knockout mice are refractory to muscarinic cholinergic stimulation 
and show increased sensitivity to PGE2 (Hansen et al., 2000). Therefore an alteration in 
PDE4D could affect smooth muscle contraction and relaxation, suggesting the increased 
expression of PDE4D5 could also be involved in the hypoxic pulmonary vasoconstrictive 
response. As PDE4D5 increased levels are maintained whereas the PDE4B2 levels return 
to normal, it is possible that PDE4D5 is involved in the maintenance of contraction, while 
PDE4B2 is involved in the initial phase of contraction.
PDE4D5 levels have been reported to increase in human airway smooth muscle in 
response to cAMP-elevating agents (Le Jeune et al., 2002). This response was shown to be 
due to a cAMP-response element (CRE) within the promoter region of PDE4D5. This 
again is suggestive of an initial rise in cAMP levels in hypoxia which cause an increase in 
PDE4D5 expression. Indeed, the PDE4D5 increase was shown to be due, at least in part, to 
increased transcription as RT-PCR identified a 115% increase in transcript levels after 7 
days hypoxia. PDE4D1 and PDE4D2 also contain a CRE site within theh promoters. It 
was observed that their transcript levels increased to 115% and 116% respectively, 
although no notable increase in PDE4D1/PDE4D2 protein levels was obseiwed. The effect 
of hypoxia on these PDE4D, cAMP-inducible isoforms, is again suggestive of an increase 
in cAMP levels in hypoxia.
In this study, the increase in PDE4 expression was not mirrored by a significant increase in 
total PDE4 activity after seven days of hypoxic exposure. Examining PDE4 subfamily 
activities, an increase in PDE4D activity to 172% of normoxic levels was observed. Total 
PDE3 activity was also unaffected, but has previously been reported to be increased after 
14 days hypoxia in hPASMCs in a manner mimicked by cAMP-raising agents and blocked 
by a PKA inhibitor (Muixay et al., 2002). In the aforementioned study (Mehats et al., 
2002), the observed increase in PDE4 activity was not an immediate effect and required 18 
hours exposure to IL-ip, not reaching maximal levels until after 24 hours. These combined 
results lend credence to the hypothesis that cAMP signalling undergoes a gradual 
remodulation during chronic hypoxia, with cAMP levels initially rising and a concomitant 
increase in PDE activity. After prolonged exposure to high cAMP levels however, the PDE
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activities increase to a sufficient level to reduce cAMP and attenuate the effect of 
cAMP-raising agents (Wagner et al., 1997) alleviating the induction of PDEs by cAMP 
(Figure 3.24). As many other pathways are altered in hypoxia, it is possible that after 
cAMP no longer regulates the expression of PDEs, other factors can affect their regulation 
and indeed maintain the increase in some PDEs.
To confirm the activation of hypoxia induced pathways in the seven day hypoxic cells, the 
presence of the transcription factor H IF-la was investigated. H IF-la  is constituitively 
expressed within cells, but is degraded within minutes under normal conditions (Sutter et 
al., 2000). Under hypoxic conditions however, degradation of the H IF-la subunit is 
attenuated allowing H IF-1 to act upon hypoxia inducible genes containing HIF-1 binding 
sites. Using a commercial H IF-la antibody, the presence of H IF-la  was confirmed in 
hypoxic hPASMC, indicating the cellular responses to hypoxia were activated.
To further confirm the increase in PDE4 protein levels and investigate other signalling 
pathways, microarray analysis was utilised to examine hypoxia dependant changes in 
expression. Increases in p53, NFicB and iNOS, all of which are already known to increase 
in hypoxia, were observed (Graeber et al., 1994; Chiarugi et al., 1999; Igari et al., 1998; 
Palmer et al., 1998). Microarray analysis indeed confirmed an increase in PDE4D5, 
PDE4A10 and PDE4A11 expression in hypoxia. The increase observed in the PDE3B 
isoform has previously been identified in hypoxic hPASMCs (Murray et al., 2002).
The increase in the Rip subunit of PKA also indicated an alteration in response to cAMP 
within hypoxic cells. PKARI has previously been shown to be a little overexpressed in 
normal cells upon stimulation of proliferation, but is constituitively expressed in tumours 
(McDaid., et al 1999). Vascular smooth muscle cells are known to proliferate in response 
to hypoxia (Yuan & Rubin 2001). This indicates upregulation of PKARIp could be 
involved in the proliferative response of vascular smooth muscle cells to hypoxia.
However, the results from the microarray analysis are only indicative of possible 
alterations in gene expression as the analysis was only performed twice and problems with 
microarray analysis have to be taken into account (Watson et al., 2000). Variations 
between chip to chip, even spot-to spot, allow for problems when considering background 
levels to normalise data. With tightly regulated genes, this problem is emphasised and 
small, significant changes are difficult to confirm. Thus, enough replicate micro array 
hybridisations require to be performed to confirm the data collected.
The data presented in this chapter indicates that the cellular response to chronic hypoxia is 
a gradual process, with certain signalling pathways being altered immediately, and others 
occurring over an extended period due to alterations in gene expression and activity. The 
results suggest cAMP levels are increased immediately, with CRE-regulated genes being 
induced including PDE4B2, PDE4D1, PDE4D2 and PDE4D5. This increase in cAMP- 
PDE isoforms reduces cAMP over time and is responsible for the desensitisation of the 
cAMP pathway in hypoxia (Figure 3.24). Unfortunately, as cAMP-PDE activity was not 
observed to increase after seven days and a time point of fourteen days was not examined, 
this would need further work to explore in detail.
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Figure 3.1 W estern blot analysis o f PDE4A isoform s expressed in hPASM C.
hPASMC cells were harvested in cKHEM buffer and cell lysate was made as described in 
section 2.3.1.1. 40pg protein was ran out on an 8% SDS-PAGE alongside 5pg recombinant 
protein standards o f PDE4A isoforms PDE4A1 (79kDa), PDE4A4 (125kDa) and 
PDE4A10 (121kDa). This was then transferred to nitrocellulose and probed with an 
antibody directed against the c-terminus o f PDE4A. As PDE4A4, PDE4A10 and 
PDE4A11 all run at similar weights on a gel, (125, 121 and 126 kDa respectively), isoform 
specific antibodies directed against the n-terminus of PDE4A4 (Panel A), PDE4A10 
(Panel B), and the c-terminus o f PDE4A to produce a general 4A antibody (Panel C) were 
used to distinguish which isoform was being expressed in hPASMC. The molecular weight 
markers are indicated. A band o f approximately 120kDa (indicated in bold), thus 
corresponding to the PD E4A 10/4A 11 isoforms, was detectable in hPASMC lysate.
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PRIMER
NAME PRIMER SEQUENCES (5' - 3")
FRAGMENT
LENGTH
# )
4A1
4A1 F TTCTTCTGCG AGACCTGCTC TAAGC
3444A1 R GGT CTT GAG CCG AAA TCG GGG 
AAT
4A 4F GGG AAA GGA GGG TGT GTC TG
2574A4 R AGT GGG ATG GAA GGA GGA GG
4A7
4A 7F GAT AAT GGT GGT TGG TTC AGA GGA 
AGGC
3484A7 R GGA GGA GTA GGT GGG TGG ACT 
GGA GGA
4A10
4A10F AGA TGT GTC AGG TTC GAG GGA G
2814A10R AGT GAG AAG TTG GTA GGG AGG G
' 4A11 4A11 F GGG TAG GGG GGA TCG GGG AGG TGG AAG T 350
Figure 3.2 Primer sequences used for analysis of PDE4A isoforms in hPASMC.
A table indicating primer sequences and fragment size expected for of human PDE4A  
splice variants, hsPDE4A 1 (Genbank accession U97584), hsPDE4A4 (Genbank accession 
L20965), hsPDE4A7 (Genbank accession U 18088), hsPDE4A10 (Genbank accession 
AF073745), and hsPDE4Al 1 (Genbank accession AF069488).
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Figure 3.3 RT-PCR analysis of hPASMC using PDE4A specific primers.
R N A  was isolated from hPA SM C  and subjected to first strand cD N A  synthesis as 
described in section 2 .4 .3 .2 ., fo llow ed  by RT-PCR using primers specific  for the P D E 4A  
isoform s, h sP D E 4 A l, hsP D E 4A 4, hsP D E 4A 7, hsP D E 4A 10 and hsP D E 4A l 1 (see figure
3.2 fo r  primer secpiences and acce.ssion numbers). The PCR products were ran out on a 2% 
agarose gel along side a negative control. W hen the negative control indicated  
contam ination, the PCR result w as discarded. D N A  marker sizes are indicated. Primer 
products o f  approxim ately 280bp, 310bp and 390bp were detected with P D E 4A 10, 
P D E 4 A 1 1 and P D E 4A 7 primer sets respectively  (indicated in bold).
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Figure 3.4 Western blot analysis of PDE4B isoforms expressed in hPASMC.
hPA SM C  cells w ere harvested in cK H EM  buffer and cell lysate w as m ade as described in 
section 2 .3 .1 .1 . 4 0 p g  protein w as ran out on an 8% SD S-P A G E  alongside 5p g  recom binant 
protein o f  PD E4B isoform s PDE4B1 (104kD a), PD E 4B 2 (SOkDa) and PD E 4B 3 (103kD a). 
This w as then transferred to nitrocellu lose and probed with an antibody directed against the 
com m on PD E4B c-term inus region. A  band o f  approxim ately 70kD a (indicated in bold) 
could  be detected. A s this was the sam e w eight as the PD E 4B 2 protein standard ran on the 
gel, this band w as assum ed to be P D E 4B 2 in hPA SM C  lysate.
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PRIMER
NAME PRIMER SEQUENCES (5' - 3')
FRAGMENT
LENGTH
(bp)
4B1
4B l F AAA GGA GGA GTG TGA TGA GGG
236
4B1 R GGT TGT GAA AGG GAG TGT GGT
4B2
4 B 2 F GGT TGA GAT GGG AAA GGA GTG
264
4B 2R AAT GAG AGT GGT GGT GTG GGT
4B3
4B 3 F AAA AGG ATT GGG GAG GGT G
214
4B3 R TGG AGA TGG GGT TTG GTG A
Figure 3.5 Primer sequences used for analysis of PDE4B isoforms in hPASMC.
A table indicating primer sequences and fragm ent size  expected  for the human PD E4B  
sp lice  variants, h sP D E 4B l (Genbank accession  L 20966), hsPD E 4B 2 (Genbank accession  
L 20971), and hsPD E 4B 3 (Genbank accession  U 85048).
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Figure 3.6 RT-PCR analysis of hPASMC using PDE4B specific primers.
R N A  w as isolated from hPA SM C  and subjected to first strand cD N A  synthesis as 
described in section 2 .4 .3 .2 , fo llow ed  by RT-PCR using primers sp ecific  for the PD E 4B  
isoform s, h sP D E 4 B l, hsP D E 4B 2 and hsPD E 4B 3 (see figure 3.5 fo r  prim er sequences and 
accession numbers). The PCR products were ran out on a 2% agarose gel along side a 
negative control. W hen the negative control indicated contam ination, the PCR result w as 
discarded. D N A  marker sizes are indicated. A  primer product o f  approxim ately 250bp w as 
detected with the P D E 4B 2 primer set (indicated in bold).
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Figure 3.7 Western blot analysis of PDE4C isoforms expressed in hPASMC.
hPA SM C  ce lls  w ere harvested in cK H EM  buffer and cell lysate w as m ade as described in 
section 2. 3 .1 .1 . 4 0 |ig  protein was run out on 8% SD S-P A G E  alongside 5p g  recombinant 
protein o f  the PDE4C isoform  PD E 4C 2 (SOkDa). This w as then transferred to 
nitrocellu lose and probed with an antibody directed against the c-term inus o f  PD E4C . A  
band o f  approxim ately 85kD a (indicated in bold) could be detected.
96
PRIMER
NAME PRIMER SEQUENCES (5' - 3')
FRAGMENT
LENGTH
(bp)
4C
4C F ATG GAT GGT AAA GCC CTT TGG 
GTC TTG G
95
4C R GTG TGG GTA AAT GGG TGG GAA  
AGT GAA G
B
5 0 0 —
100_   cyclophilin—  4C2 (lOObp)
XIV 4C
Figure 3.8 RT-PCR analysis of hPASMC using PDE4C specific primers.
Panel A, a table indicating primer sequences and fragment size  expected  o f  the transcript 
o f  the human PD E4C  sp lice variant, hsPD E4C 2 (Genbank accession  U 66346).
Panel B, R N A  w as isolated from hPA SM C , subjected to first strand cD N A  synthesis as 
described in section 2 .4 .3 .2  and fo llow ed  by RT-PCR using primers specific  for the 
PD E4C  isoform , hsPD E 4C 2. The PCR products were ran out on a 2% agarose gel along  
side a negative control. W hen the negative control indicated contam ination, the PCR result 
was discarded. D N A  marker s izes are indicated. A  primer product o f  approxim ately 1 lObp 
w as detected with the P D E 4C 2 primer set (indicated in bold).
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Figure 3.9 Western blot analysis of PDE4D isoforms expressed in hPASMC.
hPASMC cells were harvested in cKHEM buffer and cell lysate was made as described in 
section 2.3.1.1. 40pg protein was ran out on an 8% SDS-PAGE alongside 5pg recombinant 
protein o f PDE4D isoforms PDE4D1 (68kDa, PDE4D2 runs at a similar weight, 67kDa), 
PDE4D3 (95kDa), PDE4D4 (119kDa) and PDE4D5 (105kDa). This was then transferred 
to nitrocellulose and probed with an antibody directed against the c-terminus o f PDE4D. 
The molecular weight markers are indicated. Bands o f approximately lOOkDa, 89kDa and 
65kDa (indicated in bold) could be detected in hPASMC lysate.
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B PRIMERNAME PRIMER SEQUENCES (5' - 3') FRAGMENTLENGTH
(bp)
4D 1/2
4 D 1 /2 F ATA TGA AGG AGC AGC CCT CAT G
221 & 307
4D 1/2R CCA GAG GGA GTG ATT TGA GAG A
4D3
4D3 F GGG AAG ATG ATG GAG GTG AA
292
4D3 R TGG GGA AGA GGT GAG GAA AT
4D4
4 D 4 F AGA AAT GGA GGA TGT GGT GGG
347
4D 4 R TGG TAG GTG GTG GAT GTT GGA
4D5
4D5 F TGG GAG GTG TAG AAA GTT GAG G
212
4D5 R TTG TGG GAG AGA TGA GTG GAG A
Figure 3.10 Primer sequences used for analysis of PDE4D isoforms in hPASMC.
A table indicating primer sequences and fragment size  expected for the human PD E 4D  
sp lice variants, h sP D E 4 D l/2  (Genbank accession  U 50157 , U 50158 respectively), 
hsPD E 4D 3 (G enbank accession  L 20970), hsPD E 4D 4 (Genbank accession  L 20969), and 
hsP D E 4D 5 (Genbank accession  8 :1 0 59276).
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Figure 3.11 RT-PCR analysis of hPASMC using PDE>4D specific primers.
RNA was isolated from hPASMC and subjected to first strand cDNA synthesis as 
described in section 2.4.3.2., followed by RT-PCR using primers specific for the PDE4D  
isoforms, hsPD E4D l, hsPDE4D2, hsPDE4D3, hsPDE4D4 and hsPDE4D5 (see figure 3.11 
for primer sequences and accession numbers). The PCR products were ran out on a 2% 
agarose gel along side a negative control. When the negative control indicated 
contamination, the PCR result was discarded. DNA marker sizes are indicated. Primer 
products of approximately 200bp, 220bp, 300bp and 300bp were detected with the 
PDE4D1, PDE4D5, PDE4D3 and PDE4D2 primer sets respectively (indicated in bold).
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Figure 3.12 cAMP-PDE activity in hPASMC.
C ells w ere harvested in cK H EM  + 1% Triton and the lysates w ere assayed for total 
cA M P -P D E  A ctivity, PD E 4 A ctivity, determ ined as the rolipram sensitive fraction, and 
PDE3 A ctivity, determ ined as the cilostam ide sensitive fraction. Phosphodiesterase assay  
m ethod w as described in section 2 .3 .5 . R esults are expressed as panel A, mean +/- S.E. o f  
3 independent experim ents in pm ol/m in/m g protein and panel B, percentage o f  total 
cA M P -P D E  activity.
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Figure 3.13 Western blot analysis of the effect of chronic hypoxia on PDE4A isoform 
expression.
hPA SM C  were split into tw o groups, one was treated as normal and the other was 
m aintained in a 10% 0% environm ent for a period o f  two w eeks. Both sets were treated 
identically throughout. C ells w ere harvested from both groups at days throughout the time 
course and 4 0 p g  protein from each tim e point w as used for western blotting.
Panel A, blots were probed with a pan PD E 4A  antibody. Results shown are hypoxic  
sam ples. Panel B, densitom etry results with norm oxic and hypoxic tim e points com pared  
directly expressed as a percentage o f  the respective basal density.
B lot show n is representative o f  three independent experim ents and *, ** denotes 
sign ificance (p<0.05 , p<0.01 respectively)
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Figure 3.14a RT-PCR analysis of the effect of chronic hypoxia on PDEI4A isoform 
expression.
RNA was isolated from both normoxic and 7 day hypoxic hPASMC and subjected to first 
strand cDNA synthesis as described in section 2.4.3.2. This was followed by RT-PCR 
using Superscript II and primers specific for the PDE4A isoforms (see figure 3.2). The 
PCR products were ran out on a 2% agarose gel along side negative controls. When the 
negative control indicated contamination, the PCR result was discarded. DNA marker sizes 
are indicated. The PDE4A PCR products identified are shown and are representative of 
three independent experiments.
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Figure 3.14b Densitometry of RT-PCR analysis of the effect of chronic hypoxia on 
PDE4A isoform expression.
Q uantity-one software w as used to measure the density o f  each band which w as then 
norm alised against the density o f  the corresponding cycloph ilin  band. Panel A; 
densitom etric analysis o f  P D E 4A 7 band expressed as a percentage o f  the norm oxic band 
present at 35 cycles. Panel B; densitom etric analysis o f  P D E 4A 10 band expressed as a 
percentage o f  the norm oxic band present at 35 cycles. Panel C; densitom etric analysis o f  
PD E4A 11 band expressed as a percentage o f  the norm oxic band present at 35 cycles. 
Results shown are mean ± S.E . o f  three independent PCR reactions and * denotes 
sign ificance (p<0.05).
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Figure 3.15 Western blot analysis of the effect of chronic hypoxia on PDE4B isoform 
expression.
hPA SM C  were split into two groups, one was treated as normal and the other was 
m aintained in a 10% O 2 environm ent for a period o f  tw o w eeks. Both sets were treated 
identically throughout. C ells w ere harvested from both groups at days throughout the time 
course and 4 0 p g  protein from each tim e point w as used for western blotting.
Panel A, blots were probed with a pan PD E 4B  antibody. R esults show n are hypoxic  
sam ples. Panel B, densitom etry results with norm oxic and hypoxic tim e points com pared  
directly expressed as a percentage o f  the respective basal density. B lot show n is 
representative o f  three independent experim ents and * denotes sign ificance (p<0.05).
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Figure 3.16 RT-PCR analysis of the effect of chronic hypoxia on PDE4B isoform 
expression.
RNA was isolated from both normoxic and 7 day hypoxic hPASMC and subjected to first 
strand cDNA synthesis as described in section 2.4.3.2. This was followed by RT-PCR 
using Superscript II and primers specific for the individual PDE4B isoforms (see figure 
3.5). The PCR products were ran out on a 2% agarose gel along side negative controls. 
When the negative control indicated contamination, the PCR result was discarded. DNA 
marker sizes are indicated. Panel A, PDE4B PCR products, panel B, densitometric analysis 
of PDE4B2 band expressed as a percentage of the normoxic band present at 40 cycles. The 
results shown are indicative of three independent experiments.
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Figure 3.17 Western blot analysis of the effect of chronic hypoxia on PDE4C isoform 
expression.
hPASM C were split into tw o groups, one was treated as normal and the other was 
maintained in a 10% O 2 environm ent for a period o f two weeks. Both sets were treated 
identically throughout. Cells were harvested from both groups at days throughout the time 
course and 40pg protein from each tim e point was used for western blotting.
Panel A, blots were probed with a pan PDE4C antibody. Results shown are hypoxic 
samples. Panel B, densitom etry results with normoxic and hypoxic time points com pared 
directly expressed as a percentage of the respective basal density.
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Figure 3.18 Western blot analysis of the effect of chronic hypoxia on PDE4D isoform 
expression.
hPA SM C  were split into tw o groups, one was treated as normal and the other was 
maintained in a 10% O 2 environm ent for a period o f  two w eeks. Both sets were treated 
identically throughout. C ells w ere harvested from both groups at days throughout the tim e 
course and 4 0 p g  protein from each tim e point w as used for western blotting.
Panel A, blots were probed with a pan P D E 4D  antibody. R esults show n are hypoxic  
sam ples. Panel B, densitom etry results with norm oxic and hypoxic tim e points com pared  
directly expressed as a percentage o f  the respective basal density.
B lot show n is representative o f  three independent experim ents and ** denotes sign ificance
(p<0.01).
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Figure 3.19a RT-PCR analysis of the effect of chronic hypoxia on PDE4D isoform 
expression.
R N A  w as isolated from both norm oxic and 7 day hypoxic hPA SM C  and subjected to first 
strand cD N A  synthesis as described in section 2.4 .3 .2 . T his w as fo llow ed  by RT-PCR  
using Superscript II and primers specific  for the PD E4D  isoform s (see figure 3.11). The 
PCR products were ran out on a 2% agarose gel along side negative controls. W hen the 
negative control indicated contam ination, the PCR result w as discarded. D N A  marker sizes  
are indicated. The P D E 4D  PCR products identified are show n and are representative o f  
three independent experim ents. PD E 4D 3 results are not show n due to only n = l without 
contam ination.
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Figure 3.19b Densitometry of RT-PCR analysis of the effect of chronic hypoxia on 
PDE4D isoform expression. Densitometric analysis of results shown in figure 3.19a. 
Quantity-one software was used to measure the density of each band which was then 
normalised against the density of the corresponding cyclophilin band. Panel A; 
densitometric analysis of PDE4D1 band expressed as a percentage of the normoxic band 
present at 35 cycles. Panel B; densitometric analysis of PDE4D2 band expressed as a 
percentage of the normoxic band present at 35 cycles. Panel C; densitometric analysis of 
PDE4D5 band expressed as a percentage of the normoxic band present at 35 cycles. 
Results shown are mean ± S.E. of three independent PCR reactions and *** denotes 
significance (p<0 .0 0 1 ).
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Figure 3.20 H IF-la expression in normoxic and hypoxic hPASMC.
Seven day hypoxic and normoxic hPASMC were harvested as described in section 2.3.1. 1 
and used for western blotting with an anti-HIF-la antibody. H IF-la is 120kDa (Hanze et 
al., 2003), and a band was detected at 121 kDa in hPASMC exposed to seven days hypoxia, 
but not in normoxic cells. Blot shown is representative of three independent experiments.
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Gene Ratio= norm/hyp Number of spots 
changed/number of 
spots analysed
PDE5A 1.5 4/4
PDE4A 0.9 4/6
PDE4A11 0.9 3/4
PDE5A3 0.9 5/6
PDE8A 0.9 4/6
PDE4B 0.8 6/6
ERK1 0.8 4/6
ERK2 0.8 4/4
PKAR1B 0.8 5/6
iNOS 0.8 3/6
NFkB 0.8 6/6
p53 0.8 6/6
PDE4D5 0.7 4/6
PDE9A 0.7 2/2
PDE3B 0.7 5/6
RaplB 0.7 5/6
Figure 3.21 Microarray analysis of RNA from normoxic and hypoxic hPASMC. Total 
RNA from normoxic and seven day hypoxic cells was used for hybridisation on a custom 
microarray chip (MWG Biotech). Results shown are from two separate chips, with reverse 
labelling of samples.
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Figure 3.22 Effect of chronic hypoxia on cAMP-PDE activity.
N orm oxic and seven day h ypoxic ce lls  were harvested in cK H EM  + 1% Triton and the 
lysate w as assayed for cA M P -P D E  activity as in section 2 .3 .5 . Panel A, total cA M P -P D E  
activity, m eans ±  S.E. o f  6 independent experim ents. Panel B, PD E 4 activity, m eans ± 
S.E . o f  6 independent experim ents. Panel C, PDE3 activity, m eans ±  S.E. o f  3 independent 
experim ents. A ll results are expressed  in pm ol/m in/m g protein.
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Figure 3.23 Effect of chronic hypoxia on PDE4 subfamily activity.
PDE4A, PDE4B, PDE4C and PDE4D activities were immunoprecipitated as described in 
section 2.3.6. Samples were then used in a cAMP-PDE assay as described in section 2.3.5. 
Results shown are mean ± S.E. of 6  independent experiments. Results were calculated in 
pmol/min/mg protein and converted to a percentage of normoxic activity for each PDE4 
subfamily. Significance is denoted by ** (p<0.01).
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Start hy poxia
Initial phase hypoxia cAMP levels rise and PDE 
expression induced
Mid-phase hypoxia
Latter phase hypoxia
cAMP levels reach maximum and 
PDE levels continue to increase
PDE activity reaches ‘threshold’ where 
it starts to impact upon cAMP levels. 
Other factors affected by hypoxia 
impact upon PDE regulation? Or, 
delayed response to reduced cAMP 
levels similar to that witnessed with an 
increase in cAMP?
cAMP levels reduced through PDE 
actions and responses to cAMP raising 
agents ‘dampened’ by high PDE 
activity
cAMP levels continue to decrease 
below normal levels due to 
maintained high levels of PDE 
activity
Figure 3.24 Proposed model of cAMP regulation during chronic hypoxia
Above is a model of a proposed theory to explain the desensitisation of the cAMP pathway 
in hypoxia and during prolonged increased cAMP. Hypoxia causes a rise in cAMP levels, 
possibly through prostacyclins which are known to increase in hypoxic conditions. This 
rise in cAMP levels induces PDE expression. cAMP levels continue to rise to maximum 
rapidly, preventing increases in PDE to have an impact. Once at maximum, cAMP levels 
remain steady until PDE expression and activity reaches a ‘threshold’ point where the 
amount of cAMP hydrolysed is more than the amount generated. This causes a reduction in 
cAMP levels and attenuates cAMP generation in response to exogenous cAMP elevating 
agents.
Chapter 4
Effect of Chronic Hypoxia on cAMP Levels in 
hPASMC
1 1 6
4.1 Introduction
4.1.1 Cyclic Nucleotide Signailing in Models of Hypoxia-Induced Pulmonary 
Hypertension
4.1.1.1 Cyclic Nucleotides in Hypoxia
It is well established that raising intracellular levels of cAMP and cGMP can lead to 
smooth muscle relaxation and inhibit VSMC proliferation (Koyama et al., 2001; Rybalkin 
& Bornfeldt 1999; Osinski & Shror 2000; Indolfi et ah, 2001; Boy ton & Whitfield 1983, 
Hayashi et al., 2000; Kronemann 1999; Hofmann 2000; Hakonarson & Grunstein 1998). 
Raising cAMP levels is known to be more effective at inhibiting VSMC proliferation than 
elevating cGMP (Murray 1990; Koyama et al 2000). The effects of these cyclic nucleotides 
are thought to occur through the activation of protein kinase A (PKA) and protein kinase G 
(PKG) which phosphorylate contractile proteins and channels. For example, PKA acts on 
the vasodilator-stimulated phosphoprotein, or VASP, which promotes actin nucléation and 
binds to actin filaments in vitro and associates with stress fibres in cells (Shabb 2001). 
PKA phosphorylation has a negative effect on VASP interaction with actin filaments 
(Harbeck et al., 2000). PKA and PKG can induce relaxation by acting on downstream 
targets of Ca2+ mobilisation (Shabb 2001; Marin et al., 1998).
It has been demonstrated that the chronic hypoxic rat displays reduced levels of both cyclic 
nucleotides in all pulmonary arteries with the exception of the resistance arteries (MacLean 
et al., 1996). It should be noted that other studies have indicated a rise in cGMP levels in 
chronic hypoxic rats compared to controls (Cohen et al., 1996). An increase in cyclic 
nucleotides would be beneficial under hypoxia, aiding to restore the normal tone of the 
pulmonary circulation. In fact, it has been suggested that hypoxia initially leads to an 
increase in cAMP through PGI2 activation, yet after prolonged exposure to hypoxia, 
desensitisation occurs and pathways are initiated to remove cAMP.
4.1.1.2 Cyclases in Hypoxia
Studies of guanylyl cyclase activity have observed that soluble guanylyl cyclase activity is 
increased in hypoxia with a corresponding increase in cGMP levels (Li et ah, 1999). In the 
rat lung, the adenylyl cyclase isoforms AC2, AC3 and AC5/6 predominate in pulmonary 
VSMC, although the isoforms AC 2, AC5 and AC8  are the most functionally important. 
Looking at these isoforms in hypoxia in the rat, there was no change of expression 
observed, (Jourdan et al 2001) although there are reduced responses to adenylyl cyclase 
activators such as forskolin. Under chronic hypoxic conditions, it has been demonstrated
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that adenylyl cyclase activity measured under GTP, forskolin or isoproterenol 
stimulation is reduced in rat hearts (Pei et al., 2000; Hrbasova et al., 2003). Other studies 
have demonstrated no effect of hypoxia on AC activity however (Pei et al., 2000).
4.1.1.3 Attenuated responses in Hypoxia
It is well established that responses to agents known to stimulate cAMP production such as 
P-adrenergic agonists are diminished in hypoxia (Hrbasova et al., 2003). Hearts from 
chronic hypoxic animals indeed display a reduction in p-adrenoceptors and a 
desensitisation of adenylyl cyclase (Leon-Velarde et al, 2001; Voelkel et al, 1981) 
However, other studies have demonstrated an increase in P-adrenoceptors and unchanged 
adenylyl cyclase activity in isolated cardiac myocytes in response to chronic hypoxia (Li et 
a l, 1996), highlighting the different effects of chronic hypoxia due to experimental 
differences. This is also apparent on studies investigating the effect of hypoxia on Gg and 
Gj signalling. Gg protein levels have been reported to be decreased or unchanged and G, 
protein levels have reported to be increased or unaltered (Hrbasova et al, 2003; Leon- 
Velarde et al, 2001; Pei et al., 2000).
Precontracted pulmonary arteries relaxed by the addition of the P-adrenoceptor agonist, 
isoproterenol, demonstrated p-adrenergic relaxation is significantly attenuated in chronic 
hypoxic rat pulmonary arteries compared (Wagner et al, 1997). In addition, forskolin- 
stimulated relaxation is also attenuated in the chronic hypoxic rat (Wagner et al, 1997). As 
no change in adenylyl cyclase activity has been observed in hypoxia (Shaul et a l, 1990), it 
was hypothesised that there was an increased hydrolysis of cAMP. Indeed, this attenuation 
was alleviated by the addition of either PDE3 or PDE4 inhibitors (Wagner et al, 1997).
As I observed PDE4 levels to increase in hypoxia without any marked increase in total 
PDE4 activity in the previous chapter, I set out to determine cAMP levels in both normoxic 
and hypoxic cells and the response of these levels to various agonist and inhibitors. All 
assays were carried out after seven days of hypoxia. This was in order to gain insight into 
why there was so little change in PDE4 activity in hypoxia at this time point by uncovering 
other pathways that can affect upon cAMP aird also regulate PDE4 expression and activity 
in hPASMC. Also, the response to cAMP-elevating agents in hypoxic hPASMC has not 
yet been investigated.
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Results 
4.1 cAMP signalling In normoxic and hypoxic hPASMC
All methods used in this chapter are described in full in section 2, materials and methods. 
Results are calculated as pmol cAMP per ng protein and expressed as a percentage of 
basal, with basal figures equal to 100%. This normalisation was done due to the variability 
in absolute amounts of cAMP noted in the various preparations of smooth muscle cells. 
This could be due to a wide vaiiety of factors including differences caused by serum, 
PGEl-mediated autocrine stimulation of adenylyl cyclase, cell numbers and cell cycle. 
However, I have also given an approximate value for cAMP levels, which gives an 
indication of the magnitude of the level experienced.
4.1.1 cAMP levels in normoxic and hypoxic hPASMC
Cells were maintained in hypoxia for seven days before being harvested, whilst the 
conesponding contiols were maintained under normoxic conditions. These were then used 
for analysis of intracellular cAMP levels. cAMP levels were measured using a 
modification of the procedure of Savage, (Savage, 1995), as described in section 2.3.7. 
Intracellular levels of cAMP in hypoxia were observed to be elevated to three times that of 
normoxic levels with normoxic cAMP levels = 5.5 ± 2.2 pmol/ng protein and hypoxic 
cAMP levels = 15.8 ± 1.3 pmol/ng protein, n=3 (Figure 4.1).
4.1.2 PKA Activity in hypoxic hPASMC
With this unexpected increase in cAMP levels in hypoxia, other methods were employed to 
confirm this observation independently. In doing this I chose to evaluate protein kinase A 
(PKA) activity as this enzyme provides a prime downstream signalling system that is 
activated by elevation of intracellular cAMP. Seven day hypoxic and normoxic hPASMC 
were collected and used for analysis of PKA activity levels as described in section 2.3.7. 
As can be seen in figure 4.2, under normoxic conditions the percentage of PKA activity 
activated was 5.5 ± 4.5 % of the total. In marked contrast to this, under hypoxic conditions 
the percentage of the total PKA activity that was activated had increased to 23.4 ± 6.8 % of 
the total (n=2). These data are entnely consistent with an increase in cAMP levels 
occurring in hypoxia.
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4.1.3 PKA Expression in hypoxic hPASMC
Seven day hypoxic and normoxic cells were harvested and used for western blotting to 
identify if PKA subunit expression was altered along with cAMP signalling in hypoxia. 
Commercial antibodies for PKA RIa, PKA R lla and PKA RII{3 were employed to detect 
protein levels of the different PKA subunits. No antibodies are available for the detection 
of PKA RI(3 as yet. Comparing normoxic and hypoxic cell lysates, there was no change in 
the observed PKA subunits expression levels.(Figure 4.3).
4.2 Regulation of cAMP levels in hypoxic hPASMC
After identifying an increase in intracellular cAMP levels, the effect of cAMP pathway 
effectors was investigated to study the regulation of cAMP with an altered basal level. 
Previously, cAMP responses have been reported to be attenuated in models of chronic 
hypoxia (Wagner et al., 1997).
4.2.1 cAMP levels in normoxic and hypoxic hPASMC in response to PDE 
inhibitors
PDE inhibitors were employed to determine PDE regulation of cAMP levels in normoxic 
and hypoxic hPASMC. Thus 7d hypoxic and normoxic cells were treated with PDE 
inhibitors for 20 min prior to being harvested for analysis of intracellular cAMP levels. 
Rolipram and cilostamide were used to inhibit PDE4 and PDE3 activity, respectively and 
the non-specific PDE inhibitor IB MX was also used. After this treatment, not only were 
cells harvested for assay of intracellular cAMP, but the growth medium that the cells were 
maintained in was aspirated to examine extracellular cAMP levels. cAMP levels were 
measured as described in section 2.3.7.
4.2.1.1 Intracellular cAMP levels
Intracellular levels of cAMP were seen to increase significantly in response to rolipram 
(p<0.001), cilostamide (p<0.001) and IBMX treatment (p<0.001) in normoxic cells only 
(Figure 4.4a). Treating hypoxic cells with the inhibitors for the same length of time was 
observed to have no effect over hypoxic basal (Figure 4.4a). Rolipram increased normoxic 
cAMP levels to 16.4 pmol cAMP/ng protein, cilostamide increased cAMP levels to 14.5 
pmol cAMP/ng protein and IBMX increased cAMP levels to 24.7 pmol cAMP/ng protein 
(Figure 4.4b). The increased levels of cAMP that occurred in normoxic cells in response to 
PDE4 or PDE3 inhibition was therefore approximately equal to that of hypoxic basal 
levels; 15.8 pmol/ng protein.
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Comparing the effect of PDE inhibitors on normoxic samples against hypoxic samples, 
there was no significant difference between the cAMP levels reached in normoxia or 
hypoxia (Figure 4.4b).
4.2.1.2 Extracellular cAMP levels
As intracellular cAMP levels in hypoxic hPASMC were not witnessed to rise in response 
to PDE inhibition, it was hypothesised that the basal levels of cAMP in hypoxia were 
maximal and extra cAMP generated might have been extruded from the cell. Thus, I set 
out to determine extracellular levels of cAMP in response to PDE inhibition also.
Extracellular cAMP levels in response to hypoxia were seen to rise to approximately 
double that of the normoxic extracellular cAMP levels (Figure 4.5a, b). Basal normoxic 
extracellular cAMP levels were 12 pmol cAMP /ng protein, and hypoxic extracellular 
cAMP levels were 25.3 pmol cAMP /ng protein (Figure 4.5a). In normoxic cells, both 
cilostamide and IBMX were observed to increase the extracellular cAMP levels to three 
times that of basal with an increase to 25.9 pmol cAMP /ng protein and 24.7 pmol cAMP 
/ng protein respectively (Figure 4.5b), reaching approximately the same levels as hypoxic 
cells under the same treatment. Rolipram appeared to have no effect on normoxic 
extracellular cAMP levels over basal. In hypoxic cells, rolipram, cilostamide and IBMX 
appeared to have no effect on the extracellular cAMP levels compared to basal (Figure 
4.5a).
Comparing the effects of rolipram, cilostamide and IBMX on hPASMC cultured in normal 
conditions on cAMP extracellular levels against the equivalent hypoxic samples showed no 
significant difference in cAMP levels between normoxic and hypoxic cells, regardless of 
treatment. This indicates that the hypoxic cells were not generating any extra cAMP in 
response to PDE inhibition.
4.2.2 cAMP levels In normoxic and hypoxic hPASMC in response to cAMP 
effectors
Seven day hypoxic and normoxic cells were pre-treated with the non-selective PDE 
inhibitor, IBMX, for 20 min prior to being treated with either the p-adrenoceptor agonist 
isoproterenol or the adenylyl cyclase stimulator forskolin for 5 mins or isoproterenol only 
for 5 min. The cells were then harvested for analysis of intracellular cAMP levels. The 
growth medium the cells were maintained in was also aspirated to examine extracellular 
cAMP levels. cAMP levels were measured as described in section 2.3.7.
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4.2.2.1 Intracellular cAMP levels
Intracellular levels of cAMP in normoxic cells were seen to increase in response to 
isoproterenol, IBMX and isoproterenol and IBMX and forskolin treatment (p<0.001) to 3.6 
times, 4.4 times and 13.3 times that of normoxic basal levels respectively (Figure 4.6a). 
Treating hypoxic cells did not have the same effect (Figure 4. <5aj. Instead; isoproterenol 
only increased hypoxic cAMP levels to 1.6 times that of hypoxic basal. Using both 
isoproterenol and IBMX together raised hypoxic cAMP levels to 1.7 times that of hypoxic 
basal levels and IBMX used in conjunction with forskolin raised cAMP levels to only 2.9 
times that of hypoxic basal (Figure 4.6a).
Isoproterenol increased normoxic cAMP levels to 20.2 pmol cAMP /ng protein and 
hypoxic cAMP levels to 22.4 pmol cAMP /ng protein. IBMX and isoproterenol increased 
normoxic cAMP levels to 25.8 pmol cAMP /ng protein and hypoxic cAMP levels to 27.6 
pmol cAMP /ng protein. However, IBMX and forskolin increased normoxic cAMP levels 
to 81.8 pmol cAMP /ng protein whereas they increased hypoxic cAMP levels to only 59.3 
pmol cAMP /ng protein (Figure 4.6b).
The increased levels of cAMP in response to p-adrenergic stimulation was therefore 
approximately equal in both normoxic and hypoxic cells with no significant difference 
between them (Figure 4.6b), although hypoxic basal levels are higher than that of 
normoxic basal levels. Inhibition of PDE activity potentiated the effect of isoproterenol, 
but, again, there was no significant difference between the normoxic and hypoxic cAMP 
levels. Maximally raising cAMP levels with the adenylyl cyclase stimulator, forskolin, and 
at the same time inhibiting PDE activity, served to raise normoxic cAMP levels to 
approximately 81.8 pmol cAMP/ng protein. In hypoxic cells, cAMP was only elevated to
59.3 pmol cAMP/ng protein in response to IBMX and forskolin treatment. Therefore, the 
previously reported attenuation of the cAMP response in the chronic hypoxic rat is also 
apparent in chronically hypoxic hPASMC (Wagner et al., 1997).
Comparing the effect of isoproterenol, isoproterenol and IBMX, and forskolin with IBMX, 
there was no significant difference between the cAMP levels reached in normoxic or 
hypoxic cells (Figure 4.6b).
4.2.2.2 Extracellular cAMP levels
Treating normoxic and hypoxic hPASMC with isoproterenol had no significant effect on 
extracellular cAMP levels compared to their respective basal cAMP levels (Figure 4.7a, b)
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This was also the case for treatment with IBMX and isoproterenol or IBMX or 
forskolin. Although these treatments did induce a rise in normoxic extracellular cAMP 
levels, this increase was not significant over basal. Comparing the extracellular cAMP 
levels in response to these stimulations, it was also observed that there was no significant 
difference between normoxic and hypoxic extracellular cAMP levels.
4.2.3 cAMP levels in normoxic and hypoxic hPASMC in response to U0126
It had been previously reported that active ERK within smooth muscle cells can feed into 
the PGE2  pathway and lead to an increase of cAMP levels through activating adenylate 
cyclase (Baillie et al., 2001; see figure 1.3), ERK inhibitors were then used to determine if 
this pathway was in effect in hPASMC. U0126 is an ERK inhibitor (Duncia et al., 1998) 
that works by inhibiting MEKl (IC50  = 72nM) and MEK2 (IC5 0  = 58nM). As it was used at 
lOpM, both MEKl and MEK2 were fully inhibited. Normoxic and hypoxic cells were 
treated with U0126 for a period of either two or forty-eight hours and cells immediately 
assayed for levels of intracellular cAMP. In this set of assays, basal normoxic cAMP levels 
were 192.7 pmol cAMP/ng protein and untreated hypoxic cAMP levels were 1531.8 pmol 
cAMP/ng protein (893% of basal; Figure 4.8a).
It was discovered that U0126 had no significant effect on cAMP levels in normoxic cells. 
In hypoxic cells however, cAMP levels were significantly reduced to 434 ± 138% of basal 
levels (p<0.05). This effect was further potentiated after 48 hrs with a reduction in cAMP 
to 315 ± 135 % of basal (p<0.0\\ figure 4.8a, b). By comparing normoxic and hypoxic 
values against each other, it was observed that there was no longer any significant 
difference in cAMP levels following treatment with U0126 (Figure 4.8b). In addition, 
when comparing the hypoxic cAMP levels in response to U0126 with normoxic basal 
cAMP levels, there was no significant difference (Figure 4.8c).
4.2.4 cAMP levels in normoxic and hypoxic hPASMC in response to 
PD980589
PD980589 is another ERK inhibitor that works by inhibiting MEKl (IC50 = 4pM) and 
MEK2 (IC50 = 50pM) and as such was also used to investigate the effect of inhibiting ERK 
on cAMP levels to confirm the results seen with U0126 (Alessi et al., 1995). By using 
PD980589 at 20pM, only MEKl was fully inhibited. In this set of assays, basal normoxic 
cAMP levels were 192.7 pmol/ng protein and basal hypoxic cAMP levels were 1531.8 
pmol/ng protein (893% of basal; Figure 4.8a).
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It was discovered that PD980589 had no effect on cAMP levels in normoxic cells 
after 2 hrs and 48 hours treatment (Figure 4.8a,b) In hypoxic cells, PD980589 reduced 
cAMP levels significantly to 319 ± 96% of basal levels (p<0.01) and this reduction was 
maintained after 48 hours at 293 ± 83% (p<0.0\', figure 4.8a,b). By comparing normoxic 
and hypoxic values against each other, it was observed that as with UO126 treatment, there 
was no longer any significant difference following treatment with PD980589 (Figure 
4.8b). In addition, when comparing the hypoxic cAMP levels in response to PD980589 
with normoxic basal cAMP levels, there was no significant difference (Figure 4.8c).
4.2.5 Effect of PGE2  and indomethacin on cAMP levels In normoxic and 
hypoxic hPASMC
As inhibition of the ERK pathway reduced cAMP levels in hypoxic cells to the equivalent 
of that in normoxia, it was proposed that the autocrine loop was indeed in effect in these 
cells. In order to address this experimentally, hPASMC were exposed to either PGE2 or 
indomethacin to directly stimulate adenylyl cyclase or inhibit the actions of COX-2 and 
thus reduce production of endogenous PGE2 . Normoxic and hypoxic cells were treated 
with IpM  PGE2 and lOpM indomethacin for a period of 10 mins or 2 hours respectively 
and then intracellular cAMP levels were assayed. In this set of assays, basal normoxic 
cAMP levels were 81.5 pmol/ng protein and basal hypoxic cAMP levels were 1416.9 
pmol/ng protein (1738% of basal; Figure 4.9b).
It was discovered that PGE2 treatment raised normoxic cAMP levels to 1787 ± 131% of 
basal (p<0.001;/zgwre 4.9a, b). In hypoxic cells however, PGE2  had no significant effect 
on cAMP levels with only a reduction to 1538 ± 29% of basal (Figure 4.9a, b), suggesting 
AC function is compromised in hypoxic cells. Treatment with the COX inhibitor, 
indomethacin, reduced cAMP levels to 212 + 5% that of basal levels in normoxic cells. 
cAMP levels in hypoxic indomethacin treated cells were reduced to 304 ± 38 % of basal, a 
level at which there was no significant difference between normoxic and hypoxic 
indomethacin treated samples (Figure 4.9b).
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4.3 Discussion and Conclusions
It was obsei-ved in the previous chapter that exposing hPASMC to hypoxic conditions 
altered their PDE4 profile when compared to normoxic hPASMC. The increased 
expression of PDE4 did not result in higher levels of cAMP hydrolysis however as no 
change in PDE4 activity or indeed total cAMP-PDE activity was observed in response to 
hypoxia. I then chose to investigate cAMP levels in response to cAMP effectors to see if 
they could induce different effects within hypoxia and normoxia and investigate if 
desensitisation was apparent in hypoxic hPASMC.
Hypoxia was observed to induce a three-fold increase in basal levels of cAMP in hypoxic 
hPASMC. This is in contrast with previous studies that have reported a reduction in cAMP 
in hypoxic rat lung (MacLean et al., 1997). However, the increase in cAMP levels in 
hypoxia was confirmed by an approximate two-fold increase in the activity of the cAMP- 
dependant kinase, PKA, after 7 days hypoxia. This increased activity was not due to an 
increase in PKA RIa, PKA Rlla or PKA RIIp expression. It is conceivable that as PKA 
Rip protein levels were not investigated, then this PKA isoform might possibly be 
increased in hypoxia. It has also been indicated in studies in mice with PKA RI or RE 
‘knocked-out’ that adaptive changes occur in the other subunit to compensate, thus it may 
be difficult to see any change of expression (Veugelers et al., 2003). The difference 
between these studies can be explained by the different time point of hypoxia studied. 
MacLean et al. measured cAMP levels after 14 days of hypoxia and it is possible that 
cAMP levels are modulated throughout this time course. Indeed, the effect of hypoxia on 
PDE3 is suggestive of an initial increase in cAMP levels as the increase in the PDE3A 
isoform observed in hPASMCs is PKA-dependant and can be mimicked by cAMP analogs 
(Murray et al., 2002). Also, results in chapter 3 demonstrate that the cAMP-inducible 
PDE4 isoforms present within hPASMC display an increased expression after 7 days 
hypoxia.
PDE inhibitors have been previously shown to reduce smooth muscle cell proliferation and 
induce vasodilation of the pulmonary circulation (Koyama et al., 2001; Ghofrani et al., 
2004; Wagner et al., 1997; Bardou et al., 2002; Goirand et al., 2001; Palmer et al., 1998; 
Osinski & Shror 2000), both of which are characteristic responses to elevated cAMP. The
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response to the inhibition of each PDE family differs in magnitude. Eor example, 
rolipram has been observed to be more potent than PDE3 or PDE5 inhibitors at relaxing 
human intralobar pulmonary arteries (Bardou et al., 2002). Thus, the levels of cAMP 
generated in response to PDE inhibition were measured. In normoxic hPASMC, PDE4, 
PDE3 and general PDE inhibition elevated cAMP levels to approximately three times that 
of basal. Surprisingly, PDE inhibition did not appear to elevate cAMP over hypoxic basal 
in hypoxic cells. As responses to PDE inhibition are still apparent in hypoxic models 
(Wagner et al., 1997), it was hypothesised that the basal levels of cAMP in hypoxic cells 
represented a threshold level above which, excess cAMP was extruded from the cells. 
Measuring extracellular cAMP in response to PDE inhibition revealed this was not the case 
however as extracellular cAMP levels were equal in basal hypoxic cells and hypoxic cells 
with PDE inhibition. Intriguingly however, it was demonstrated that whereas the 
extracellular levels of cAMP in normoxic cells in response to cilostamide and IBMX were 
increased, extracellular cAMP generated in response to rolipram was equal to that of basal 
normoxic extracellular cAMP levels.
The levels of cAMP in response to isoproterenol and forskolin was measured in normoxic 
and hypoxic hPASMC to determine if the attenuated responses to these agents in hypoxic 
models (Leon-Velarde et al., 2001; Voelkel et al., 1981; Wagner et al., 1997) is due to a 
reduced production of cAMP. Indeed, this was demonstrated to be the case. In normoxic 
cells, isoproterenol alone and isoproterenol with IBMX, increased cAMP levels to 
approximately four times that of basal. IBMX and forskolin treated cells maximally 
increased cAMP to thirteen times basal levels. In hypoxic cells however, isoproterenol 
with and without IBMX only managed to increase cAMP levels to approximately double 
that of hypoxic basal cells. The amount of cAMP generated in response to IBMX and 
forskolin was also reduced in hypoxic cells as it was only increased to three times that of 
hypoxic basal levels. Although hypoxic basal levels are higher than that of normoxic basal 
cAMP levels, the increased cAMP levels in resjfbnse to isoproterenol and forskolin 
stimulation was greater in normoxic cells. The reduced cAMP in response to isoproterenol 
and forskolin stimulation in hypoxic cells was not due to excess cAMP being extruded 
from the cells as extracellular cAMP levels were approximately equal in normoxic and 
hypoxic cells.
ERK is known to regulate PDE4 enzymatic activity. It has been previously shown that 
ERK inhibits the activity of the long forms PDE4B1, 4C2 and 4D5 as they have an ERK 
docking motif within their catalytic domain (MacKenzie et al., 2000). PDE4A enzymes are
1 2 6
unaffected as they lack the ERK phosphorylation motif (Baillie et al. 2000), As 
PDE4D5 is seen to increase too in hypoxia, I hypothesised that due to the known increase 
in pERK in hypoxia it may become inhibited constitutively by being phosphoiylated by 
ERK. I thus investigated the effects of ERK inhibitors on cAMP levels to see if this could 
perhaps release the PDE4D5 from inhibition and allow it to hydrolyse cAMP within 
hypoxia. It was observed that the ERK inhibitors PD985089 and U0126 reduced hypoxic 
cAMP levels to half of hypoxic basal levels. This reduced level of cAMP was not 
significantly different to normoxic basal levels. This indicates ERK regulates the increased 
level of cAMP witnessed initially in hypoxia. However, ERK inhibition of PDE4D5 is 
transient due to the resultant PKA phosphorylation of PDE4D5 overriding any effect of 
ERK, indicating another mechanism for ERK regulation of cAMP levels.
Previous research into PDE4 in smooth muscle cells revealed an autocrine loop whereby 
active ERK fed into the PGE2 pathway leading to a rise in cAMP, activating PKA thus 
activating PDE4D5 and decreasing cAMP levels (Baillie et al 2001; see figure 1.3). It is 
known that levels of PGE2 and active ERK are increased in hypoxia (Shaul et al., 1991; Jin 
et al., 2000), also COX-2 expression is observed to increase in response to sustained 
hypoxia (Bradbury et al., 2002; Yang et al., 2002). Thus, I set out to investigate if this is 
how ERK affects cAMP levels in hypoxia by examining cAMP levels in response to PGE2  
and indomethacin. I observed that PGE2 increased normoxic cAMP levels to that of basal 
hypoxic cells and indomethacin reduced hypoxic cAMP levels to that of basal normoxic 
cells. In hypoxic cells, the response to exogenous PGE2 was desensitised, with no increase 
in cAMP levels over basal. This indicates that the autocrine effect observed previously in 
human aortic smooth muscle cells (Baillie et al., 2001) was in effect within my cells. Thus 
an increased level of cAMP could be due to an increase in endogenous PGE observed 
previously in hypoxia (Bradbury et al., 2002).
The results shown in this chapter demonstrate desensitisation to cAMP-elevating agents in 
hypoxia is due to reduced cAMP production in response to Gs stimulation. Desensitisation 
was most likely caused by the prolonged exposure to increased cAMP induced by 7 days 
of hypoxia as maintained exposure of cells to cAMP analogs or AC stimulators has 
previously been shown to cause desensitisation (Moon et al., 2002). In addition, the known 
elevation of ERK in hypoxia (Jin et al., 2000) I have shown here is intimately involved in 
mediating the hypoxia-induced increase of cAMP. This presumably occurs through the 
actions of ERK on PLA2 and the generation of PGE2, with consequent autocrine effect
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(Pinelli et al., 1999), coupled perhaps with the ability (Baillie et al., 2000) of ERK to 
modify the activity of members of the PDE4 family.
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Figure 4.1 Effect of chronic hypoxia on intracellular cAMP levels.
Cell lysates were assayed for cAMP levels in normoxic and seven day hypoxic hPASMC 
as described in section 2.3.7. Normoxic and hypoxic samples show 5.5 ± 2.2 and 15,8 ±
1.3 pmol cAMP/ng protein respectively. Results are expressed as mean +/- S.E. of 3 
independent experiments as pmol cAMP per ng protein and denotes significance 
(p<0.05) between normoxic and hypoxic cAMP levels.
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Figure 4.2 Effect of chronic hypoxia on PKA activity.
Cell lysates were assayed for PKA activity in normoxic and seven day hypoxic hPASMC 
as described in section 2.3.7. Nonnoxic and hypoxic samples show 5.5 ± 4.5 % and 23.4 ± 
6.8 % activated PKA respectively. Results aie expressed as mean +/- S.E. of 2 independent 
experiments as percentage of activated PKA.
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Figure 4.3 Effect of chronic hypoxia on PKA subunit expression.
Panel A, seven day hypoxic and corresponding norm oxic ce lls were harvested as described  
in section 2.3.1.1 and used for western blotting with antibodies raised against the specific  
subunits o f  PK A. A ll isoform s are 50kD a in w eight so blots were done separately. The 
blots show n are representative o f  three individual experim ents.
Panel B, densitom etry analysis o f  bands for each subunit expressed as mean ±  S.E. o f  3 
independent blots as INT/mm^.
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Figure 4.4a Effect of PDE inhibitors in chronic hypoxia compared with normoxic 
levels on intracellular cAMP levels.
Cells were pre-treated with lOpM rolipram, lOpM cilostamide or lOpM IBMX for 20 min 
and were immediately assayed for cAMP levels in normoxic and seven day hypoxic 
hPASMC as described in section 2.3.7.
Panel A, results graphed as mean cAMP ± S.E. of fold normoxic basal. Panel B, results 
expressed as mean ± S.E. of fold basal for both normoxic and hypoxic samples.
Results shown are mean ± S.E. of three independent experiments and *** denotes 
significance (p<0.001).
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Figure 4.4b Effect of PDE inhibitors in chronic hypoxia compared with normoxic 
levels on intracellular cAMP levels.
Cells were pre-treated with lOpM rolipram, lOpM cilostamide or lOpM IBMX for 20 min 
and were immediately assayed for cAMP levels in normoxic and seven day hypoxic 
hPASMC as described in section 2.3.7.
Panel A, results graphed as mean cAMP ± S.E of fold normoxic basal with normoxic 
against hypoxic analysis. Panel B, approximate pmol cAMP/ng protein
Results shown are mean ± S.E. of three independent experiments and * denotes 
significance (p<0.05).
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Figure 4.5a Effect of PDE inhibitors in chronic hypoxia compared with normoxic 
levels on extracellular cAMP levels.
Cells were pre-treated with lOpM rolipram, lOpM cilostamide or lOpM IBMX for 20 
minutes and were immediately assayed for cAMP levels in normoxic and seven day 
hypoxic hPASMC as described in section 2.3.7.
Panel A, results graphed as mean cAMP +/- S.E. of fold normoxic basal. Panel B, results 
expressed as mean ± S.E. of fold basal for both normoxic and hypoxic samples.
Results shown are mean +/- S.E. o f  three independent experiments.
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Figure 4.5b Effect of PDE inhibitors in chronic hypoxia compared with normoxic 
levels on extracellular cAMP levels.
Cells were pre-treated with lOpM rolipram, lOpM cilostamide or lOpM IBMX for 20 min 
and were immediately assayed for cAMP levels in normoxic and seven day hypoxic 
hPASMC as described in section 2.3.7.
Panel A, results graphed as mean cAMP ± S.E of fold normoxic basal with normoxic 
against hypoxic analysis. Panel B, approximate pmol cAMP/ng protein
Results shown are mean +/- S.E. o f three independent experiments.
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Figure 4.6a Effect of cAMP effectors in chronic hypoxia compared with normoxic 
levels on intracellular cAMP levels.
C ells  were pre-treated with lOpM IBM X for 20  m inutes prior to stim ulation with lOpM  
forskolin or lOpM  isoproterenol for 5 m inutes, or only stim ulated for 5 m inutes with  
isoproterenol and were im m ediately assayed for cA M P levels in norm oxic and seven day  
hypoxic hPA SM C  as described in section  2 .3 .7 .
Panel A, results graphed as mean cA M P  ± S.E . o f  fold norm oxic basal.
Panel B, results expressed as mean ± S.E . o f  fold  basal for both norm oxic and hypoxic  
sam ples. R esults show n are mean ±  S.E . o f  three independent experim ents and *** denotes 
sign ificance (p<0.001 ).
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Figure 4.6b Effect of cAMP effectors in chronic hypoxia compared with normoxic 
levels on intracellular cAMP levels. Cells were pre-treated with lOpM IBMX for 20 
minutes prior to stimulation with lOpM forskolin or lOpM isoproterenol for 5 minutes, or 
only stimulated for 5 minutes with isoproterenol and were immediately assayed for cAMP 
levels in normoxic and seven day hypoxic hPASMC as described in section 2.3.7.
Panel A, results graphed as mean cAMP ± S.E of fold normoxic basal with normoxic 
against hypoxic analysis. Panel B, approximate pmol cAMP/ng protein.
Results shown are mean ± S.E. o f  three independent experiments.
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Figure 4.7a Effect of cAMP effectors in chronic hypoxia compared with normoxic 
levels on extracellular cAMP levels.
C ells were pre-treated w ith lOpM  IBM X for 20  m inutes prior to stim ulation with lOpM  
forskolin or lOpM isoproterenol for 5 m inutes, or on ly  stim ulated for 5 m inutes with 
isoproterenol and were im m ediately assayed for extracellular cA M P  levels in norm oxic  
and seven day hypoxic hPA SM C  as described in section 2 .3 .7 .
Panel A , results graphed as mean cA M P +/- S.E. o f  fold norm oxic basal. Panel B, results 
expressed as mean ±  S .E . o f  fold basal for both norm oxic and hypoxic sam ples.
Results shown are mean +/- S.E. o f three independent experiments.
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Figure 4.7b Effect of cAMP effectors in chronic hypoxia compared with normoxic 
levels on extracellular cAMP levels.
C ells were pre-treated with lOpM IBM X for 20 m inutes prior to stim ulation with lOpM  
forskolin  or lOpM  isoproterenol for 5 m inutes, or on ly  stim ulated for 5 m inutes with  
isoproterenol and w ere im m ediately assayed for extracellular cA M P  levels in norm oxic 
and seven day hypoxic hPA SM C  as described in section 2 .3 .7 .
Panel A, results graphed as mean cA M P  ± S.E  o f  fold norm oxic basal with norm oxic 
against hypoxic analysis. Panel B, approxim ate pm ol cA M P /ng protein.
Results shown are mean +/- S.E. o f three independent experiments.
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Figure 4.8a Effect of IVIEK inhibitors on cAMP levels in hypoxic and normoxic 
hPASMC.
Cells were treated with lOpM U0126 or 20pM PD980589 for 2 and 48 hours and were 
immediately assayed for cAMP levels in normoxic and seven day hypoxic hPASMC as 
described in section 2.3.7.
Panel A, results graphed as mean cAMP +/- S.E. of fold normoxic basal. Panel B, results 
expressed as mean ± S.E. of fold basal for both normoxic and hypoxic samples.
Results shown are mean +/- S.E. o f four independent experiments and *, ** denotes
significance (p<0.05, p<0.01 respectively).
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Figure 4.8b Effect of IVIEK inhibitors on cAMP levels in hypoxic and normoxic 
hPASMC.
Cells were treated with lOpM U0126 or 20pM PD980589 for 2 and 48 hours and were 
immediately assayed for cAMP levels in normoxic and seven day hypoxic hPASMC as 
described in section 2.3.7.
Panel A, results graphed as mean cAMP ± S.E of fold normoxic basal with normoxic 
against hypoxic analysis. Panel B, approximate pmol cAMP/ng protein.
Results shown are mean +/- S.E. o f  four independent experiments and ** denotes
significance (p<0.01).
41
600
S(dX)o
XoEoc
?
Normoxic basai 
Hypoxic DO 2hrs 
Hypoxic DO 48hrs 
Hypoxic PD9 2hrs 
Hypoxic PD9 48hrs
Figure 4.8c Effect of IVIEK inhibitors on cAMP levels in hypoxic and normoxic 
hPASMC.
Cells were treated with lOpM U0126 or 20pM PD980589 for 2 and 48 hours and were 
immediately assayed for cAMP levels in normoxic and seven day hypoxic hPASMC as 
described in section 2.3.7. This graphs shows hypoxic levels of cAMP in response to ERK 
inhibition compared to normoxic basal cAMP levels.
Results shown are mean +/- S.E. o f  four independent experiments.
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Figure 4.8c Effect of IVIEK inhibitors on cAMP levels in hypoxic and normoxic 
hPASMC.
Cells were treated with lOpM U0126 or 20pM PD980589 for 2 and 48 hours and were 
immediately assayed for cAMP levels in normoxic and seven day hypoxic hPASMC as 
described in section 2.3.7. This graphs shows hypoxic levels of cAMP in response to ERK 
inhibition compared to normoxic basal cAMP levels.
Results shown are mean +/- S.E. o f  four independent experiments.
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Figure 4.9a Effect of PGE2 and indomethacin on cAMP levels in hypoxic and 
normoxic hPASMC.
Cells were treated with IpM PGE2 for 10 mins and lOpM indomethacin for 2 hours and 
were immediately assayed for cAMP levels in normoxic and seven day hypoxic hPASMC 
as described in section 2.3.7.
Panel A, results graphed as mean cAMP +/- S.E. of fold normoxic basal. Panel B, results 
expressed as mean ± S.E. of fold basal for both normoxic and hypoxic samples.
Results shown are mean +/- S.E. o f two independent experiments and *** denotes
significance (p<0.001).
143
cd
cdXIÜ
XoEbc
2000-1
1500-
1000 -
500-
■ ■  Normoxic 
rZZI Hypoxic
i
Basal PGE2 Indomethacin
B
Normoxic Hypoxic
Basal
PGE2
Indomethacin
81.5 
1456.8
261.5
1416.9
1253.2
247.8
Figure 4.9b Effect of PGE2 and indomethacin on cAMP levels in hypoxic and 
normoxic hPASMC.
Cells were treated with IpM PGE2 for 10 mins and lOpM indomethacin for 2 hours and 
were immediately assayed for cAMP levels in normoxic and seven day hypoxic hPASMC 
as described in section 2.3.7.
Panel A, results graphed as mean cAMP ± S.E of fold normoxic basal with normoxic 
against hypoxic analysis. Panel B, approximate pmol cAMP/ng protein.
Results shown are mean +/- S.E. of two independent experiments.
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Chapter 5
ERK in Hypoxic hPASMC
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5.1 Introduction
5.1.1 The ERK pathway
The mitogen activated protein kinases (MAPK) are activated by a wide range of stimuli 
including growth factors, hormones, extracellular matrix components, GPCR agonists, 
cellular stress and cytokines (reviewed in Gutkind 2000; Tibbies & Woodgett 1999; 
Wildman et al., 1999; see general introduction for further details). The best characterised 
MAPK are the extracellular regulated kinases 1 and 2, also known as p44 and p42 
respectively. The involvement of ERK 1/2 in cell proliferation is well established (reviewed 
in Stork & Schmitt 2002).
ERK 1/2 is activated by the binding of e.g. EGF to its tyrosine kinase receptor (RTK) 
which results in the activation of the Ras -  Raf -  MEKl/2 -  ERKl/2 pathway (reviewed in 
Kolch 2000). It was originally thought that ERK 1/2 could also be activated by cAMP 
through Epac activating Rap I and thus B-Raf, leading to M EKl/2 activation and finally 
the activation of ERK (figure 1.5). However, recent work has demonstrated that Rapl 
activation is PKA-independent and does not act through B-Raf to lead to the activation of 
ERK, instead Rapl is now known to activate ‘inside-out’ signalling to integrins (Bos et al., 
2003). This presents a model whereby cAMP activation of ERK via Raf is mediated 
through PKA and activation of Epac leads to integrin activation which has also been 
demonstrated to activate ERK (figure 5.1). ERK is activated specifically by dual 
phosphorylation (Prowse & Lew 2001) and, upon activation, moves to the nucleus to act 
upon its transcription factors and becomes dephosphorylated (Volmat et al., 2001). ERK 
remains inactive in the nucleus until it translocates back to the activating MEK in the 
cytoplasm (Peyssonnaux, et al., 2001).
5.1.1.1 Regulation of ERK activation by cAMP
Regulation of the ERK cascade by the cAMP pathway provides vital crosstalk between 
hormone and growth factor signalling (reviewed in Houslay & Kolch 2000). ERK can be 
inhibited or activated by cAMP in a cell specific manner (reviewed in Stork & Schmitt 
2002).
Inhibition occurs through the actions of PKA. PKA blocks Raf-1 activation and inhibits 
Raf-1 activity (Cook & McCormick 1993; Mischak et al., 1996), thus blocking Ras- 
dependant signals to ERK. PKA has been demonstrated to act indirectly through
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phosphoiylation of Sic upon Rapl to inhibit ERK (Ribeho-Neto et al., 2002; Schmitt 
& Stork 2002b). Another PKA-mediated inhibition of ERK is the activation of Akt (PKB) 
which inhibits Raf-1 (Zimmerman & Moelling 1999) and thus prevents activation of ERK. 
cAMP can also inhibit ERK through activation of MAP kinase phosphatases (MKP; 
Burgun et al., 2000)
cAMP can lead to the activation of ERK. In cell types that express B-Raf, for example 
endothelial cells (Wojnowski et al., 1997), PKA activates B-Raf, leading to activation of 
ERK. PKA activation of Rapl through Src can therefore lead to activation as well as 
inhibition of ERK. Indeed, ERK activation by PKA has been shown to require members of 
the Src family of kinases (Lindquist et al., 2000). The recently discovered cAMP substrate, 
Epac (de Rooij et al., 1998) may also activate Rapl independently of PKA.
5.1.1.2 Regulation of cAMP levels by ERK
ERK is also capable of regulating cAMP levels through the actions of the cAMP-specific 
PDE4 family. Although isoforms encoded by the PDE4A, PDE4B, PDE4C and PDE4D 
genes contain the ERK2 docking sites, KIM and FQF (MacKenzie et al., 2000), PDE4A 
does not act as a substrate for ERK (Baillie et al., 2000). Phosphorylation of PDE4 long 
forms by ERK2 has been demonstrated to lead to a 75 % reduction in enzyme activity 
(Hoffmann et al., 1999). This ERK-mediated inhibition of PDE4 is transient as the result is 
a rise in cAMP levels, and the consequential activation of PKA. PKA phosphorylation of 
PDE4 negates the ERK2 phosphorylation (Baillie et al., 2000; Hoffmann et al., 1999), 
hence the reversal of inhibition of PDE4 activity.
ERK can also lead to activation of the long form, PDE4D5 (Baillie et al., 2001, figure 1.3). 
This is apparent in human aortic smooth muscle cells whereby activated ERK caused an 
increase in PGE2 which was released from the cell and activated adenylyl cyclase. This 
induced a rise in cAMP levels with a concomitant increase in PKA activity and resultant 
PDE4D5 phosphorylation. This phosphorylation ablated the effect of ERK phosphorylation 
and a net activation of PDE4D5 was observed.
ERK2 phosphorylation of PDE4 short forms results in their activation (Baillie et al., 2000). 
This differential regulation of PDE4 activity by ERK2 is due to the upsheam conserved 
region 1 (UCRl) which is only found in PDE4 long foims and contains the PKA 
phosphorylation site. Intriguingly, the super short form PDE4D2, which lacks UCRl and
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has a truncated UCR2, is inhibited by ERK2 phosphorylation, indicating the 
requirement of the N-terminal portion of UCR2 for activation of PDE4 short forms 
(MacKenzie et al., 2000). As PDE4D2 also lacks the PKA phosphorylation site, it is not 
subject to feedback regulation by PKA.
5.1.1.3 ERK in hypoxia
The activation of ERK in hypoxia has been characterised in pulmonary artery fibroblasts, 
pulmonary artery endothelial cells and in pulmonary arteries from the chronic hypoxic rat 
(Minet et al., 2000b; Scott et al., 1998; Welsh et al., 2001; Jin et al., 2000). ERKl/2 
phosphorylation has been shown to promote the transcriptional activity of HIE-1 a (Richard 
et al., 1999) and therefore the transcription of the vascular endothelial growth factor, 
VEGF.
In this chapter, I set out to investigate ERK expression specifically in hypoxic hPASMC. 
In chapter 4, I observed ERK to play a key role in the regulation of hypoxic cAMP levels 
in hPASMC. As ERK is known to achieve this regulation through the PDE4 family, I thus 
also set out to investigate the effect of ERK on PDE4 activity and expression in an attempt 
to uncover the hypoxia mediated rise in cAMP. Also, I investigated the effect of PDE4 on 
active ERK expression by employing siRNA technology.
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Results
5.2 The autocrine loop and PDE activity in hypoxic hPASMC
Results from the previous chapter indicated an autocrine loop whereby active ERK can 
lead to an increase in cAMP levels through the production of PGE2 and stimulation of 
adenylyl cyclase. In a previous study, this mechanism has been shown to override 
inhibition of PDE4D5 by ERK and lead to net activation of PDE4D5 in human aortic 
smooth muscle cells due to the rapidity of the response and the magnitude of the resultant 
PKA phosphorylation of PDE4D5 (Baillie et al,, 2001).
5.2.1 Effect of ERK inhibitors on PDE4 activity
In order to determine the effect of ERK on overall PDE4 activity in these cells, cells were 
treated with the MEK inhibitors, 20pM PD980589 and lOpM U0126 for either 30 min or 
48 h and then harvested for use in a cAMP-PDE activity assay.
5 .2 .1.1 Effect of PD980589 on PDE4 activity
Treating cells with 20pM PD980589 for 30 mins or 48 hours had no significant effect on 
total cAMP-PDE activity or PDE4 activity in noimoxic or hypoxic hPASMC (Figure 
5.2).Normoxic basal PDE4 activity was 9.0 ± 1.3 pmol/min/mg protein, 30 minutes 
treatment reduced this to 8.0 ± 0.5 pmol/min/mg protein and 48 hours treatment reduced 
this to 6.4 ± 0.8 pmol/min/mg protein (SEM; n=2). Hypoxic cells displayed a similar trend 
with basal PDE4 activity being 9.0 ± 0.2 pmol/min/mg protein, 30 mins treatment reduced 
this to 7.5 ± 1.8 pmol/min/mg protein and 48 hours reduced PDE4 activity to 6.7 ±0.1 
pmol/min/mg protein (SEM; n=2).
5.2.1.2 Effect of U0126 on PDE4 activity
Treating cells with lOpM U0126 for 30 min or 48 hours again had no significant effect on 
either total cAMP-PDE activity or PDE4 activity in either normoxic or hypoxic hPASMC 
(Figure 5.3). Normoxic basal PDE4 activity was 9.6 ± 0.5 pmol/min/mg protein , 30 
minutes treatment with lOpM U0126 had no significant effect on PDE4 activity, whereas 
48 hours treatment with lOpM U0126 significantly reduced PDE4 activity to 6 ± 0.5 
pmol/min/mg protein (SEM; n=4; p<0.05). Hypoxic basal PDE4 activity was 7.7 ± 1.1 
pmol/min/mg protein and 30 mins treatment with lOpM U0126 had no significant effect on
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this. 48 hours of treatment with lOpM U0126 induced a small, but insignificant 
increase in PDE4 activity to 9 ± 0.3 pmol/min/mg protein (SEM; n=4).
These results suggest little effect of ERK on total PDE4 activity. However, ERK 
differentially regulates long, short and super short forms which are all present in hPASMC. 
PDE4B2 and PDE4D1, whose expression increases in hypoxia, can potentially be activated 
by ERK phosphorylation, so inhibition of ERK might be expected to reduce their activity if 
they were so ERK phosphorylated. PDE4D2 and PDE4D5, whose expression is also 
increased in hypoxia, can be inhibited upon phosphorylation by ERK. Thus inhibiting ERK 
might be expected to alleviate this and thereby activate these isoforms if they were so ERK 
phosphorylated. Hence, ERK inhibition might be expected to result in contrasting effects 
on the activity of various PDE4 isoforms in hPASMC. Indeed, this may be complicated 
further if the actions of ERK are compartmentalised and only certain PDE4 isoforms are 
available for phosphorylation by ERK.
5 .2 .1.3 Effect of U0126 on ERK phosphorylation
To ensure that ERK was fully inhibited for the full 48 h, cells were treated with U0126 for 
30 min and 48 h and prepared for gel electrophoresis. The proteins were transferred onto 
nitrocellulose and probed with anti-pERK to detect levels of active ERK. Figure 5.3 shows 
that U0126 does inhibit ERK activity after 30 minutes and 48 hours treatment as the 
densitometry results compared with basal levels show. (Figure 5.4)
5.2.2 PDE Activity in response to PGE2  and indomethacin in hypoxic 
hPASMC
As the cAMP assay results in the previous chapter indicate that active ERK feeds into an 
autocrine pathway involving generation of PGE2 ,1 set out to investigate the effect of PGE2 
and the COX inhibitor, indomethacin on cAMP-PDE activity in normoxic and hypoxic 
hPASMC. PGE2 directly stimulates adenylyl cyclase to increase cAMP while 
indomethacin inhibits the actions of COX and thus reduces production of endogenous 
PGE2 in response to elevated ERK. In order to determine the effect of PGE2 and 
indomethacin on overall PDE4 activity in these cells, cells were treated with IpM  PGE2  
for 10 mins and lOpM indomethacin for 2 hours and then harvested for use in a cAMP- 
PDE activity assay.
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5.2.2.1 Total cAMP-PDE activity
As can be seen in panel A of fig 5.5, both PGE2 and indomethacin had no effect on 
hypoxic or normoxic total cAMP-PDE activity.
5.2.2.2 PDE4 activity
Seven day hypoxic and normoxic cells were treated with IpM  PGE2 for 10 min or lOpM 
indomethacin for 2 hours. In figure 5.5, panel B, the results are shown. Basal PDE4 
activity was 5.7 ± 0.2 pmol/min/mg protein and 6 ± 0.2 pmol/min/mg protein in normoxic 
and hypoxic cells respectively. Addition of PGE2  significantly reduced PDE4 activity in 
normoxic cells to 4.6 ± pmol/min/mg protein (p<0.05). In hypoxic cells however, an 
insignificant increase in PDE4 activity to 7.2 ± pmol/min/mg protein was observed (SEM; 
n=2). An increase in PDE4 activity was expected as PGE2 activates adenylyl cyclase. The 
COX-2 inhibitor indomethacin caused a decrease in both normoxic and hypoxic PDE4 
activity. This reduction was only significant in hypoxic cells, with PDE4 activity being 
reduced to 2.2 ± 1.5 pmol/min/mg protein (SEM; n=2). These results are indicative of an 
autocrine effect in hPASMC, and suggest that this loop is enhanced in hypoxia through 
increased PGE2 and ERK. However, it was observed that PGE2  fails to increase PDE4 
activity in normoxic cells, suggesting further analyses are required.
5.2.3 Effect of U0126 and Indomethacin on PDE4 expression levels
As U0126 and indomethacin were both observed to normalise hypoxic intracellular cAMP 
levels, their effect on the expression levels of the PDE4 isoforms previously observed to 
increase in hypoxia was investigated. Hypoxic and normoxic cells were treated with lOpM 
U0126 or lOpM indomethacin for 24 hours and harvested as described in section 2.3.1.1 
for use in western blotting.
5.2.3.1 PDE4A10/4A11
Lysates from hypoxic and normoxic cells treated with lOpM U0126 and lOpM 
indomethacin for 24 hours and were run out on gels alongside basal controls and a 
PDE4A10 protein standard, then transferred to nitrocellulose and probed with an anti- 
PDE4A antibody to investigate PDE4A10/4A11 expression levels. The resulting blots 
were scanned for densitometry analysis. As can be seen in figure 5.6, panel A and B, 
U0126 and indomethacin had no significant effect on normoxic or hypoxic protein levels 
of PDE4A10/4A11, although U0126 did increase normoxic PDE4A levels slightly.
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5.2.3.2 PDE4B2
Normoxic and hypoxic lysates from cells treated with lOpM U0126 or lOpM 
indomethacin, as in section 5.2.3.1, were used for gel electrophoresis alongside a 4B2 
protein standard and basal controls. The resulting membranes after transfer were probed 
with an anti-4B antibody. The blots were used for a densitometry analysis. U0126 and 
indomethacin were found to have no significant effect on normoxic or hypoxic PDE4B2 
protein levels after 24 hours (Figure 5.7).
5.2.3.3 PDE4D5
Cells maintained in hypoxia for seven days and their corresponding normoxic controls 
were treated with lOpM U0126 or lOpM indomethacin for 24 hr sand used for gel 
electrophoresis as in section 5.2.3.1. After transfer, the membranes were probed with an 
anti-PDE4D specific antibody and it was revealed that U0126 and indomethacin had no 
significant effect on PDE4D5 protein levels. There was a slight decrease in PDE4D5 
levels, but this was apparent in both normoxic and hypoxic cells (Figure 5.8).
5.3 ERK in normoxic and hypoxic hPASMC
ERK is known to inhibit PDE4B, PDE4C and PDE4D long form activities within cells by 
causing the phosphorylation of their catalytic unit (Baillie et al., 2000). In contrast to this, 
ERK is known to activate the PDE4B2 short form by such phosphorylation (Baillie et al., 
2000). Numerous studies have revealed a hypoxia-dependant induction of the ERKl/2 
pathway in many cell types (Minet et al 2000a). In the chronic hypoxic rat, ERKl and 2 
are shown to be increased in pulmonary arteries (Jin et al., 2000). Due to this and the 
results from the previous chapter which indicate the involvement of ERK in the regulation 
of cAMP levels, the effect of activating ERK directly through the use of the epidermal 
growth factor (EGF) was investigated to determine the effect of ERK activation in 
hPASMC on PDE4 activity and also the effect of raising cAMP on ERK.
5.3.1 ERK in normoxic and hypoxic hPASMC
5.3.1.1 Effect of EGF on pERK levels
Seven day hypoxic and normoxic cells were treated with 50pg/pl EGF for up to 20 min 
and then harvested for analysis by gel electrophoresis. After transferring, the membranes 
were probed with anti-pERK. This revealed that basal levels of pERK in hypoxic cells 
were not significantly increased compared to normoxic levels although levels of pERK2 
were slightly elevated in hypoxia. EGF stimulation increased normoxic levels of pERKl
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and 2 to approximately 6 times that of basal and continued to increase until they 
reached approximately 8 times that of basal levels after 10 minutes of EGF stimulation 
(Figure 5.9). In hypoxic cells, phosphorylation of ERKl and 2 peaked at approximately 17 
times that of hypoxic basal levels at 5 mins stimulation. After 10 mins, ERK 
phosphorylation was reduced, although at approximately 10 times that of hypoxic basal 
levels (Figure 5.9). This demonstrates that a more rapid and potentiated phosphorylation 
of ERK occurs in hypoxia than in normoxia.
5.3.1.2 Effect of EGF on PDE4 activity levels
Cell lysates of normoxic cells treated with 50pg/pl EGF for both 4 min and 10 min were 
used in a cAMP-PDE activity assay in the presence of lOpM rolipram to determine the 
effect of raising active ERK within noimoxic hPASMC on PDE4 activity levels. Assay 
results showed that PDE4 activity reached 2.5 times that of basal levels after 4min of EGF 
stimulation and this increased level was maintained up to lOmin (Figure 5.10). This 
indicates ERK acts to increase PDE4 activity in hPASMC, presumably through the 
autocrine loop whereby active ERK leads to active PKA which can phosphorylate and 
negate any inhibition of ERK on PDE4D5. Also, ERK would directly activate 4B2 and 
4D1 present in hPASMC.
5.4 Knockdown of PDE4D5 in normoxic and hypoxic hPASMC
To investigate the relationship determined previously between 4D5 and pERK (Baillie et 
al., 2001), siRNA technology was employed (Schutze et al., 2004). The discovery of a 
natural method of gene silencing has provided an invaluable tool in gene functioning 
studies (Dykxhoorn et al., 2003), although the mechanism by which siRNA works is still 
unclear.
5.4.1 Effect of PDE4D5 siRNA on PDE4D5 expression
Normoxic hPASMC were transfected with 60nM of the PDE4D5 siRNA construct and 
harvested after 24 hours incubation as in section 2.3.1.1 for western blotting to examine 
levels of PDE4D5 expression. This constmct worked successfully to knock down levels of 
endogenous PDE4D5 as can be seen in figure 5.11 with over 80% reduction in PDE4D5 
protein levels.
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5.4.2 Effect of PDE4D5 siRNA on pERK expression
Seven day hypoxic and normoxic cells transfected with the PDE4D5 siRNA construct were 
also harvested for analysis of basal pERK expression. It was observed that knocking out 
PDE4D5 resulted in an increase of basal pERK expression within normoxic cells to 
approximately double and a decrease in hypoxic cells to 20% of basal hypoxic levels 
(Figure 5.12). This demonstrates that the cross-talk between cAMP and ERK is modified 
in hypoxia with a reversal of effect.
Many thanks to Dr. M. Lynch, Gardiner Lab who created siRNA constructs.
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5.5 Discussion and Conclusions
The results in chapter 4 demonstrate the regulation of cAMP levels through the MAPK, 
ERK. This has previously been hypothesised to occur through the production of PGEz and 
the consequential AC stimulation (Baillie et al., 2001). Indeed, it is known that ERK, 
COX-2 and PGEz display increased levels in hypoxia (Jin et al., 2000; Scott et al., 1998; 
Bradbury et al., 2002), contributing to the increased cAMP observed in hPASMC in 
chapter 4. PDE4 is also involved in this loop as ERK and the cAMP-dependant kinase, 
PKA, both act upon PDE4 with opposing effects and thus impact upon the regulation of 
cAMP levels. The increased PDE4D5 discussed in chapter 3 is subject to inhibition by the 
increased ERK levels in hypoxia. The increased levels of ERK are transient however (Jin 
et al., 2000; Scott et al., 1998), as hypoxia has also been observed to stimulate MAPK 
phosphatase 1 (MKP-1 ; Laderoute et al., 1999). ERK phosphorylation peaks at day 7 (Jin 
et al., 2000; Scott et al., 1998), the time point studied throughout this investigation. 
Maximal levels of active ERK would therefore inhibit PDE4D5 activity (Baillie et al., 
2000; Hoffmann et al., 1999) and result in a maintained increase of cAMP levels generated 
by PGEz. This increase would lead to increased levels of active PKA and activation of 
PDE4D5 as PKA phosphorylation negates the inhibitory effect of ERK (Baillie et al., 
2000). Thus cAMP levels would be reduced and, along with the hypoxia-induced 
activation of MKP-1 and resultant decrease in ERK activity, PDE4D5 would continue to 
reduce cAMP levels below that of normal cells.
I thus initially set out to investigate the effect ERK has on PDE4 activity in hPASMC by 
employing two different ERK inhibitors. Both U0126 and PD980589 inhibit ERK 
activation by inhibiting its upstream kinases, MEK. U0126 was used at a concentration that 
inhibited both MEKl and MEK2, whereas PD980589 was used at a concentration that 
inhibited MEKl only. Examining the effects of ERK inhibition on PDE4 activity, 
inhibiting MEKl only had no significant effect in either normoxic or hypoxic cells. 
However, inhibition of both MEKl and MEK2 induced a significant reduction in PDE4 
activity after 48 hours in normoxic cells. This could possibly be due to a reduced 
generation of PGEz, and thus reduced cAMP levels, decreased PKA activity and therefore 
decreased PKA activation of PDE4. This indicates ERK is required to maintain a balanced 
effect with PKA on PDE4 activity. In hypoxic cells, this effect was not observed. Instead, 
there was no significant effect on PDE4 activity after 48 hours of U0126 treatment. This 
could occur due to the desensitised response to PGE2  on cAMP levels in hypoxic hPASMC 
observed in chapter 4. This would result in reduced activation of PKA compared to
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normoxic cells and thus ERK inhibition of PDE4 activity could balance the reduced 
level of PKA activation of PDE4. This would mean that in normoxic cells, ERK would 
lead to the activation of PDE4 by PKA and reduce cAMP levels. Indeed activation of ERK 
by EGF was observed to elevate PDE4 activity to three times that of basal in hPASMC. 
Raised cAMP levels would remain increased in hypoxic cells due to the inhibition of PDE4 
by ERK. This could also be responsible for the lack of increased PDE4 activity in hypoxia 
demonstrated in chapter 3.
To further examine this effect on PDE4 activity, the effect of either PGE2 or indomethacin 
treatment on PDE4 activity was measured. Exogenous PGE2 had no significant effect on 
PDE4 activity in hypoxic cells, but induced a small reduction in PDE4 activity in normoxic 
cells (p<0.05). This contrasts with the earlier results indicating ERK leads to activation of 
PDE4 through PGE2 in normoxic cells. However, the amount of PGE2 added to the cells is 
far greater than the amount of endogenous PGE2 produced though ERK activity. As a 
result, the effects of exogenous PGE2 will be greatly enhanced compared to that witnessed 
normally in the cell through ERK. Therefore it is possible that the increased PKA activity 
caused by this amount of PGE2 has a greater effect on its substrates. As well as PDE4, the 
vast range of PKA substrates includes GPCRs. Upon PKA phosphorylation, the 
“switching” of GPCR from the Gs subunit to the Gi subunit of the G-protein occurs and this 
leads to increased levels of receptor activated ERK and reduced cAMP. This increased 
ERK could then override PKA phosphorylation of PDE4 and result in net inhibition. In 
hypoxic cells, the lack of effect of PGE2  on PDE4 activity could be explained by the 
desensitisation of AC mentioned above. Indeed, it was observed in chapter 4 that PGE2 
failed to increase cAMP levels over hypoxic basal levels.
Treating hPASMC with the COX-2 inhibitor indomethacin induced a significant decrease 
in PDE4 activity in both normoxic and hypoxic cells. This is due to the lack of PGE2  
generated by ERK because of COX-2 inhibition and therefore a decrease in cAMP (as 
observed in chapter 4) and PKA activity. This would mean PDE4 would be regulated 
solely by basal levels of ERK and thus an inhibition of PDE4 activity would be apparent. 
With the increased levels of active ERK in hypoxia, indomethacin would then be expected 
to have a greater inhibitory effect on PDE4 activity than in normoxic cells. However, the 
increased basal levels of PKA activity could affect this, and reduce the effect of ERK on 
PDE4.
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As ERK and COX-2 inhibition by U0126 and indomethacin reduce cAMP levels in 
hPASMC, it was hypothesised that this could affect the increase in PDE4 expression in 
hypoxia. As such, normoxic and hypoxic hPASMC were treated with U0126 or 
indomethacin and examined for levels of PDE4A, PDE4B and PDE4D expression. U0126 
and indomethacin had no effect on PDE4A, PDE4B or PDE4D expression, however, 
treatment with these compounds was only for 24 hours and a more chronic treatment could 
display an alteration in PDE4 expression.
ERK activation can occur through a number of direct and indirect pathways (see general 
introduction for more details; reviewed in Peyssonnaux & Eychene 2001). As such, the 
activation of ERK by EGF in normoxic and hypoxic hPASMC was investigated. In 
normoxic cells, EGF induced a gradual activation of ERK, reaching an increase of eight 
times that of basal levels after ten minutes. In hypoxic cells, the activation of ERK is 
potentiated and more rapid, peaking after 5 minutes at 17 times that of hypoxic basal 
levels, and falls again to 10 times that of hypoxic basal levels after 10 minutes.
Following on from the effect of ERK on cAMP and PDE4 activity, siRNA constructs to 
effectively ‘knock-out’ PDE4D5 in normoxic and hypoxic hPASMC were used to 
investigate any effect of PDE4D5 on active ERK. It was observed that a successful 
reduction of PDE4D5 expression induced increased levels of activated ERK in normoxic 
hPASMC. This could be due to the increased PKA mediated phosphorylation of the p- 
adrenoceptor and the resulting increase in receptor activated ERK by Gs to G, switching. 
Indeed, it has been observed in cardiomyocytes that rolipram increases levels of ERK 
through this mechanism (Baillie et al., 2002), although this effect was witnessed with p- 
adrenoceptor stimulation.
In hypoxic cells, silencing PDE4D5 expression resulted in a significant reduction of pERK 
levels (p<0.01). This indicates PDE4D5 is essential for phosphorylation of ERK in 
hypoxic hPASMC and suggests the mode of activation of ERK is altered in hypoxia. ERK 
can be either inhibited or activated by elevated cAMP levels, usually in a cell-specific 
manner (reviewed in Houslay & Kolch 2000; Stork & Schmitt 2002). PKA is capable of 
acting upon Raf, which results in an inhibition of ERK activation in some cell types 
(Mischak et al., 1996; Cook et al., 1993) and an activation in others. Therefore the effect of 
cAMP on the ERK pathway is dependant upon the predominant Raf isoform within a cell. 
The results presented here suggest cAMP activates the ERK pathway in normoxic 
hPASMC and inhibits ERK activation in hypoxic hPASMC, possibly by switching from
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signalling through B-Raf signalling in normoxia to R af-1 signalling in hypoxia. 
However, this would contrast with the increase of ERK witnessed in hypoxia (Jin et a l, 
2000; Scott et a l, 1998).
Other studies have demonstrated a switch from cAMP inhibition of proliferation to cAMP 
stimulated proliferation. In normal human kidney cells, cAMP acts in an anti-proliferative 
manner. However, in cells derived from polycystic kidney patients, cAMP stimulates 
proliferation (Yamaguchi et a l, 2004). This was due to a disruption in calcium 
mobilisation that alleviated B-Raf/ERK inhibition through the reduction of Akt.
It has been demonstrated that Rapl does not always activate B-Raf, (Zwartkruis 1998) and 
this is dependant on the B-Raf isoform expressed. Thus, if B-Raf activity is altered in 
hypoxia, this could explain the activation of ERK observed. It could be that PDE4D5 aids 
the activation of B-Raf by Rapl and knocking out PDE4D5 prevents this, by increasing 
cAMP and resulting in an inhibition of ERK, possibly through PKA mediated activation of 
Src.
The results presented in this chapter show a delicate balance of ERK and PKA 
phosphorylation exists to regulate PDE4 activity within the autocrine loop demonstrated in 
smooth muscle cells (Baillie et al., 2001) and indicates a complex method of cAMP 
regulation, dependant on various factors and tailored by the cell in a concentration 
dependant manner. In hypoxia, modifications to this pathway appear to result in a 
confusion of signals attempting perhaps to return to normal signalling.
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Adenylyl cyclase
cAMP
EPAC
B-Raf
MEK1/2 integrins
EGF Receptor
Figure 5.1 cAMP activation of ERK
F ollow ing  generation o f  cA M P , PK A  and Epac are activated. PKA can lead to the 
activation o f  ERK through B-R af, or inhibition o f  ERK through c-R af-1. Thus, ERK  
responses to cA M P are dependant on R af isoform s present within the cell. A ctivation o f  
Epac has no impact upon PK A  signalling to ERK, instead it leads to the activation o f  
integrin signalling (B os et al., 2003). Integrin-m ediated adhesion has been demonstrated to 
lead to the partial activation o f  the epiderm al growth factor receptor, resulting in the 
activation o f  ERK (B ill et al., 2004).
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30 mins 20 +/- 0.4 2 2  +/- 0.06
48 hours 18 +/- 0.7 2 2  +/- 0 .2
PDE4 Activity Normoxic Hypoxic
Basal 9 +/- 1.3 9 +/- 0.2
30 mins 8  +/- 0.5 7.5 +/- 1.8
48 hours 6.4 +/- 0.8 6.7+/- 0.1
Figure 5.2 Effect of PD980589 on PDE Activity in normoxic and hypoxic hPASMC.
C ells were treated with 20pM  P D 980589  for 30 m ins or 48 hours and w ere im m ediately  
harvested to be used in a cA M P -P D E  activity assay for cA M P levels in norm oxic and 
seven  day hypoxic hPA SM C  as described in section  2 .3 .5 . Panel A , total cA M P -P D E  
activity results graphed as mean cA M P  ± S.E . Panel B, PD E 4 activity results graphed as 
mean ± S.E. Panel C, results expressed as mean ±  S.E. in pm ol/m in/m g in tabular form. 
M eans ±  S.E. o f  2 independent experim ents
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Figure 5.3 Effect of U0126 on PDE Activity in hypoxic and normoxic hPASMC.
Cells were treated with lOpM U0126 for 30 mins or 48 hours and were immediately 
harvested to be used in a cAMP-PDE activity assay for PDE activity in normoxic and 
seven day hypoxic hPASMC as described in section 2.3.5. Panel A, total cAMP-PDE 
activity results graphed as mean cAMP ± S.E. Panel B, PDE4 activity results graphed as 
mean ± S.E. Panel C, results expressed as mean ± S.E. in pmol/min/mg in tabular form. 
Means ±S.E. of 4 independent experiments.
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Figure 5.4 Effect of U0126 treatment on ERK 1/2 phosphorylation.
Seven day norm oxic and hypoxic hPA SM C  w ere treated with lOpM o f  the M EK inhibitor, 
U 0126 , for differing lengths o f  tim e to ensure ERK 1/2 phosphorylation was inhibited. 
C ells were harvested as in section  2.3.1.1 and subjected to gel electrophoresis before being  
transferred onto a n itrocellu lose membrane and probed with and anti-phospho-E R K l/2  
antibody. The membrane was then stripped prior to probing with total ERK2 antibody. The 
blot show n is indicative o f  three separate experim ents. D ensitom etry analysis o f  the three 
experim ents is show n below  the blot.
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Figure 5.5 Effect of PGE2 and indomethacin on PDE Activity in hypoxic and 
normoxic hPASMC
Cells were treated with IpM PGE2 for 10 mins and lOpM indomethacin for 2 hours and 
were harvested to assay for cAMP-PDE activity levels in normoxic and seven day hypoxic 
hPASMC as described in section 2.3.5. Panel A, total cAMP-PDE activity results graphed 
as mean cAMP ± S.E. Panel B, PDE4 activity results graphed as mean ± S.E. Panel C, 
results expressed as mean ± S.E. in pmol/min/mg in tabular form. Means ± S.E. of 2 
independent experiments. Significance is as compared with basal and is denoted by *, ** 
(p<0.05, p<0.01 respectively.)
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Figure 5.6 Effect of U0126 and indomethacin on PDE4A10/11 expression levels in 
hypoxia and normoxia.
Cells were treated with lOpM U0I26 and lOpM indomethacin for 24 hours and were 
harvested as described in section 2.3.1.1 20pg protein of each sample was used for SDS- 
PAGE alongside a basal control sample on a 4-12% gel. Panel A, The proteins were 
transferred to nitrocellulose and probed with a PDE4A antibody. Panel B, the densitometry 
results as compared to normoxic samples expressed in INT/mm^. Blots shown are 
representative of two independent experiments.
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Figure 5.7 Effect of U0126 and indomethacin on PDE4B2 expression levels in hypoxia 
and normoxia.
Cells were treated with lOpM U0126 and lOpM indomethacin for 24 hours and were 
harvested as described in section 2.3.1.1 20|ag protein of each sample was used for SDS- 
PAGE alongside a basal control sample on a 4-12% gel. Panel A, the proteins were 
transferred to nitrocellulose and probed with a PDE4B antibody. Panel B, the 
densitometry results as compared to normoxic samples expressed in INT/mm^. Blots 
shown are representative of two independent experiments.
165
B Ind UO B Ind UO
4D5
Normoxic Hypoxic
3  7000
6000  
E 5000 
H 4000 
^  3000 
g  2000 
1000
□  Normowc 
O  Hypoxic
Basal Indomethacin U0126
Figure 5.8 Effect of U0126 and indomethacin on PDE4D5 expression levels in hypoxia 
and normoxia.
Cells were treated with lOpM U0126 and pM indomethacin for 24 hours and were 
harvested as described in section 2.3.1.1. 20pg protein of each sample was used for SDS- 
PAGE alongside a basal control sample on a 4-12% gel. Panel A, the proteins were 
transferred to nitrocellulose and probed with a PDE4D antibody. Panel B, the 
densitometry results as compared to normoxic samples expressed in INT/mm2. Blots 
shown are representative of two independent experiments.
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Fig 5.9 Effect of EGF on pERK in normoxic and hypoxic hPASMC.
Seven day hypoxic and normoxic hPASMC were treated with 50ng/pl EGF for five or ten 
minutes and also pre-treated with lOpM rolipram for 40 min prior to EGF treatment for 
five minutes. These cells were then collected as described in section 2.3.1.1 and 30pg 
lysate used on a 10% agarose gel. Panel A, After transferring onto nitrocellulose, an anti- 
phospho ERK 1/2 antibody was used to identify the phosphorylated forms of ERK. Panel 
B, the densitometry results as compared to normoxic samples expressed in INT/mm^. 
Results not shown for rolipram due to differences of n=2. Levels of pERK shown are 
representative of four independent experiments.
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Figure 5.10 Effect of EGF on PDE4 activity levels. Cells were stimulated with 50ng/|ul 
EGF for four and ten minutes prior to being immediately harvested for use in a cAMP- 
FDE activity assay as described in section 2.3.5. Results shown are mean ± S.E. of three 
independent assays.
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Figure 5.11 PDE4D5 knockdown in hPASMC
Normoxic and 7d hypoxic hPASMC were nucleofected with 60nM PDE4D5 siRNA. After 
nucleofection, the cells were transferred into 6 well plates and incubated for 24 hours. 
Cells were then harvested as described in section 2.3.1.1 20pg protein of each sample was 
used for SDS-PAGE alongside a basal control sample on a 4-12% gel. Panel A, the 
proteins were transferred to nitrocellulose and probed with an antibody directed against the 
c-terminus of PDE4D. Panel B, the densitometry results as compared to normoxic samples 
expressed as a percentage of the control PDE4D5 band.
169
Normoxic
Control KD KD KD
Phospho-p44
Phospho-p42
Hypoxic Phospho-p44
Phospho-p42
Densitometry of pERK with PDE4D5 Knockdown
6000n
5000-
CMEE 4000-PZ 3000-
£(/)c 2000-<DQ 1000-
■ ■ I  Normoxic 
Z Z U  Hypoxic
Control KD average
Figure 5.12 Effect of knockdown of 4D5 on pERK expression in normoxic and 
hypoxic hPASMC
Normoxic and 7d hypoxic hPASMC were nucleofected with 60nM PDE4D5 siRNA. After 
nucleofection, the cells were transferred into 6 well plates and incubated for 24 hours. 
Cells were then harvested as described in section 2.3.1.1 20pg protein of each sample was 
used for SDS-PAGE alongside a basal control sample on a 4-12% gel. Panel A, the 
proteins were transferred to nitrocellulose and probed with a phospho-ERK antibody. 
Panel B, the densitometry results as compared to control samples expressed in INT/mm^ 
and ** denotes significance (p<0.01).
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Chapter 6
Proliferation in hPASMC
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6.1 Introduction
6.1.1 The Cell Cycle
The eukaryotic cell cycle is a tightly regulated process. It is divided into four phases; Gapl 
(Gi) phase, S phase. Gap 2 (Gz) phase and M phase. The restriction point at which the cell 
becomes committed to completing the cell cycle is within the G| phase. During Gi phase, 
the cell cycle is under the influence of extracellular stimuli which it requires for the 
induction of necessary proteins to pass the restriction point. Following this, and entering 
into the S phase, DNA synthesis occurs. The second Gap phase, Gz, is where the cell 
prepares for cell division by confirming DNA duplication is completed and the DNA is 
undamaged. Once this checkpoint is passed, the cell enters into the M phase where mitosis 
occurs. When cells have exited the cell cycle they are quiescent and are said to be in Go.
The cell cycle is regulated by complexes of cyclin dependant kinases and cyclins. The 
cyclin dependant kinases (cdk) are expressed at similar levels throughout the cell cycle and 
cyclins are expressed and degraded throughout the cell cycle at appropriate points to allow 
the cycle to continue. The cycUn-dependant kinases therefore undergo a sequential 
activation and inactivation through the cell cycle, providing regulatory phosphorylation.
6.1.2 Cyclic AMP inhibition of the celi cycle
The ability of cAMP to regulate the cell cycle was first reported 29 years ago (Pastan et al., 
1975). Whilst it has been shown that raising the intracellular level of cAMP can promote 
the proliferation of certain cell types such as pituitary cells and thyrocytes, (Yonehara et 
al., 2001; lacovelli et al., 2001) this action has also been noted to inhibit proliferation in 
most cell types, including endothelial cells, NIH 3T3 cells, Rat-1 fibroblasts and smooth 
muscle cells (D’Angelo 1997; Schmitt & Stork 2001; Osinki et al., 2000).
In vascular smooth muscle cells cAMP attenuates proliferation induced by vascular injury 
(Indolfi et al., 1997). It also prevents cells from entering S phase by arresting them within 
the G] phase of the cell cycle. This is achieved by various means. For example, cAMP has 
been shown to reduce levels of cyclin D 1 and cyclin D3 by increasing their degradation 
(Kronemann et al., 1999; Stewart et al., 1999; Van Oirschot et al., 2001). This decrease in 
cyclin D levels results in a reduced phosphorylation of Rb (Boucher et al., 2001) and 
therefore reduces availability of proteins required for the Gi/S phase transition. Such a 
reduction of cyclin D also increases the amount of free p27 '^ '^^ protein which can then 
inhibit cyclin E/cdk2 (L’Allemain et al., 1997). An overexpression of cyclin D1 in cells
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can result in abnormal cell cycle control as seen in cancer cells (Musat et al, 2004). 
This is seen to be the case in breast and lung cell carcinomas, as well as in tumour cell 
lines (Bos et al, 2004; Yuan et al, 2004).
p27 '^^  ^binds to active cdk complexes resulting in their inactivation and a GI block in the 
cell cycle (Kato et al, 1994, L’Allemain et al, 1997). Interestingly, increases in the cell 
cycle inhibitor proteins p21 '^^  ^ (Hayashi et al, 2000, Bauer et al, 2001) and p27 '^^  ^
(L’Allemain et al, 1997, Van Oirschot et al, 2001) have also been shown to be elicited by 
increased levels of cAMP.
cAMP can also in certain circumstances block growth factor activation of the extracellular 
regulated kinases, ERK 1 and 2. This can be achieved through PKA mediated inhibition of 
Raf“l (Cook & McCormick 1993; Mischak et al, 1996). PKA has also been demonstrated 
to act indhectly through the phosphorylation of Src upon Rapl to inhibit ERK (Ribeiro- 
Neto et al, 2002). However, the Src family of kinases have also been implicated in 
activating ERKl/2 through a process involving cAMP (Schmitt & Stork 2002). Activation 
of ERKl/2 promotes the expression of cyclin Dl, cyclin E, cyclin A and the degradation of 
(Lavoie et al, 1996; Stork & Schmitt 2002). This allows the cell to pass through 
the Gi/S phase transition (Schmitt & Stork 2001). However, inhibition of the ERKl/2 
pathway is not a prerequisite for cAMP induced growth arrest (Balmanno et al, 2003).
6,1.3 Epac
Until recently, the main target of cAMP within cells was thought to be protein kinase A 
(PKA). In 1998 however, an exchange protein directly activated by cAMP (Epac) was 
uncovered as another major target of cAMP within cells (deRooij et al, 1998). Epac was 
uncovered by investigating a PKA-insensitive activation of Rapl by cAMP. Epac is a 
guanine nucleotide exchange factor for the Ras like small GTPases Rapl and Rap2. 
Although cAMP is well established to play a role in cell cycle control, it has been 
previously attributed to act solely through the actions of PKA. Recent studies show that 
there are PKA independent mechanisms involved in cAMP regulation of the cell cycle 
(Cass et al, 1999, Fujita et al, 2002). It has been shown that endogenous Epac localisation 
is dependant on cell cycle. During interphase, Epac is mainly localised to the nuclear 
membrane and mitochondria in COS-7 cells. Epac disassociates from these membranes in 
metaphase and localises to the mitotic spindle and centrosomes. Once the cell cycle is 
completed, however, Epac returns to the nuclear’ membrane (Qiao et al, 2002). Initial work 
on the cAMP-ERK pathway suggested the Epac activation of Rapl lead to the activation of
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ERK through B-Raf; however, recent studies have shown that Rapl does not activate 
B-Raf (Bos et al., 2003). Instead, Rapl is involved in integrin signalling which can 
activate the EGF receptor, leading to ERK activation (Bill et a l, 2004). Notwithstanding 
this, the effect of Epac-mediated cAMP effects on cellular proliferation has not been 
investigated to date.
6.1.4 Phosphodiesterases and proliferation
In many disease states where excessive cellular proliferation is a hallmark, an increase in 
PDE activity and consequential decrease in cAMP levels has been observed (Savini et a l, 
1995; Vignola 2004; Schmidt et a l, 1999; Essayan 1999; Spina 2003). Indeed, cAMP- 
specific PDE inhibitors have been shown to attenuate proliferation in various cell types, 
including vascular smooth muscle cells and glioma cells by inducing the cell cycle 
inhibitor proteins, p21^^' and p27 '^ '^  ^ (Chen et a l, 2002, Ogawa et a l, 2002). Stimulation 
of proliferation itself has also been shown to induce the expression of PDE 1C in human 
smooth muscle cells (Rybalkin et a l, 2003). Using umbilical cord blood mononuclear 
cells, the PDE4 selective inhibitor rolipram has been shown to have an inhibitory effect on 
proliferation whilst specific inhibitors of PDE3, PDE5 and PDEl did not, indicating both 
compartmentalisation of cAMP actions and specificity for cAMP over cGMP (Banner et 
a l, 2000).
In A -172 glioma cells, rolipram has been observed to induce p21*^ '^ ^^  and p27 proteins 
and to decrease the activity of cdk2, leading to a G| block (Chen et a l, 2002). In human 
acute lymphoblastic leukaemia cells, rolipram, but not selective inhibitors for either PDE3 
or PDEl, suppressed growth. The resultant increase in cAMP caused by PDE4 inhibition 
led to an induction of p53 and p21*^ '^ \^ G| and Gz/M cell cycle arrest and increased 
apoptosis (Ogawa et a l, 2002).
In human aortic smooth muscle cells, both the PDE4 selective inhibitor, rolipram and the 
PDE3 selective inhibitor, CI-930 attenuated proliferation by reducing the number of cells 
entering S phase (Johnson-Mills et a l, 1998). Indeed, using both PDE4 and PDE3 
inhibitors together produced an additive inhibitory effect on proliferation. It was 
interesting to note that whilst using either inhibitor alone did not appear to raise cAMP 
levels significantly, it was only when they were used in tandem was there a substantial 
increase in intracellular cAMP.
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6.1.5 Proliferation in Hypoxia Induced Pulmonary Hypertension
Vascular smooth muscle cell growth and hypertrophy are being intensely studied in an 
effort to uncover the mechanisms governing thickening of the pulmonary arteries in PHT 
and other chronic lung disorders (VoeUcel & Tuder 1997). This thickening has been 
demonstiated (Heath 1993) to be due to progressive muscularisation of the pulmonary 
arteries due to smooth muscle cell hypertrophy and hyperplasia. Vascular smooth muscle is 
normally contractile and quiescent, but stress or injury to the vessel wall results in a 
conversion of the cells to a migratory, secretory and proliferative phenotype (Heath 1993). 
Hyperplasia plays an important part in hypertension as shown by a significant increase in 
smooth muscle cell proliferation in pulmonary vessels from chronic hypoxic animals 
(Meyrick & Reid 1978, Wohrley et al., 1995). The normal aortic smooth muscle cell 
growth in rat is 0.01 %/day which increases to 1 %/day in hypertensive rats. This thickening 
of the pulmonary aitery contributes to the rise in pulmonary artery pressure witnessed in 
PHT (Rich et al., 1987).
The thi'ee cell types of the pulmonary aitery; endothelial cells, smooth muscle cells and 
fibroblasts can all show increased proliferation when maintained in hypoxic conditions 
compared to those in normoxia (Stenmark et al., 2002; Voelkel et al., 1997; Cool et al., 
1995; reviewed in Humbert et al., 2004). The mechanism by which hypoxia increases the 
proliferation of vascular cells is unknown, although it is known that many of the growth 
factors which induce proliferation in vascular smooth cells are upregulated in hypoxia e.g. 
ET-1, PDGF, VEGF and 5-HT (Brij & Peacock 1998).
In this chapter, I set out to investigate whether the increased rate of proliferation in hypoxic 
hPASM cells compared to normoxic hPASM cells could be affected by compounds known 
to interfere with cAMP signalling. Thus, for example, I used agonists and antagonists to 
allow for selective perturbation of signalling through the RI and RII isoforms of PKA as it 
has suggested from studies done on HL-60 cells that RI is growth stimulatory while RB is 
growth inhibitory (Cho-Chung et al., 1993). I also employed two novel Epac agonists, 8 - 
pCPT-2^-O-Me-cAMP and 8 -pMeOPT-2^-O-Me-cAMP so as to, for the first time, 
evaluate the putative role that Epac might play in mediating aspects of the cAMP 
regulation of the cell cycle. I also used selective inhibitors of PDE4 and PDE3, so as to 
appreciate any role of these key cAMP degrading enzymes. The methods employed in this 
chapter are described in full in section 2.2, with a table of drug concentrations at the end of 
this chapter.
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Results
6.2 Basal Proliferation Rates in Normoxic and Hypoxic hPASM 
cells
All proliferation assays were carried out after seven days of hypoxia to evaluate the effect 
of compounds in normoxic cells compared to cells with the PDE4 profile maximally 
altered.
To determine the basal proliferation rates in both seven day hypoxic and corresponding 
normoxic controls, DNA synthesis was measured by [^H]-thymidine incorporation as 
described in section 2.2. Briefly, cells were cultured in 96-well plates in both normoxic and 
hypoxic conditions as normal until day five of hypoxic exposure. The cells were quiesced 
overnight in serum free medium and on day six, serum was reintroduced to the medium in 
one set of plates, while another was refreshed with serum free medium. After 20 hours, 0.5 
pCi [^H]-thymidine was added to each well and the cells were harvested after a further 4 
hours to measure radioactivity.
In all results in this chapter, results are presented as a percentage with 100% being equal to 
mean normoxic basal proliferation rate. Two-way ANOVA with Bonferroni's post test was 
performed using GraphPad Prism version 4.00 for Windows, GraphPad Software, San 
Diego California USA, to analyse raw data. Where only two groups of data were to be 
analysed, an unpaired t-test was performed, and ’"=p<0 05 was considered to be significant.
6.2.1 Basal Proliferation Rates
It was observed that hypoxia induced a 0.5 fold increase in proliferation over basal in 
serum-free cells, however this increase was not significant. This increase was larger in 
cells with serum re-introduced. With serum, hypoxia caused a significant increase in 
proliferation (p<0.001). Serum induced proliferation was doubled in hypoxic cells 
compared to normoxic proliferation (Figure 4.1, Panel A and B).
6.3 Effect of Raising cAMP on Proliferation Rates in Normoxic and 
Hypoxic hPASMC
It has been previously reported that an increase in cAMP levels exerts an anti-proliferative 
effect in vascular smooth muscle cells (Kronemann et al., 1999; Koyama et al 2000;
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Hayashi et ah, 2000; Bornfeldt & Krebs 1999; Indolfi et a l, 2001). The extent of this 
effect has not been measured in hypoxic hPASM cells specifically however.
6.3.1 Effect of PDE inhibitors
The effect of PDE inhibition on proliferation in normoxic and seven day hypoxic cells was 
investigated using the selective PDE4 inhibitor, rolipram; the selective PDE3 inhibitor, 
cilostamide; a mixed PDEl and PDE5 inhibitor, zaprinast and also using both rolipram and 
cilostamide together as such actions have been observed to potentiate the effect of either 
inhibitor alone (Johnson-Mills et a l, 1998).
6.3.1.1 Effect of Rolipram
Treating serum-starved cells with rolipram for 24 hours had no significant effect on 
normoxic or hypoxic cells in serum-free medium (Figure 6.2, Panel A), although it was 
observed to reduce the rate of proliferation in hypoxic cells to basal levels seen in 
normoxic cells.
Rolipram treatment of cells with serum re-introduced, again had no significant effect on 
proliferation in either normoxic or hypoxic cells.
6.3.1.2 Effect of Cilostamide
Cilostamide did not significantly reduce proliferation in normoxic serum starved cells. 
However, in contrast to this, cilostamide significantly reduced proliferation (p<0.05) in 
hypoxic serum starved cells, (62 % of hypoxic basal levels). This reduced rate was 
equivalent to 90% of normoxic basal levels (Figure 6.2, Panel A).
Cilostamide had a significant inhibitory effect on serum-induced proliferation in both 
normoxic and hypoxic cells. Proliferation was significantly reduced following cilostamide 
addition to 38% (p<0.05) in normoxic cells and 56% (p<0.05) in hypoxic cells of 
respective serum induced control rates. Thus, hypoxic proliferation was reduced to almost 
that of normoxic serum induced proliferation (Figure 6.2, Panel B). The increased effect of 
cilostamide was consistent with the data in chapter 4 which showed cilostamide increased 
cAMP levels to 3 times that of basal in normoxic cells, whereas it didn’t significantly 
affect cAMP levels in hypoxia.
6.3.1.3 Effect of Zaprinast
Evaluating serum-starved cells treated with zaprinast, there was no significant effect on 
normoxic or hypoxic cells after 24 hours treatment (Figure 6.2, Panel A). With cells
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grown in serum-containing medium for the same 24 hours, there was still no significant 
effect (Figure 6.2, Panel B).
6.3.1.4 Effect of Rolipram and Cilostamide
Using both PDE4 and PDE3 inhibitors together has previously been shown to potentiate 
the effect of either single inhibitor in studies on human coronary artery smooth muscle 
cells (Johnson-Mills et ah, 1998). Indeed, treating normoxic and hypoxic serum starved 
cells with both rolipram and cilostamide together induced a larger inhibition of 
proliferation than with either inhibitor alone. This effect was significant in hypoxic cells 
(p<0.01) where proliferation was reduced to 50% of hypoxic basal proliferation rate 
(Figure 6.2, Panel A). In normoxic cells however, this effect was not significant.
The combined inhibition of PDE3 and PDE4 activity had the largest inhibitory effect of 
any of the inhibitors on the proliferation status of both normoxic and hypoxic cells grown 
with serum for the last 24 hours. Under conditions for serum-stimulated proliferation, it 
was observed that rolipram and cilostamide acted synergistically to reduce proliferation 
rates to 45% in normoxic cells and to 30% (p<0.01) in hypoxic cells of respective serum 
induced control rates (Figure 6.2, Panel B).
6.3.2 Effect of cAMP effectors
Another way of raising cAMP within the cell is through activating adenylyl cyclase 
directly with an adenylyl cyclase activator such as forskolin, or indirectly through a beta- 
adrenergic agent such as isoproterenol. As such, the effect of both isoproterenol and 
forskolin on proliferation was investigated in hPASM cells.
6.3.2.1 Effect of Isoproterenol
24h treatment with isoproterenol had no significant effect on proliferation in normoxic or 
hypoxic cells, whether in serum free or serum containing medium (Figure 6.3, Panel A and 
B).
6.3.2.2 Effect of Isoproterenol and Rolipram
In contrast to using either isoproterenol or rolipram alone, when used together for the 24h 
treatment, then a highly noticeable inhibition of proliferation was evident. This inhibition 
was significant in hypoxic serum induced proliferation where proliferation was reduced to 
20% (p<0.05) in hypoxic cells of respective serum-induced control rates (Figure 6.3, Panel
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B). The effect on serum starved normoxic and hypoxic cells and normoxic serum 
induced proliferation was not significant.
Rolipram and isoproterenol have no effect on proliferation when used alone, thus these 
results indicate that a ‘threshold’ level of cAMP activation is required to be breached in 
order for it to inhibit proliferation in hPASMC.
6.3.2.3 Effect of Forskolin
Introducing forskolin alone to the cells had no significant effect under either hypoxic or 
normoxic conditions in either serum starved cells or cells with serum re-introduced 
(Figure 6.3, Panel A and B). Furthermore, adding the non-selective PDE inhibitor, 3- 
isobutyl-1-methylxanthine, (IBMX), along with forskolin appeared to increase the rate of 
proliferation of control levels in serum-treated normoxic cells, although not significantly. 
In hypoxic serum-induced proliferation, the combination of forskolin together with IBMX 
acted in an anti-proliferative manner, where proliferation was reduced to 20% (p<0.05) of 
the hypoxic serum induced control rate (Figure 6.3, Panel B).
These results indicate that indeed a threshold level of cAMP is required for cAMP to act in 
an inhibitory fashion on proliferation in hPASMC. However, it was observed in the chapter 
4 that the cAMP produced in hypoxic cells in response to IBMX and forskolin is less than 
that in normoxic cells. Thus, this is suggestive of IBMX acting through a different 
mechanism to ovenide the proliferative mechanism induced in hypoxia.
6.4 Effect of Growth Factors on Proliferation Rates in Normoxic 
and Hypoxic hPASMC
Epidermal growth factor (EGF) has been thoroughly studied in a wide range of cell types 
and is well known to serve as a growth factor and mitogen. In chapter 5, EGF was shown 
to activate PDE4 in hPASMC, thus it was used in this study to investigate any effect on 
proliferation.
Transforming Growth Factor-pi (TGF-PO has been under the spotlight in PHT research 
since uncovering the role of inherited mutations in the BMPR2 gene in the development in 
PAH (see general introduction section 1.5; Thomson et al., 2000; Machado et al., 2001). 
TGF-p is an important regulator of cellular differentiation and proliferation in the 
lung(Vicencio et al., 2002) and has been shown to be both a stimulator of cell growth and
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an inhibitor, depending on cell type. In rat aortic vascular smooth muscle cells, TGF-pi 
decreased serum-induced proliferation (Grainger et al., 1994). Therefore, I used TGF-Pi in 
these proliferation assays to see if it can impact upon hPASMC proliferation also.
6.4.1. Effect of EGF
EGF had no effect on serum starved proliferation in either normoxic or hypoxic cells 
{Figure 6.4, Panel A). In cells cultured in serum, 50 pg/pl medium EGF induced a 25% 
increase in proliferation compared to the normoxic serum induced control rate of 
proliferation. In hypoxic cells, this increase was even greater with an increase of 50% in 
proliferation (p<0 .0 1 ) compared to the hypoxic serum induced control proliferation rate 
(Figure 6.4, Panel B). Therefore, EGF requires a serum-induced pathway to elicit a 
proliferative effect in hPASMC.
6.4.2 Effect of EGF and Rolipram
Using EGF or rolipram has been demonstrated to have no effect on serum starved 
proliferation in hPASMC. It was also shown here that when used together, EGF and 
rolipram do not affect proliferation of serum starved cells (Figure 6.4, Panel A.)
Serum-induced proliferation of normoxic hPASMC was not affected by the addition of 
EGF and rolipram. EGF alone has previously been shown to elicit a 25% increase in serum 
induced proliferation in normoxic cells and rolipram caused a 40% reduction in hPASMC 
proliferation in normoxic serum-induced proliferation (6.3.3.1). Thus, it appears here that 
when used together they negate the effect of each other. In hypoxic cells, rolipram alone 
was previously shown to reduce serum-induced proliferation by 28% and EGF caused a 
50% increase. Again, when used together, EGF and rolipram appear to negate the effect of 
one another on hypoxic serum-induced proliferation as no effect is seen compared to 
hypoxic serum-induced control rate of proliferation (Figure 6.4, Panel B).
6.4.3 TGF-f3i
TGF-pi appeared to have no effect on proliferation in either normoxic or hypoxic hPASM 
cells that had been serum starved (Figure6.5, Panel A.). Serum-induced proliferation of 
normoxic and hypoxic hPASMC is also unaffected by TGF-(3i (Figure 6.5, Panel B).
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6.5 Effect of the Sro Family Inhibitor, PP2, on Proliferation 
Rates in Normoxic and Hypoxic hPASMC
The Src family of kinases have previously been implicated in activating ERKl/2, and has 
also been shown to be required for cAMP activation of Rap 1 in fibroblast cells(Schmitt & 
Stork 2002). PP2 is a potent inhibitor of the Src family kinases which also inhibits many 
other kinases including CSK, LCK and SAPK 2a/p38.
I also investigated here a compound called PP3, which inhibits selectively the EGF 
receptor tyros y 1 kinase but not the activity of Src family tyrosyl kinases, which are 
inhibited selectively by PP2. These two compounds allow the potential to gain insight into 
the relative roles of the EGER tyrosyl kinases and SRC family tyrosyl kinases in 
proliferation of the hPASM cells under normoxic and hypoxic conditions.
6.5.1 Effect ofPP2
PP2 elicited no significant effect on proliferation in normoxic serum starved cells. In 
hypoxia however, PP2 reduced proliferation to 38% (p<0.05) of the basal proliferation rate 
in normoxic serum starved cells (Figure 6.6, Panel A). PP2 had no effect on normoxic 
serum induced proliferation, but reduced hypoxic proliferation to 25% (p<0.01) of hypoxic 
serum-induced proliferation control rate (Figure 6.6, Panel B).
6.5.2 Effect of PP3
PP3 had no significant effect on proliferation in normoxic or hypoxic serum starved cells 
(Figure 6.6, Panel A). PP3 also had no significant effect on serum induced proliferation in 
normoxic or hypoxic cells (Figure 6.6, Panel B).
These results indicate that Src is involved in the increased hypoxic proliferation rate of 
hPASMC. The Src family of kinases have been demonstrated to activate Rapl (Schmitt 
and Stork 2002b) which can activate B-raf and activate ERK. Indeed, ERK activation by 
PKA has been demonstrated to require Src (Lindquist et ah, 2000). This suggests the 
increased PKA activity shown in chapter 4 in hypoxic hPASMC acts on Src to activate the 
ERK pathway through Rap 1 -B-raf. This would also explain the increased levels of ERK 
witnessed in hypoxia (Jin et al., 2000; Scott et al., 1998).
6.6 The cAMP Pathway
As mentioned previously (see general introduction section 1.5.8.2; reviewed by Koyama et 
al., 2000; Hay as hi et ah, 2000), it is known that cAMP acts as an anti-proliferative agent 
within vascular smooth muscle cells. Although no significant effect was observed using the 
AC stimulator, forskolin alone or the beta-adrenergic agent, isoproterenol alone on 
proliferation, there was an inhibition of proliferation using the combined PDE inhibitors 
rolipram and cilostamide. It is well known that cAMP signalling is compartmentalised in 
cells and that for effects to be seen then increased cAMP levels must occur in a 
functionally relevant compartment. One way to achieve this and to evaluate whether 
actions are actually due to cAMP is to swamp the cell with a cAMP analogue. When 
cAMP elicited effects are observed, it can be determined if this is through specific PKA 
isoforms or EPAC, using selective agonists and antagonists. As PKA activity was observed 
to increase in hypoxic hPASMC in chapter 3, specific PKA isoform agonists and 
antagonists were employed to investigate the effect of this on hPASMC proliferation.
6.6.1 Effect of PKA Agonists
PKA is a heterodimer consisting of two regulatory and two catalytic subunits. Previous 
research has indicated differing roles in growth regulation effected by the RI and RII 
subunits. Specific agonist pairs for the PKA RI and PKA RII subunits were employed to 
investigate any differing effect on proliferation by cAMP signalling through these two 
PKA isoforms.
6.6.1.1 PKA RI Agonist
The cAMP analogs 8 -PIP-cAMP and 8 -HA-cAMP were used to activate PKA RI 
selectively. In serum starved cells, the PKA RI agonist had no significant effect on 
proliferation in normoxic or hypoxic cells (Figure 6.7, Panel A). The PKA RI agonist also 
had no effect on normoxic serum induced proliferation. However, it did reduce hypoxic 
serum induced proliferation to 50% (p<0.001) of the control hypoxic serum induced 
proliferation rate (Figure 6.7, Panel B).
6.6.1.2 PKA RII Agonist
The cAMP analogs 8 -PIP-cAMP and 8 -MBC-cAMP were used to activate PKA RII 
selectively. The PKA RII agonist had no significant effect on proliferation in normoxic 
serum starved cells (Figure 6.7, Panel A). It did reduce hypoxic proliferation to 47%
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(p<0.05) of the basal hypoxic proliferation rate in serum starved cells. Serum-induced 
proliferation was reduced to 57% (p<0.001) in hypoxic cells compared to the hypoxic 
control serum induced proliferation rate {Figure 6.7, Panel B). There was no effect on 
normoxic serum-induced proliferation however.
6.6.1.3 PKA RI and RII Agonists
Using both the PKA RI and PKA RII agonists together had no significant effect on 
normoxic or hypoxic proliferation in serum starved cells (Figure 6.7, Panel A). Normoxic 
serum induced proliferation was reduced to 6 8 % (p<0.05) of normoxic control serum 
induced proliferation rate. This effect was greater in hypoxic cells, where these agonists 
used together reduced serum induced proliferation to 35% (p<0.001) of the hypoxic control 
proliferation rate (Figure 6.7, Panel B).
These results indicate PKA RI:RII exists in a balanced activation state within hPASMC, 
and if this is altered in favour of either subunit, then this elicits an inhibitory effect on 
proliferation. In particular, PKA RII appears to have a significant role in the increased 
hypoxic proliferation rate seen in hPASMC as activating this subunit reduces hypoxic 
proliferation to that of normoxic cells, in both serum starved cells and those with serum 
reintroduced. Agonising the PKA RI subunit was also capable of returning the hypoxic 
serum induced proliferation rate to that of normal, but only when the serum response 
pathways were in effect, similar to the treatment with forskolin and IB MX (6 .3.2.3).
6.6.1.4 Effect of the PKA Agonist, 6-BnZ-cAMP
The non-selective PKA agonist, 6 -BnZ-cAMP, which activates both RI and RII forms of 
PKA, was used to confirm the results witnessed using the RI and RII agonists in 
combination. In serum starved cells, 6 -BnZ had no significant effect on proliferation in 
normoxic or hypoxic cells (Figure 6.7, Panel A). 6 -BnZ also had no significant effect on 
normoxic serum induced proliferation, but did reduce hypoxic serum induced proliferation 
to 71% (p<0.01) of the hypoxic control serum induced proliferation rate (Figure 6.7, Panel 
B).
This again confirms the role of PKA in the hypoxic induced proliferation witnessed in 
hPASMC as it has no effect on normoxic proliferation, whether in the presence or absence 
of serum. The magnitude of the effect induced by the PKA RI and RII agonists together 
compared to 6 -BnZ suggests the separate agonist somehow synergise to enhance their 
effect whereas 6 -BnZ perhaps has a more ‘real’ effect on PKA.
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6.6,2 Effect of PKA Antagonists and Inhibitor
6.6.2.1 Effect of the PKA Inhibitor, H89
H89 has been used by various investigators to inhibit protein kinase A selectively. 
However it is now known that H89 is also capable of inhibiting various other kinases, 
including Rho kinase (Davies et al., 2000). H89 had no significant effect on normoxic 
serum induced proliferation or on proliferation in serum starved normoxic cells (Figure 
6.7, Panel A and B). Intriguingly, H89 induced a similar reduction in proliferation in 
hypoxic cells to that of the PKA agonist, although with a more potent effect. In serum 
starved hypoxic cells, H89 reduced proliferation to 49% (p<0.05) of basal hypoxic 
proliferation, while it reduced hypoxic serum induced proliferation to 64% (p<0.001) of 
the hypoxic seram induced proliferative control rate (Figure 6.7, Panel A and B).
The results obtained using PKA agonists and the PKA inhibitor, H89, suggest PKA is 
involved in a balance to maintain the increased hypoxic proliferation as any alteration to 
PKA signalling ultimately leads to a reduction in proliferation, decreasing levels to that of 
normoxic proliferation or lower. Thus, antagonists of the PKA RI and PKA RII were 
employed to investigate if this also occurs with one of the subunits inhibited.
6.6.2.2 Effect of PKA RI Antagonist
The PKA RI antagonist had no significant effect on proliferation in hPASMC whether in 
normoxic, hypoxic cells or in the presence or absence of serum (Figure 6.8, Panel A and 
B).
6.6.2.3 Effect of the PKA RII Antagonist
The PKA Rn antagonist reduced proliferation in serum starved cells, although this effect 
was only significant in hypoxic cells with proliferation reduced to 37% (p<0.05) of the 
hypoxic basal proliferation rate (Figure 6.8, Panel A). The PKA RII antagonist completely 
ablated serum induced proliferation in normoxic and hypoxic cells, reducing proliferation 
rates to < 5% in both normoxic and hypoxic cells (Figure 6.8, Panel Rj.This highly 
significant reduction in serum induced proliferation is indicative of the cells undergoing 
apoptosis when PKA RII is inhibited, thus PKA RII appears to be essential for the normal 
growth of hPASMC.
6.6.3 Effect of cAMP analogs
The majority of downstream effects of cAMP have been attributed to the cAMP dependant 
kinase, PKA. However, in 1998, another major cAMP target was uncovered in cells (de
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Rooij et al., 1998). This cAMP-GEF was an Exchange Protein Activated by cAMP, 
(Epac), and has recently been shown to be involved in cell adhesion (Rangarajan et ah, 
2003). Localisation of Epac within cells is cell-cycle dependant. As such, two cAMP 
analogs were employed in this assay. Both of these analogs activate PKA and Epac 
(Enserink et al., 2002). 8 -bromo-cAMP has a higher affinity for PKA than Epac, whilst 
another, CPT-cAMP, is known to have a higher affinity for Epac. These cAMP analogs 
were used to determine if PKA or EPAC had the larger role in regulation of proliferation in 
hPASMC under normoxic and hypoxic conditions.
6.6.3.1 Effect of 6-Br-cAMP
The cAMP analog 8 -Br-cAMP was observed to have no significant effect on the 
proliferation of hPASMC (Figure 6.9, Panel A and B).
6.6.3.2 Effect of CPT-cAMP
In serum starved cells and cells cultured with serum, the cAMP analog, CPT-cAMP, 
induced a highly significant reduction in proliferation of normoxic and hypoxic cells 
(Figure 6.9, Panel A and B). Cells appeared morphologically normal after treatment in all 
cases. In normoxic and hypoxic serum starved cells, CPT-cAMP reduced proliferation to 
44% and 10% (p<0.01) of basal rates respectively. Serum induced proliferation was 
reduced to approximately 17% (p<0.001) in both normoxic and hypoxic cells when 
compared to their respective serum induced proliferation control rate.
6.6.4 Specific EPAC agonist
Although CPT-cAMP has a higher affinity for EPAC over PKA, there is still some 
activation of PKA reported in the use of this analog. At the time of this study, there was 
originally one cAMP analog altered to specifically activate EPAC available. This was 8  - 
pCPT-270-Me-cAMP (Enserink et al., 2002). This agonist was used in the proliferation 
assay to confirm the results observed with CPT-cAMP and to investigate this anti­
proliferative effect further.
6.6.4.1 Effect of 8 ~pCPT-2^-0-Me-cAMP
It was observed that the EPAC agonist, 8  -pCPT-2'-0-Me-cAMP, had no significant effect 
on proliferation in normoxic or hypoxic serum starved cells (Figure 6.10, Panel A).
8  -pCPT-2^-0-Me-cAMP reduced serum-induced proliferation to approximately 50% 
(p<0.01) in normoxic cells and 36% (p<0.001) in hypoxic cells when compared with their 
respective control rate of serum induced proliferation (Figured. 10, Panel B).
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6.6.5 Effect of cAMP Effectors on the ant'hproliferative capacity of 8 - 
pCPT~2 '-O-Me-cAMP
In an attempt to understand the effect of the EPAC agonist on proliferation, PDE inhibitors 
and other cAMP effectors were used in conjunction with the agonist to see if they could 
recover the cells from this or further potentiate the effect.
6.6.5.1 Rolipram
Including rolipram with the EPAC agonist for 24 hours potentiated the effect seen with 
rolipram alone or the 8  -pCPT-2'-0-Me-cAMP alone. In serum starved hypoxic cells, this 
combined treatment reduced proliferation to 65% in normoxic cells and 56% (p<0.01) in 
hypoxic cells (Figure 6.11, Panel A).
Treatment with rolipram and 8  -pCPT-2"-0-Me-cAMP reduced serum induced 
proliferation to 45% in normoxic cells and 27% (p<0.001) in hypoxic cells (Figure 6.11, 
Panel .6 ). Again this was greater than the effect seen with either compound used alone.
6.6.5.2 Cilostamide
Using the PDE3 inhibitor cilostamide with 8  -pCPT-2'-0-Me-cAMP again potentiated the 
effect of using either compound alone. Normoxic proliferation was reduced to 73% in 
serum starved cells, although this was not significant to treatment with either cilostamide 
or the Epac agonist alone. Hypoxic proliferation in serum starved cells was significantly 
affected with a decrease to 47% (p<0.01) of basal hypoxic proliferation (Figure 6.11, 
Panel A). Serum induced proliferation was reduced to 34% in normoxic cells and 34% 
(p<0 .0 0 1 ) in hypoxic cells when compared to the respective control serum induced 
proliferation rates (Figure 6.11, Panel B).
6.6.5.3 Rolipram and Cilostamide
Using both rolipram and cilostamide with 8  -pCPT-2^-0-Me-cAMP potentiated the effect 
seen with 8  -pCPT-2'“0-Me-cAMP alone. However, this effect was not as great as that 
seen when using rolipram and cilostamide alone. In serum-starved cells, the combined 
treatment had no effect on normoxic proliferation, but reduced hypoxic proliferation to 
62% (p<0.05) of hypoxic basal proliferation (Figure 6.11, Panel A). The combined 
treatment also redueed normoxic proliferation to 30% of control serum induced 
proliferation, although this was not significant. In hypoxic cells with serum reintroduced, 
this effect was greater, with a reduction to 2 2 % (p<0 .0 0 1 ) of hypoxic control serum 
induced proliferation (Figure 6.11, Panel B).
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6.6.5.4 8-br-cAMP
8 -bromo-cAMP used with 8  -pCPT-2LO-Me-cAMP had no effect on the anti-proliferative 
capacity of 8  -pCPT-l'-O-Me-cAMP alone (Figure 6.12, Panel A and B).
6.6.5.5 6-BnZ
The PKA agonist, 6 -BnZ, slightly potentiated the inhibitory effect of 8  -pCPT-2'-0-Me- 
cAMP when used together in all conditions (Figure 6.12, Panel A and B).
6.6.5.6 PKA RI agonist
Normoxic serum starved cells treated with both the EPAC agonist and a specific PKA RI 
agonist did not have any significant effect on proliferation when compared to 8  -pCPT-2'- 
O-Me-cAMP used alone. However, the combined effect was increased in hypoxic serum 
starved cells compared to using either compound alone (Figure 6.13, Panel A). Hypoxic 
serum starved proliferation was reduced to 55% (p<0.05) of basal hypoxic proliferation.
The combined effect of the Epac agonist and PKA RI agonist did not have any effect over 
that of 8  -pCPT-2''-0-Me-cAMP alone in serum induced proliferation in normoxic and 
hypoxic cells (Figure 6.13, Panel B).
6.6.5.7 PKA RII agonist
Using the PKA RII agonist in conjunction with the Epac agonist slightly reduced the anti­
proliferative effect of using either agonist alone in serum starved normoxic and hypoxic 
cells, although not significantly (Figure 6.13, Panel A). There was no effect observed, 
however, in cells with serum reintroduced (Figure 6.13, Panel B).
6.6.5.8 PKA RI and RII agonists
Using both the RI and RII agonists, along with the EPAC agonist, potentiated the anti­
proliferative effect of using either both the RI and RII agonists or the Epac agonist alone 
on proliferation in serum starved cells. This effect was significant (p<0.01) in hypoxic 
serum starved cells where proliferation was reduced to 50% of hypoxic basal (Figure 6.13, 
Panel A.)
Using both the RI and RII agonists along with the Epae agonist had no significant effect on 
normoxic serum induced proliferation when compared with the Epac agonist alone. 
However, it did potentiate the effect of the RI and RII agonist or the Epac agonist observed 
in hypoxic serum induced proliferation, further reducing it to 17% (p<0 .0 0 1 ) of the 
hypoxic control serum induced proliferation rate (Figure 4.13, Panel B).
187
6.7 Effect of the EPAC Agonist, 8 "pMe0PT-2'-0-Me-cAMP, and a 
Rap1 Inhibitor on Proliferation compared to 8 -pCPT-2'-0-Me- 
cAMP
6.7.1 Arresting ceii cycie using a Rapl inhibitor, GGTi-298
GGTI-298 (Calbiochem) is a GGTase I inhibitor that inhibits the processing of Rapl A 
without affecting H-Ras. It is also capable of arresting cells in the Go/Gj phase of the cells 
cycle, but it has previously been reported that using GGTI-298 can reduce the inhibitory 
effects on proliferation seen with cAMP-elevating agents in RPE cells (Hecquet et ah, 
2002). As can be seen in figure 6.14, the Rapl inhibitor reduced both normoxic and 
hypoxic proliferation rates to 30% and 20% respectively of control levels. Including the 
EPAC agonist along with this inhibitor had no significant effect on normoxic or hypoxic 
proliferation over that of the Rapl inhibitor alone (Figure 6.14). Epac has been 
demonstrated to activate Rapl (Enserink et ah, 2002), therefore these results suggest the 
anti-proliferative effect of the Epac agonist is independent of Rapl as the Rapl inhibitor 
can not preserve the proliferative capacity of hPASM cells when used with the Epac 
agonist. However, as the Rapl inhibitor reduces proliferation significantly when used 
alone, this can not be assumed.
6.7.2 A second EPAC agonist, 8 -pMe0PT-2'-0-Me-cAMP
As a second novel EPAC agonist became available towards the end of this study, I decided 
to use this to confirm the anti-proliferative effect of the first EPAC agonist and to compare 
the potency of both. Biolog reported this new agonist to have a higher activity and 
membrane permeability compared with 8  -pCPT-2'-0-Me-cAMP. Anti-proliferative 
activities were compared in cells with serum re-introduced.
In normoxic and hypoxic cells, 8  -pCPT-2'-0-Me-cAMP had an IC50 of approximately 
50pM. The IC50 for 8  -pMeOPT-2''-Q-Me-cAMP was different to this. In normoxic cells, 
it had an IC50 of ImM and in hypoxic cells, an IC5 0 of 500pM. Although both agonists 
elicit an anti-proliferative effect on both normoxic and hypoxic cells, the original agonist, 8  
-pCPT-2'-Q-Me-cAMP was far more potent at inhibiting proliferation in normoxic and 
hypoxic hPASMC (Figure 6.15).
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6.8 Discussion and Conclusions
Exposing vascular smooth muscle cells to hypoxia has been shown to increase their 
proliferative capacity as witnessed in the rat model of hypoxia induced pulmonary 
hypertension(Meyrick & Reid 1978, Wohrley et ah, 1995) I have shown that human 
pulmonary artery smooth muscle cells are also useful as cellular model of pulmonary 
hypertension for proliferation studies as they double their serum-induced proliferation rate 
when exposed to 1 0 % O2  for seven days.
Previous studies have established that raising cAMP within smooth muscle cells acts in an 
anti-proliferative manner (reviewed in Bornfeldt & Krebs 1999) The adenylyl cyclase 
stimulator, forskolin has been shown to achieve this, in part by reducing serum stimulated 
cyclin D1 and cyclin A levels in vascular smooth muscle cells (Kronemann et al., 1999) 
Raising cAMP through PDE4 inhibition can also elicit an antiproliferative effect as shown 
in A172 glioma cells and human acute lymphoblastic leukaemia cells (Chen et ah, 2002, 
Ogawa et ah, 2001) In human aortic and pulmonary arterial smooth muscle cells, PDE3 
and PDE4 inhibitors have previously been shown to attenuate proliferation (Johnson-Mills 
et ah, 1998, Indolfi et ah, 1997). These effects have not been investigated in hypoxia 
however.
Rolipram did not have a significant effect on hPASMC proliferation, which contrasts with 
previous studies demonstrating rolipram can significantly reduce the proliferation of 
smooth muscle cells (Pan et ah, 1994). However, other studies suggest there is no decrease 
in proliferation (Souness et ah, 1992; Osinski and Schror, 2000). Cilostamide however, 
did significantly reduce proliferation of hPASMC as observed previously (Tsuchikane et 
ah, 1999) with a greater effect observed in normoxic cells than in hypoxic cells. This can 
perhaps be explained by the desensitisation of the cAMP pathway demonstrated to occur in 
hypoxia in chapter 4. Using both of these inhibitors together, produced a supra-additive 
effect as observed in previous studies on smooth muscle cells (Johnson-Mills et ah, 1998; 
Pan et ah, 1994).
Raising cAMP levels with the (3 2-adrenoceptor agonist, isoproterenol, appeared to have no 
effect on cell proliferation in hypoxia or normoxia. However, an action of isoproterenol 
was uncovered when cells were pre-treated with the PDE4 inhibitor, rolipram. Prior work 
with Albuterol, a (3 2-adrenoceptor agonist has shown (Stewart et ah, 1999) it inhibits
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thrombin-stimulated proliferation when used prior to the restriction point. This it 
seemingly does by reducing cyclin D1 levels. Such inhibition could, however, be alleviated 
by treating cells with either the ERK inhibitor, PD98059 or the proteasome inhibitor 
MG 132 (Stewart et ah, 1999). Here I showed that treating cells with isoproterenol and 
rolipram together produced a highly significant inhibition of proliferation in both normoxic 
and hypoxic cells, indicating that the cells either immediately exited the cell cycle or 
underwent apoptosis. This suggests the pathway induced by p2 -adrenoceptor stimulation is 
under great influence by PDE4. Indeed, it has been shown that PDE4 is recruited in a 
complex with (3-Arrestin to the P2-adrenoceptor upon stimulation of the receptor and plays 
a role in the phosphorylation of the receptor, one consequence of which is to regulate Gs to 
Gi switching in HEK 293 cells (Baillie et ah, 2002, Perry et ah, 2002).
There has been no indication that the role of PDE4 in mediating G-protein switching 
affects cell proliferation, however it is known that G-protein coupled receptors (GPCRs) 
play a role in cell growth. Mutations affecting Ga.s are known to be present in different 
types of tumours (Chen & Iyengar 1994). It is also possible that PDE4 plays a role in the 
interaction of (3-AiTestin 2 with the oncoprotein Mdm2. Mdm2 associates with p-Arrestin 2 
when a GPCR is stimulated, interfering with it’s self ubiquitination and thus p53 
degradation, allowing an increase in p53 activity (Wang et ah, 2003). p53 is a tumour 
suppression protein capable of inducing growth arrest and apoptosis. An increase in p53 
might help to explain the results seen using both rolipram and isoproterenol together 
suggesting that PDE4 perhaps enhances the binding of p-Arrestin 2 to Mdm2, thus 
reducing p53 ubiquitination.
Similarly, forskolin had no effect on cell proliferation unless the non-selective PDE 
inhibitor, IB MX, was first used. In normoxic cells, this treatment unexpectedly increased 
the rate of DNA synthesis, whereas in hypoxic cells, this rate was reduced to 20% of the 
control hypoxic serum induced proliferation rate. Stimulation of cAMP with forskolin 
alone has previously been reported to result in an attenuation of serum induced 
proliferation in vascular smooth muscle cells (Kronemann et al., 1999). This was not 
observed with the hPASMC. In certain conditions however, stimulation of cAMP levels 
can result in increased DNA synthesis in neonatal but not adult pulmonary 
SMC(Guldemeester et al., 1998). The use of forskolin and IB MX together has also been 
shown to inhibit serum-induced proliferation previously in pancreatic cancer cells 
(Boucher et ah, 2001).
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EGF is a well known mitogen and in this study was shown to induce a significant 
increase in serum induced proliferation but, interestingly, not in serum free cells. This 
suggests that EGF requires an additional input, supplied by a serum factor, to exert its 
effects on these cells. This increase caused by EGF in serum-treated cells was unaffected 
by rolipram in normoxic cells but was reduced to control levels in hypoxic cells, indicating 
the effects of EGF and rolipram can negate one another. EGF acts on the 
Ras/Raf/MEK/ERK pathway to activate cell growth and proliferation, therefore these 
results suggest rolipram exerts an inhibitory effect on this pathway. Another growth 
factor, TGF-Pi has been used in studies of activation of ERK and cell proliferation as it is 
an important regulator of cellular proliferation in the lung (Vicencio et al., 2002) and has 
been shown to be both a stimulator of cell growth and an inhibitor, depending on cell type. 
The results are, however, conflicting. In epithelial cells, TGF-Pi has been reported to both 
induce a G l bloek in the cell cycle with a corresponding inhibition of ERK (Howe et ah, 
1993) and also to activate ERK and promote cell proliferation (Hartsough & Mulder 1995). 
In hPASMC, TGF-Pi had no effect on proliferation.
Src has been demonstrated to be essential in both PC I2 cells and NIH 3T3 fibroblasts to 
witness forskolin-stimulated ERK activation (Klinger et ah, 2002). It has also been 
demonstrated in both NIH3T3 cells and mouse embryonic fibroblasts that Src 
phosphorylation by PKA is required for cAMP inhibition of ERK and cell proliferation 
(Schmitt & Stork 2002). Using the Src inhibitor, PP2, in hPASMC significantly reduced 
hypoxic serum induced proliferation and also hypoxic proliferation in serum starved cells. 
There was no significant effect on normoxic cells under either condition. This suggests 
there is a pathway not mediated by the serum response factor that is altered in hypoxic 
cells and requires Src for the increased proliferation observed in hypoxia.
The anti-proliferative actions of cAMP on cell proliferation have routinely been attributed 
to the cAMP-dependant kinase, PKA. PKA has been demonstrated to increase the levels of 
p27Kipl and decrease the levels of cyclins D1 and D3 (L’Allemain et ah, 1997, 
Kronemann et ah, 1999, Stewart et ah, 1999, Van Oirschot et ah, 2001). This results in a 
Gl block in the cell cycle. As mentioned previously, PKA can also exert an effect upon 
ERK activation, which can lead to either cell proliferation or differentiation or apoptosis 
(Schmitt & Stork 2002). PKA is a heterodimer consisting of two regulatory and two 
catalytic subunits. Activation of PKA requires binding of cAMP to the regulatory subunits 
which releases the catalytic subunits. Opposing functions for the two regulatory isoforms 
of PKA in the cell cycle have been observed (reviewed in Cho-Chung et ah, 1995). Indeed,
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the balance of the RI/RII ratio is critical as alterations can lead to tumour formation 
(Stergiopoulos & Stratakis 2003). PKA RI is a little overexpressed in normal cells upon 
stimulation of proliferation, yet is constitutively overexpressed in cancer cells and is 
associated with a poor prognosis in different human cancers (Miller et ah, 1993, McDaid et 
ah, 1999). Inhibition of PKA results in a significant reduction of cellular proliferation in 
hypoxic hPASMCs only, whether serum starved or not. Activation of PKA is also capable 
of reducing cell proliferation, although only significantly in hypoxic serum induced 
proliferation. This effect appears to be predominantly due to the PKA RII subunit as the 
PKA RII agonist elicits a greater effect than the RI agonist. These effects are only 
significant in hypoxia, suggesting an alteration in PKA signalling in hypoxia. This is 
confirmed by the significant reduction of serum induced proliferation by the general PKA 
agonist, 6 -BnZ, in hypoxia, but not in normoxic cells. As stimulation of total PKA has no 
effect on normoxic serum induced proliferation, this suggests an alteration of PKA RI/RII 
ratio in hypoxic cells. When the specific subunit agonists are used together however, it 
does not mirror the effect of a general PKA agonist. They appear to synergise and reduce 
serum induced proliferation more dramatically. PKA RI inhibition has no significant effect 
on hPASMC proliferation, although it does appear to cause a slight increase in normoxic 
serum starved cells. RII inhibition results in a highly significant reduction of cell 
proliferation in both normoxic and hypoxic cells. These results suggest that PKA RII is 
essential for normal cell proliferation and is involved in the hypoxia-induced increase of 
proliferation. It should be noted that the PKA RI subunit was also demonstrated to induce a 
small, albeit not statistically significant, increase in normoxic proliferation in serum 
starved cells. This suggests the PKA RI subunit can act in a growth inducing manner, 
which is regulated by the PKA RII subunit and, vice versa, the PKA RII subunit can act in 
an inhibitory manner which is regulated by PKA RI. This again is indicative of an 
alteration in the RI to RII ratio in hypoxic cells. In chapter 3 however, western blotting of 
the PKA RIa, R lla and RIip subunits did not show any change in expression. PKA Rip 
expression was not investigated.
PKA is not the only effector of cAMP signalling in cells. Epac is another target for cAMP 
signalling in mammalian cells, although its effects on proliferation have not yet been 
investigated. Using the cAMP analog, CPT-cAMP, it was clear this activated something 
different to the cAMP analog, 8 -bromo-cAMP as it produced a more potent inhibition of 
proliferation. Indeed, it was later discovered that CPT-cAMP has a higher affinity for Epac 
than PKA. Using the novel Epac agonists, 8  -pCPT-2'-0-Me-cAMP and 8  -pM e0PT-2'-0- 
Me-cAMP, it was revealed for the first time that Epac is capable of potently inhibiting
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proliferation. Epac appears to require the serum response to have an impact as this 
inhibition only occurs in serum induced proliferation. This is similar to the effect of the Src 
inhibitor PP2. Thus, this suggests that Epac affects proliferation in a manner similar to that 
of Src inhibition. It is known that both Epac and Src activate the GTPase Rapl. Activation 
of Rapl has been associated with both the cAMP mediated activation of ERK I and thus 
cell proliferation (Ribeiro-Neto et ah, 2002) and the cAMP mediated inhibition of ERK 
and cell proliferation (Schmitt & Stork 2001). The Epac agonist used in this study has 
previously been shown to have no direct effect upon ERK activity in NIH3T3 cells stably 
transfected with Epacl and CHO cells (Enserink et ah, 2002). However, it is possible that 
Epac could act indirectly on ERK activity. The divergent roles of Rapl in cAMP mediated 
cell proliferation are indicative of numerous stimuli acting on Rapl. As Epac is already 
known to activate Rapl, it seems possible that the levels of activation of Epac could 
regulate the PKA directed aetivation of Rapl. Indeed, increasing cAMP levels in the eell 
through PDE inhibition, raising PKA activation by addition of a cAMP analog or direct 
PKA stimulation, or even specific PKA regulatory subunit activation, showed only slight 
potentiation or alleviation of this effect. This is suggestive of a cAMP threshold level at 
which Epac is activated and elicits its effect rather than a concentration dependant effect. It 
also appears that the level of PKA cannot influence the effect of Epac once activated. 
Thus, Epac perhaps acts as an ‘o ff  switch for PKA mediated signalling through R ap l.
In this chapter, I have presented results that suggest a role for PKA RIiRII imbalance in 
hypoxia-induced proliferation and demonstrate a new role for Epac in cell proliferation.
193
A Serum starved cells
_QIE
oc
co
?§
2Q_
Normoxic Hypoxic
B
IÜ
XoE
g
co
§2Q_
Cells with serum reintroduced
Normoxic Hypoxic
Figure 6.1 Effect of chronic hypoxia on proliferation in hPASMC.
Normoxic and hypoxic cells were cultured in 96-well plates for five days prior to serum 
starvation overnight. One set of cells was maintained in serum free medium, (Panel A), and 
another had serum re-introduced (Panel B). After twenty hours, [^H]-thymidine was added 
to all plates for a further four hours before being harvested as described in section 2.2 to 
measure incorporation rates as a measure of DNA synthesis.
Results shown are means ± S.E. o f 4 independent experiments expressed as a percentage
o f the normoxic basal proliferation rate. Significance is denoted by (p<0.001).
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Figure 6.2 Effect of PDE inhibitors on proliferation in hPASMC.
C eils were treated as in figure 6.1 and all PDE inhibitors were added when the serum free 
m edium  was replenished, (Panel A), or serum w as re-introduced to the ce lls (Panel B). 
A fter twenty hours, [^H]-thym idine w as added to all plates for a further four hours before 
being harvested as described in section 2 .2  to measure incorporation rates as a m easure o f  
D N A  synthesis.
Results shown are means ± S.E. o f 3 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by *, ** (p<0.05, p<0.01
respectively).
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Figure 6.3 Effect of cAMP effectors on proliferation in hPASMC.
Cells were treated as in figure 6.1 and all additions were made when the serum free 
medium was replenished, (Panel A), or serum was re-introduced to the cells (Panel B). 
After twenty hours, f^HJ-thymidine was added to all plates for a further four hours before 
being harvested as described in section 2.2 to measure incorporation rates as a measure of 
DNA synthesis.
Results shown are means ± S.E. o f 3 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by * , ** (p<0.05, p<0.01
respectively).
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Figure 6.4 Effect of EGF on proliferation in hPASMC.
Cells were treated as in figure 6.1. 50pg/p 1 medium of EGF was added when the serum 
free medium was replenished, (Panel A), or serum was re-introduced to the cells (Panel B). 
After twenty hours, [^H]-thymidine was added to all plates for a further four hours before 
being harvested as described in section 2.2 to measure incorporation rates as a measure of 
DNA synthesis.
Results shown are means ± S.E. o f 3 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by *** (p<0.001).
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Figure 6.5 Effect of TGF-pi on proliferation in hPASMC.
Cells were treated as in figure 6.1. TGF-Pi was added when the serum free medium was 
replenished, (Panel A), or serum was re-introduced to the cells (Panel B). After twenty 
hours, [^Hj-thymidine was added to all plates for a further four hours before being 
harvested as described in section 2.2 to measure incorporation rates as a measure of DNA 
synthesis.
Results shown are means ± S.E. of 3 independent experiments expressed as a percentage of 
the normoxic basal proliferation rate.
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Figure 6.6 Effect of Src inhibitor on proliferation in hPASMC.
C ells were treated as in figure 6.1. PP2 and PP3 were added when the serum free m edium  
w as replenished, (Panel A), or serum w as re-introduced to the ce lls (Panel B). After 
twenty hours, [^H]-thymidine w as added to all plates for a further four hours before being  
harvested as described in section 2 .2  to m easure incorporation rates as a measure o f  D N A  
synthesis.
Results shown are means ± S.E. o f 4 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by *** (p<0.001).
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Figure 6.7 Effect of PKA agonists and inhibitor on proliferation in hPASMC.
As in figure 6.1, agonists and inhibitors were added when the serum free medium was 
replenished, (Panel A), or serum was re-introduced to the cells (Panel B). After twenty 
hours, [^Hj-thymidine was added to all plates for a further four hours before being 
harvested as described in section 2.2 to measure incorporation rates as a measure of DNA 
synthesis.
Results shown are means ± S.E. of 3 independent experiments expressed as a percentage of 
the normoxic basal proliferation rate. Significance is denoted by *** (p<0.001).
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Figure 6.8 Effect of PKA antagonists on proliferation in hPASMC.
Cells were treated as in figure 6.1. Antagonists were added when the serum free medium 
was replenished, (Panel A), or serum was re-introduced to the cells (Panel B). After twenty 
hours, [^H]-thymidine was added to all plates for a further four hours before being 
harvested as described in section 2.2 to measure incorporation rates as a measure of DNA 
synthesis.
Results shown are means ± S.E. o f  3 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by *, *** (p<0.05, p<0.001
respectively).
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Figure 6.9 Effect of cAMP analogs on proliferation in hPASMC
Cells were treated as in figure 6.1. 8-bromo-cAMP or CPT-cAMP were added when the 
serum free medium was replenished, (Panel A), or serum was re-introduced to the cells 
(Panel B). After twenty hours, [‘^ H]-thymidine was added to all plates for a further four 
hours before being harvested as described in section 2.2 to measure incorporation rates as a 
measure of DNA synthesis.
Results shown are means ± S.E. o f 3 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by **, *** (p<0.01, p<0.001
respectively).
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Figure 6.10 Effect of 8 -pCPT-2-O -M e-cA M P on proliferation in hPASMC.
Cells were treated as in figure 6.1. 8 -pCPT-2'-0-Me-cAMP was added when the serum 
free medium was replenished, (Panel A), or serum was re-introduced to the cells (Panel B) 
After twenty hours, ['^H]-thymidine was added to all plates for a further four hours before 
being harvested as described in section 2.2 to measure incorporation rates as a measure of 
DNA synthesis.
Results shown are means ± S.E. o f  3 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by **, *** (p<0.01, p<0.001
respectively).
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Figure 6.11 Effect of PDE inhibitors in combination with 8 -pCPT-2-O-Me-cAMP on 
proliferation in hPASMC.
As in figure 6 ,1, 8 -pCPT-2-O-Me-cAMP plus inhibitors were added when the serum free 
medium was replenished, (Panel A), or serum was re-introduced to the cells (Panel B). 
After twenty hours, [^H)-thymidine was added to all plates for a further four hours before 
being harvested as described in section 2.2 to measure incorporation rates as a measure of 
DNA synthesis.
Results shown are means ± S.E. o f 3 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by *, **, *** (p<0.05,
p < 0 .01, p < 0 .001 respectively).
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Figure 6.12 Effect of cAMP effectors in combination with 8 -pCPT-2-O-Me-cAMP on 
proliferation in hPASMC.
A s in figure 6 .1 ,8  -p C P T -2-O -M e-cA M P  and other additions were made when the serum  
free m edium  was replenished, (Panel A), or serum was re-introduced to the ce lls  (Panel B). 
A fter tw enty hours, [^H]-thymidine w as added to all plates for a further four hours before 
being harvested as described in section 2.2 to measure incorporation rates as a m easure o f  
D N A  synthesis.
Results shown are means ± S.E. o f 3 independent experiments expressed as a percentage o f
the normoxic basal proliferation rate. Significance is denoted by *, *** (p<0.05, p<0.001
respectively).
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Figure 6.13 Effect of PKA agonists in combination with 8 -pCPT-2-O-Me-cAMP on 
proliferation in hPASMC.
A s in figure 6 .1 , 8 -p C P T -2-O -M e-cA M P  and agonists w ere added when the serum free 
m edium  was replenished, (Panel A), or serum was re-introduced to the ce lls (Panel B). 
After twenty hours, [‘^ H]-thymidine w as added to all plates for a further four hours before 
being harvested as described in section  2.2 to measure incorporation rates as a measure o f  
D N A  synthesis.
Results shown are m eans ±  S.E . o f  3 independent experim ents expressed as a percentage o f  
the norm oxic basal proliferation rate. S ign ificance is denoted by *, **, *** (p < 0.05 , 
P<0.01, p<0.001 respectively).
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Figure 6.14 Effect of Rapl inhibitor on proliferation in hPASMC.
Cells were treated as in figure 6.1. GGTI-298 and the EPAC agonists were added when the 
serum was re-introduced to the cells. After twenty hours, [^H|-Thymidine was added to all 
plates for a further four hours before being harvested as described in section 2.2 to measure 
incorporation rates as a measure of DNA synthesis.
Results shown are means ± S.E. of 3 independent experiments expressed as a percentage of 
the normoxic basal proliferation rate. Significance is denoted by *** (p<0.001 ).
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Figure 6.15 Inhibition of proliferation in response to EPA C agonists.
Cells were treated as in figure 6.1. 8-pCPT-2'-0-Me-cAMP, (Panel A), or 8-pMeOPT-2'- 
O-Me-cAMP, (Panel B), was added at varying concentrations when serum was re­
introduced to the cells. After twenty hours, [^H]-thymidine was added to all plates for a 
further four hours before being harvested as described in section 2.2 to measure 
incorporation rates as a measure of DNA synthesis.
Results shown are means +/- S.E. o f  3 independent experiments as percentage inhibition
compared to 1 nM treatments which showed no effect on proliferation. Significance is
denoted by *, *** (p<0.05, p<0.001 respectively).
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Drug Final Concentration
Rolipram lOpM
Cilostamide lOpM
Zaprinast lOpM
IBMX lOpM
Isoproterenol lOpM
Forskolin lOpM
EGF 50pg/p l
TGF -P i lOng/pl
PP2 lOpM
PP3 lOpM
PKA RI agonists; 
8-PIP-cAMP 
8-HA cAMP
lOpM
5pM
PKA RII agonists; 
8-PIP-cAMP 
8-MBC-cAMP
lOpM
5pM
H89 lOpM
PKA RI antagonist; 
Rp-8-Cl-cAMPS lOpM
PKA RII antagonist; 
Rp-8-CPT-cAMPS lOpM
6-BnZ-cAMP lOpM
8-bromo-cAMP lOOpM
CPT-cAMP lOpM
8 -pCPT-2 -O-Me-cAMP lOpM
GGTI-298 lOpM
8-pM e0PT-2'-0-M e-cAM P lOpM
Table 6.1 Drugs used and their final concentration in the proliferation assays 
T his table lists the com pounds used throughout this chapter and the concentration used at 
in the proliferation assays.
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Chapter 7
General Discussion and Future Directions
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The cyclic nucleotides cAMP and cGMP have well characterised functions including roles 
in cell proliferation, differentiation, inflammation and maintenance of vascular tone 
(Murray 1990; Koyama et al., 2001; Pellegrino & Wang 1997; Dousa 1999; Torphy et al., 
1999; Wong & Koh 2000; Essayan 2001). The cell tailors its response to these second 
messengers through a complex interplay of the synthesis and degradation mechanisms 
available for cAMP and cGMP. For example, there are nine forms of adenylyl cyclase 
(AC; Antoni et al., 2000, Hanoune & Defer 2001) capable of regulating the synthesis of 
cAMP and eleven families of phosphodiesterases, all able to efficiently degrade cAMP or 
cGMP (Francis et al., 1999; Dousa 1999; Sodeiiing & Beavo 2000; Yuasa et al., 2000; 
Conti 2000; Mehats et al., 2002; Maurice et al., 2003).To add to this regulation, it is also 
well documented that compartmentalised responses to cAMP exist within a cell due to 
localised cAMP production, anchored cAMP substrates and targeted PDE isoforms. The 
net result of this is a highly specialised form of signalling, enabling the cell to tailor the 
response to cAMP and act in the desired manner.
The superfamily of phosphodiesterases is well established as a crucial component in the 
regulation of cAMP signalling. Differential tissue distribution and regulatory properties of 
PDEs add a further complexity to cAMP signalling, along with the generation of multiple 
splice variants. In addition, the expression of PDE isoforms has been demonstrated to be 
altered in response to hypoxia (Murray et al., 2002) and COPD (Barber et al., 2004). For 
example, in the pulmonary arteries of the chronic hypoxic rat model of pulmonary arterial 
hypertension (PAH), increased levels of the PDE3 and PDE5 expression and activity 
(Murray et al., 2002) have been demonstrated to be responsible for the reduction in cAMP 
and cGMP levels witnessed after 14 days exposure to 10% O2 (MacLean et al., 1997). This 
alteration in PDE expression was also observed in the cellular model of PAH, hypoxic 
human pulmonary artery smooth muscle cells (Murray et al., 2002). Thus, the reduced 
levels of cyclic nucleotides have been attributed to an increased hydrolysis induced by 
hypoxia.
The PDE4 family of enzymes represent a major part of the cAMP hydrolysing activity 
within vascular smooth muscle cells (Palmer et al., 1998) but their activity and expression 
has not previously been investigated in hypoxia. PDE4 inhibitors are considered 
therapeutic targets for cardiovascular diseases such as COPD and asthma (Spina et al., 
1998; Landells et al., 2001; Spina 2003). PDE4 inhibitors have also been considered for
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Lise in treating PAH, as they are capable of synergising with PDE3 inhibitors to 
produce an enhanced relaxation of arteries and potentiated inhibition of smooth muscle cell 
proliferation (Pan et al., 1994; Palmer et al., 1998; Chen et al 2002, Ogawa et al 2002). I 
thus set out to determine if PDE4 has a role in the altered signalling apparent in models of 
PAH.
The main finding of the work presented here demonstrates that specific PDE4 isoforms are 
indeed affected by hypoxia. Increased PDE4 expression was detectable in hypoxic 
hPASMC after 7 days of hypoxic treatment, although there was no discernable affect on 
overall PDE4 activity. Indeed, it was also discovered that, in contrast with previous 
studies, cAMP levels are elevated following 7 days hypoxia treatment in hPASMC. Taken 
together, it was concluded from these results that the response to chronic hypoxia is a 
gradual one, with an initial increase in cAMP in an attempt to restore normal signalling, 
but instead causing the increased expression of the PDE3A isoform (Murray et al., 2002) 
and cAMP-inducible PDE4D1, PDE4D2, PDE4D5 isoforms. The elevated levels of 
cAMP-PDE isoforms possibly then leads to the marked reduction in cAMP and the 
desensitisation of further cAMP stimulation as observed previously (MacLean et al., 1997; 
Wagner et al., 1997). The elevated levels of PDE4B2 could also be due to the increased 
cAMP as an increase in PDE4B2 has been observed in human myométrial cells directly in 
response to cAMP raising agents (Mehats et al., 1999). The increased PDE4A10 and 
PDE4A11 expression highlights the importance of uncovering the regulatory properties 
and specific roles of these isoforms within a cell.
The increased expression of PDE4B2 and PDE4D5 also indicates a role for these isoforms 
in the hypoxic vasoconstrictive response in the pulmonary circulation. Previous studies 
have implicated increased levels of PDE4B2 in the contraction of myométrial strips 
(Mehats et al., 2002). In addition, PDE4D knockout mice display altered responses to 
muscarinic cholinergic stimulation (Hansen et al., 2000)
Further work in chapter 4 identified a role of the extracellular regulated kinase (ERK) in 
the increased levels of cAMP observed in hypoxia. ERK has previously been shown to act 
in an autocrine manner to stimulate production of PGEz and raise cAMP levels in human 
aortic smooth muscle cells (Baillie et al 2001; see figure 1.3). As cAMP has been 
demonstrated to regulate ERK activity within this loop (Pinelli et al., 1999), this provides a 
mechanism whereby cAMP levels and ERK activity can directly influence one another and 
themselves. Such a mechanism should enable the cell to regulate proliferative signals
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correctly through inhibition of proliferation by cAMP and stimulation of proliferation 
through ERK activation, for example. In chapter 6 ,1 demonstrated that hypoxic hPASMC 
have an increased proliferation rate, therefore the balance between cAMP signalling and 
ERK activation is altered. In fact, ERK was demonstrated to be directly involved in the 
hypoxia-induced increase in cAMP levels as MEK inhibitors used on hypoxic cells 
reduced cAMP levels to that of normoxic cells. It appears that the aforementioned 
components of the autocrine loop are increased in response to hypoxic stimulus. An 
increased ERK activity is well documented, and PGEg and COX-2 levels correspondingly 
have been noted to increase in hypoxia (Shaul et a l, 1991; Jin et a l, 2000; Bradbury et a l, 
2002; Yang et a l, 2002). Interestingly, the increased ERK activity observed in hypoxia is 
transient (Jin et a l, 2000; Scott et a l , 1998). This is also suggestive of ERK regulation of 
cAMP levels in hypoxia as I have proposed that the increased cAMP observed is also 
temporary.
A recent study has shown that cAMP also regulates the autocrine loop albeit in a negative 
fashion. In human bronchial epithelial cells, stimulation of ERK leads to the increased 
production of prostaglandins in a manner which was potentiated by using a protein kinase 
A inhibitor (Pinelli et a l , 1999). This indicates cAMP has an inhibitory effect on the ERK 
pathway in human bronchial epithelial cells thus providing a mechanism to down regulate 
the production of prostaglandins and thus cAMP.
In addition, the increased ERK activity in hypoxia regulates cAMP through its actions on 
the PDE4 family (Baillie et a l , 2000). Dependant on isoform type, ERK can either inhibit 
or promote PDE4 activity (Houslay 2003; Baillie et a l, 2000; Hoffmann et a l, 1999), thus 
providing a cell specific ERK regulation of cAMP which is dependant on the PDE4 
isoform profile within the eell. This is further complicated with the tight 
compartmentalisation of cAMP and ERK signalling within cells (Zaccolo et a l, 2002; 
Pouyssegur et a l, 2002). Pools of cAMP exist in regions of cells and can thus be localised 
away from the degrading action of ERK activated PDE4 short forms, or next to ERK 
inhibited PDE4 long forms within the cell and vice versa.
In combination, these results suggest the observed increase in cAMP levels in hypoxia may 
be an initial attempt by the cell to down regulate the enhanced ERK activity (Jin et a l, 
2000; Scott et a l, 1998) and prostaglandin production (Shaul et a l, 1991) witnessed in 
hypoxia that leads to increased smooth muscle cell proliferation (Yau & Zahradka 2003). 
Instead, the increased ERK maintains the increased level of cAMP through PGE%
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production and PDE4 inhibition, and levels continue to rise until a ‘threshold’ is 
breached whereby PKA phosphorylation of PDE4 overturns the inhibitory effect of ERK 
and cAMP is degraded at a faster rate than synthesised. ERK would then be reduced as a 
result. The decrease in ERK activity would completely alleviate inhibition of the PDE4 
long forms present in hPASMC and increase the rate of cAMP hydrolysis even more, 
resulting in a desensitisation of the cell to cAMP raising agents. Indeed a negative 
feedback of cAMP has been demonstrated before and is thought to exist to protect against 
excessive accumulation of cAMP (Moon et al., 2002; Degerman et al., 1997).
Unfortunately, detecting the effect of ERK on PDE4 activity is compromised by the 
opposing modes of regulation ERK exerts on PDE4 long forms and short forms. To 
address this in future, immunoprecipitated PDE4 subfamilies should be assayed for PDE4 
activity to determine the extent of inhibition. In addition, multiple time points must be used 
to gain a clearer understanding.
In conclusion, the first part of this study indicates a complex method of regulation of both 
cAMP and ERK. cAMP and ERK directly influence each other in a manner that has PDE4 
at its centre. With the change in signalling that occurs in hypoxia, the balance that exists 
between cAMP and ERK is thrown into confusion and as a result, aids the development of 
pulmonary remodelling and desensitisation of the cAMP pathway.
The second part of this study examined the effect of hypoxia on the proliferative capacity 
of hPASMC. It was observed that hypoxia induces a significant increase in hPASMC 
proliferation, both in response to serum and in serum starved cells. This suggests the 
increased proliferation occurs in response to increased mitogenic signals produced in 
hypoxia. In addition, results gained using specific PKA agonists indicate the involvement 
of cAMP signalling. It appears that the increase in cAMP levels and proliferation 
witnessed in hypoxia contrast each other, suggesting the cAMP pathway is severely 
impaired in hypoxia.
Chapter 6 also revealed a novel role for the recently discovered cAMP substrate, Epac (de 
Rooij et al., 1998). Previous studies investigating the role of cAMP and cell proliferation 
have attributed all effects to PKA, although PKA-independent pathways are being 
uncovered (Cass et al., 1999). Surprisingly, the role of Epac in cAMP-mediated inhibition 
or stimulation of proliferation has not been investigated. Using an Epac-specific agonist, 
it was discovered that Epac selectively inhibits serum-induced proliferation. Following on
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from this, identification of cell-cycle proteins altered in response to this agonist should 
be investigated to determine how Epac affects proliferation. In addition, utilising this 
agonist in cells with PKA RI or PKA RII knocked out could be useful as the results 
presented here show that Epac and PKA both serve the same function when overstimulated 
in these cells, indicating a balancing mechanism between PKA and Epac signalling. The 
result of this is either PKA or Epac inhibit cell proliferation in the absence of equal 
stimulation of the other. Also, the effect of stimulating Epac in other cells should be 
examined to determine if this is specific to smooth muscle cells.
The majority of the work presented here adds a further dimension to the role and regulation 
of cAMP in pulmonary arterial hypertension. It is obvious that PAH is a complex process, 
inducing the alteration of signalling pathways in an attempt to restore normal tone to the 
pulmonary circulation. Unfortunately, these alterations can directly and indirectly affect 
other pathways leading to enhanced signalling and the resultant remodelling of the 
pulmonary arterial tree. Due to the numerous signalling pathways involved in the hypoxic 
response, it is apparent that multiple drug therapies are required to attenuate the 
development of PAH. The results presented in this study further establish the potential of 
prostanoid therapy and PDE inhibition as a treatment for PAH. As both can impact upon 
cAMP and ERK pathways, it is possible these therapies can affect upon remodelling and 
hypoxia-induced transcription. Further studies examining the time points over the 
development of PAH should uncover a more precise characterisation of the effects of 
hypoxia on cAMP signalling and affected pathways, allowing the identification of specific 
therapeutic targets to potentiate the beneficial effects of such treatments and reduce the 
side effects associated with the non-specificity of the treatments used today.
The proliferation studies carried out here identify an exciting role for Epac in the 
regulation of proliferation. Although the Epac response is equal in both normoxic and 
hypoxic cells, a better understanding of the mechanisms controlling this response could 
help elucidate the alterations occurring in hypoxia to induce proliferation.
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